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Abstract 
This thesis investigated the role of stress in RM using both psychometric and biochemical measures. 
The majority of previous studies on the impact of stress on RM only addressed the psychological 
aspect without concurrent biochemical stress measurements. In this thesis the stress status in women 
with RM was evaluated by using a validated questionnaire package and biochemical measurements of 
stress markers including cortisol, natural killer cells and prolactin. 
  
The first part of this thesis compared the psychological stress status in a cohort of women with 
unexplained RM with that of fertile health women. The results showed that women with RM had 
higher levels of psychological stress than fertile women. RM women with higher perceived stress and 
being less optimistic appeared to have an increased likelihood of live birth. Based on the findings in 
the present study we speculate that stress coping strategies adopted by individuals may have a 
prognostic value on subsequent pregnancy outcomes more than stress levels in women with RM. 
 
The next part of this thesis investigated the biochemical stress markers including natural killer cells, 
cortisol and prolactin in the same cohort of women with unexplained RM. The increases in pNK 
CDdim cells were found to be associated with a higher risk of a subsequent miscarriage in women 
with RM, suggesting a prognostic value of measuring pNK subset of CDdim cells in RM. In addition, 
no correlation between the measurements of pNK cells and those of uNK cells was found in women 
with RM, suggesting that pNK measurements do not reflect uNK measurements in RM. 
 
Next, we conducted a study to investigate the relationship between prolactin and RM. We found that 
within normal physiological range low plasma prolactin concentrations were associated with an 
increased risk of a subsequent miscarriage in women with RM. No significant difference in the 
measurements of endometrial prolactin receptor was found between women with RM and fertile 
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women. There was also no association between the expression of endometrial prolactin receptor and 
subsequent pregnancy outcomes in women with RM. 
 
The following part of this thesis examined the activation of the hypothalamo-pituitary-adrenal (HPA) 
axis in response to stress in women with RM with cortisol measurements. No non-suppression of 
cortisol following Dexamethasone Suppression Test (DST) was found in women with RM. There was 
also no association between cortisol measurements and pregnancy outcomes in women with RM. 
Based on the findings in this study we speculate that chronic stress of RM has no effect on feedback 
dysregulation of the HPA axis. 
 
The final part of this thesis correlated the results of various stress measurements. High levels of 
fertility stress were associated with a decrease in the numbers of pNK CDbright cells. High basal 
salivary cortisol concentrations were associated with an increase in uNK cell measurements. The 
results of serum cortisol suppression following DST had an inverse correlation with the values of 
pNK CDdim cells whereas the results of salivary cortisol suppression following DST had a positive 
association with uNK cell measurements. The exact physiological mechanism of this observation is 
not known. 
  
In summary, the studies presented in this thesis showed that stress was associated with RM. There 
was some evidence that stress affected subsequent pregnancy outcomes in women with RM. 
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Chapter I: Literature review 
I. Definition of Recurrent Miscarriage 
Recurrent miscarriage (RM), which is also referred to as repeated pregnancy loss (RPL) and 
habitual abortion, is defined as three or more consecutive spontaneous miscarriages (ESHRE, 
2006). The experience of repeated pregnancy loss is physically and emotionally traumatic to 
women who are trying to have children. The overall frequency of RM was estimated from 1% 
to 3% (ESHRE, 2006, Christiansen et al., 2008). The exact prevalence of RM depends on its 
definition. To date there is no consensus on the definition of RM with regard to the numbers 
of previous miscarriages and the gestational age of RM. The American Society for 
Reproductive Medicine defines the numbers of previous miscarriages in RM as two or more 
whereas Europe Society of Reproduction and Embryology defines it as three or more 
(ASRM, 2008, ESHRE, 2006). In some studies only pregnancy losses in the first trimester 
(≤14weeks) were included whereas in other studies pregnancy losses in the second trimester 
(≤24weeks) were also investigated (Franssen et al., 2007, Raffaelli et al., 2009, Tempfer et 
al., 2006, Garrisi et al., 2009, Jaslow et al., 2009). In some studies the gestational age of 
repeated miscarriages was not clarified (Zolghadri et al., 2008). Therefore, it is possible that 
different study populations were examined in current studies. Thus the incidence of RM 
derived from these studies may not be comparable. 
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II. Aetiology of Recurrent Miscarriage 
RM is a heterogeneous condition and it is unlikely that only a single pathological factor is 
attributed to RM. Current literature suggests that the cause of RM is only identifiable in up to 
40%-50% of cases. The remaining RM cases are classified as idiopathic. Hence, this merits 
further research to seek other possible underlying causes of RM. To date the identifiable 
causes of RM have been categorized as parental, fetal, environmental and psychological 
factors. 
 
1 Parental Factors 
1.1 Chromosomal Abnormality 
Parental balanced structural chromosomal rearrangement accounts for 2%-4% of RM (Ford 
and Schust, 2009). The most common chromosomal rearrangement is balanced reciprocal or 
Robertsonian translocation which may lead to unbalanced gene translocations in the fetus, 
resulting in miscarriage (Fortuny et al., 1988, Suzumori and Sugiura-Ogasawara, 2010). 
Other chromosomal anomalies associated with RM include chromosomal inversion, 
insertions and mosaicism (De la Fuente-Cortes et al., 2009). Couples with chromosome 
defects may benefit from pre-implantation genetic diagnosis (PGD) in conjunction with in 
vitro fertilization (IVF). 
 
1.2 Maternal Factors 
i. Age 
 24 
 
It is well recognized that female fertility declines with advancing age, which manifests in 
increases in miscarriage and trisomy 21 and monosomy X of the fetus. RM as part of a range 
of reproductive failures shares common risk factors.  Studies have shown that in women with 
RM maternal age is positively associated with the numbers of repeated miscarriages (Garrisi 
et al., 2009) and also is an important factor predicting the occurrence of miscarriage 
(Metwally et al., 2010). In IVF treatment the pregnancy rate of women with RM declined 
with advancing maternal age (Zhang et al., 2008). The value of preimplantation genetic 
screening (PGS) on the reduction of pregnancy loss in RM women with advanced age is not 
yet clear.  Some studies have shown that PGS significantly reduces the rate of pregnancy loss 
following IVF treatment in RM patients older than 35 years (Munne et al., 2005). However, a 
recent randomized controlled trail (RCT) shows that PGS did not improve the pregnancy rate 
or the live birth rate in RM women with advanced age (>37 years) (Staessen et al., 2004). 
Another multicenter RCT study also found that in IVF women aged between 35 years to 41 
years and who had PGS had significantly lower ongoing pregnancy rates and live birth rates 
compared with those who did not undergo PGS (Mastenbroek et al., 2007), suggesting that 
PGS may reduce the rates of ongoing pregnancies and live births in IVF in women with 
advanced age and PGS has no beneficial effect on screening for embryonic aneuploidy in 
women with advanced maternal age (Twisk et al., 2008).  Adoption or the use of donor 
gametes may be recommended to the older couples if IVF has failed.  
 
ii. Anatomic Factors 
Anatomic abnormalities account for 16 - 18% of RM cases (Jaslow et al., 2009). The 
common anatomic abnormalities include congenital uterine anomalies, uterine adhesions, 
uterine fibroids and polyps. These abnormalities may cause inadequate vascularity of the 
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endometrium where the embryos implant, resulting in placental abruption and consequently 
miscarriage (Propst and Hill, 2000). Among these anatomic abnormalities, congenital uterine 
abnormalities such as arcuate, septate or bicornuate uterus may be associated with second 
trimester miscarriages more than early pregnancy losses (Saravelos et al., 2010). Women 
with anatomic anomalies may benefit from uterine sonography and HSG in the initial 
diagnosis. A definitive diagnosis can be obtained by using combined laparoscopy and 
hysteroscopy as well as 3D sonography (Saravelos et al., 2008). Surgical resection of the 
uterine septum and adhesions, removal of submuscous fibroids and polyps may improve 
subsequent pregnancy outcomes in these women (Propst and Hill, 2000).  
 
iii. Endocrinological Factors 
Endocrinological disorders account for approximately 17% to 20% of RM cases (Stephenson, 
1996, Li et al., 2000). Luteal phase deficiency (LPD), polycystic ovarian syndrome (PCOS) 
and hyperprolactinaemia are the commonest endocrinological abnormalities in RM. LPD is 
defined as the retardation of the endometrium development in the histological dating more 
than 2 days behind the corresponding chronological dating (Olive, 1991). The inadequate 
secretion of progesterone, premature regression of the luteal corpus and a suboptimal 
response of the endometrium to progesterone may be present in LPD. The measurements for 
LPD include LH timed endometrial biopsy characterized by the retardation of the histological 
development of endometrium, a single serum progesterone concentration < 31.8 nmol/L in 
mid luteal phase or three random serum progesterone concentrations < 95.4 nmol/L (Jordan 
et al., 1994, Li and Cooke, 1991). LPD has been associated with RM and substitution 
treatments with progesterone or human menopausal gonadotropin (HMG) have been reported 
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to reduce the risk of miscarriage in RM patients with LPD (Daya et al., 1988, Vanrell and 
Balasch, 1986, Li et al., 2001).  
 
PCOS induced increase in luteinizing hormone and androgen levels may cause premature 
ageing of oocytes and/or incoordinated development of endometrium, subsequently resulting 
in spontaneous miscarriages. Case studies have reported that successful live births had been 
achieved in RM patients with PCOS following metformin and ovarian drilling treatments 
(Palomba et al., 2006, Ballian et al., 2006), suggesting that PCOS is associated with RM. In a 
prospective study with a large cohort of 2199 women with RM, Rai et al found that the 
presence of PCO morphology in RM women was significantly higher than that in general 
population but the morphological PCO of RM patients was not linked to an increased risk of 
miscarriage in a subsequent pregnancy (Rai et al., 2000). The presence of raised LH and 
testosterone has also been found to be higher in women with RM but is not associated with an 
increased risk of miscarriage (Nardo et al., 2002, Rai et al., 2000, Clifford et al., 1994, 
Watson et al., 1993). A study suggested that free androgen index (FAI) may be a predictive 
factor of subsequent miscarriage. Raised FAI has been found to be associated with a high risk 
of subsequent miscarriage in women with RM (Cocksedge et al., 2008). 
  
The role of hyperprolactinaemia in RM remains controversial. Earlier studies have reported 
on the high prevalence of hyperprolactinaemia in the RM population and the improvement in 
pregnancy outcome after bromocriptine treatment (Bussen et al., 1999, Csemiczky et al., 
2000, Hirahara et al., 1998), suggesting that hyperprolactinaemia may be a contributory 
factor of RM. However recent studies found that hyperprolactinaemia occurs rarely in women 
with RM (Li et al., 2000). The relationship between prolactin and RM will be further 
discussed in the relevant chapter of this thesis as appropriate. 
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iv. Prothrombotic States 
A successful pregnancy requires a well developed placenta and sufficient placental function 
to sustain an adequate fetomaternal micro-circulation. This system may be compromised by 
prothrombotic disorders leading to subsequent miscarriages (Larciprete et al., 2007). 
However, recent RCTs have shown that thromboprophylaxis using aspirin combined with 
heparin, aspirin alone or placebo does not improve pregnancy outcomes in women with 
unexplained RM (Kaandorp et al., 2010, Clark et al., 2010), suggesting that it is inappropriate 
to extend thromboprophylaxis to RM women without recognized thrombophilia conditions. 
 
 It is estimated that prothrombotic states may account for 12.5% of RM (Carp et al., 2004). 
This disorder is categorized as inherited and acquired conditions.  
 
a. Inherited thrombophilia 
The most common inherited thrombophilic disorders are deficiencies of antithrombin III, 
protein C and protein S, Factor V Leiden mutation and prothrombin gene mutation 
(G20210A).  
 
a.1 Antithrombin III deficiencies 
Antithrombin III is the most important inhibitor of thrombin, factor Xa, IXa and XII a. 
Antithrombin III deficiency results from the decrease in the concentration or the function of 
antithrombin III (Patnaik and Moll, 2008). It is an autosomal disorder with a high risk of 
thromboembolism in life-long time. Women with antithrombin deficiency have been found to 
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have a high risk of miscarriage. A prospective multicenter study investigated 843 European 
women with thrombophilia disorders and 541 control women without thrombophilia. They 
found that antithrombin deficiency was associated with a high risk of recurrent late 
pregnancy losses (Preston et al., 1996).  
 
a.2 Protein C and Protein S deficiencies 
Protein C inactivates factor Va and VIIIa involved in the anticoagulant process and this 
function is enhanced in the presence of protein S. Protein C deficiency results from a 
decrease in protein C antigen or the activity of protein C. Protein S deficiency results from a 
decrease in the concentration or the function of protein S (ten Kate and van der Meer, 2008). 
Protein C and S deficiencies have been linked to an increased risk of miscarriage. For 
example, a study examined the effect of thromboprophylaxis on the reduction of pregnancy 
losses. They found that women who received low-molecular-weight heparin treatment for 
deficiency of Protein C and S had a significantly lower miscarriage rate than those who did 
not receive the treatment (Folkeringa et al., 2007), suggesting that Protein C and Protein S 
deficiencies may be a contributory factor of miscarriage. 
 
a.3 Factor V Leiden mutation 
The mutation of Factor V Leiden causes acquired protein C resistance, resulting in 
thrombophilia both in veins and spiral arteries of the placenta. This may lead to placenta 
abruption and consequently result in miscarriage. Factor V Leiden has been found to be 
associated with RM. Yenicesu et al. conducted a study among 272 homogenous Caucasian 
women with RM and 56 fertile controls to investigate the relationship between12 
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thrombophilic gene mutations and RM. They found that Factor V Leiden mutation along with 
other six gene mutations was positively associated with RM, suggesting that Factor V Leiden 
may be a causative factor of RM (Yenicesu et al., 2010). Jivraj et al also found that the 
couples with one or more thrombophilic allele of Factor V Leiden, prothrombin G20210A or 
methylenetetrahydrofolate reductase (MTHFR) C677T had an increased risk of miscarriage 
in a subsequent untreated pregnancy (Jivraj et al., 2006). However, in a recent study they 
compared the pregnancy outcomes between women with RM who were Factor V Leiden 
carriers and those with unexplained RM but did not find an association between the 
occurrence of Factor V Leiden and the increased risk of miscarriage (Jivraj et al., 2009). It 
has been suggested that the increased presence of single-nucleotide polymorphisms (SNPs) 
on the Factor V gene may predispose women to acquired activated protein C resistance and 
therefore is associated with repeated pregnancy losses (Dawood et al., 2007).  
 
a.4 Prothrombin Gene mutation (G20210 mutation) 
Prothrombin gene (G20210A) mutation is associated with an increased risk of thrombosis and 
it is the most identifiable risk factor for venous thrombosis (Zoller et al., 1999). More recent 
studies have shown that G20210A mutation is associated with RM (Yenicesu et al., 2010, 
Goodman et al., 2006). However several studies found that the incidence of G20210A 
mutation was rare in women with RM (Agorastos et al., 2002, Pickering et al., 2001, Altintas 
et al., 2007, Behjati et al., 2006).  Therefore, the role of G20210A mutation in RM still needs 
to be elucidated. 
 
b. Acquired thrombophilia 
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The most common acquired thrombophilia associated with RM is the antiphospholipid 
syndrome (APS). Antiphospholipid antibodies are autoantibodies against negatively charged 
phospholipids. APS is categorized as primary (where it occurs in isolation) and secondary 
(where it occurs concurrently with other diseases, such as systemic lupus erythematosus). 
APS is diagnosed if at least one of the following clinical criteria and one of the following 
laboratory criteria are met (George and Erkan, 2009).  
 
 Clinical criteria: 
1. Vascular thrombosis 
One or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or 
organ 
 
2. Pregnancy morbidity 
(1) One or more unexplained deaths of a morphologically normal fetus at or beyond 10 weeks 
of gestation, or 
(2) One or more premature births of a morphologically normal neonate before 34 weeks of 
gestation because of eclampsia, severe preeclampsia, or recognized features of placental 
insufficiency, or  
(3) Three or more consecutive spontaneous miscarriages before 10 weeks of gestation, 
excluded maternal anatomic and endocrinological abnormality and parental chromosomal 
anomaly. 
 
Laboratory criteria: 
1. Lupus anticoagulant presents in plasma on 2 or more occasions at least 12 weeks apart,  
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2. IgG and/or IgM isotypes of anticardiolipin antibody in plasma or serum present in medium 
or high titer on 2 or more occasions at least 12 weeks apart, 
3. IgG and/or IgM isotypes of anti-β2-glycoprotein I antibody in serum or plasma present on 
2 or more occasions at least 12 weeks apart. 
 
APS has been recognized as a cause of RM. Rai et al examined the prevalence of APS in a 
cohort of 500 consecutive women with RM and found that approximately 15% of them had 
APS (Rai et al., 1995b). Studies have reported the achievement of live birth in women with 
RM by treating APS (Farquharson et al., 2002, Sugiura-Ogasawara et al., 2008), suggesting 
that APS is a causative factor of repeated pregnancy loss. A prospective study compared the 
pregnancy outcome between women with APS and those with unexplained RM. They found 
that patients with APS were more likely to have miscarriages again in their subsequent 
pregnancies compared with those with unexplained RM (Rai et al., 1995a), confirming that 
women with APS have a high risk of repeated pregnancy loss.  
 
v. Immunological Factors 
In utero survival of the semiallogenic embryo depends on the successful adaptation of the 
maternal immune system to the fetal antigens.  Dysregulation of this immunological adaptive 
process may lead to pregnancy loss.  To date there is no systematic diagnostic workup or 
therapy for RM due to immunological abnormalities. 
 
a. Thyroid antibody 
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The association between thyroid antibody and RM has been highlighted in several studies. 
Iravani et al conducted a study in 641 patients with RM and 269 fertile controls. They found 
that the presence of thyroid antibodies including thyroglobulin and thyroid peroxide antibody 
were associated with RM, suggesting that the dysfunction of thyroid autoimmunity may 
contribute to RM (Iravani et al., 2008). Dendrinos et al examined the occurrence of 
antithyroid antibody in women with RM and found that women with RM had a significantly 
higher frequency of antithyroid antibody than those without RM (37% versus 13%, ρ<0.05) 
(Dendrinos et al., 2000), suggesting that the presence of antithyroid antibody is associated 
with RM. 
 
b. Natural killer cells 
In the past decade, considerable effort has been made to identify the relationship between 
cytokines and RM. Natural killer (NK) cells have been most extensively studied. NK cells are 
an important part of innate immunity and constitute the predominant leukocyte population of 
the endometrium at the time of implantation and in early pregnancy. NK cells play an 
immunoregulatory role in the maternal adaptive immunity to the semiallograft embryo 
through secreting cytokines, chemokines and angiogenic factors. An increasing number of 
studies have shown that the increase of NK cells both in peripheral blood and endometrium 
tissue is associated with RM (Tuckerman et al., 2007, Larciprete et al., 2007, Clifford et al., 
1999, King et al., 2010, Perricone et al., 2006, Quenby et al., 2005). Empirical treatment with 
prednisolone has been shown to have the effect of reducing the number of endometrial NK 
cells and improving subsequent pregnancy outcomes in women with RM (Quenby et al., 
2005, Quenby et al., 2003). It has been proposed that the imbalanced increase in 
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CD56+/CD16+ phenotype of endometrial NK cells may contribute to RM rather than the 
increase in the total number of NK cells (Lachapelle et al., 1996).  
 
vi. Cervical Incompetence 
Cervical incompetence, also termed as cervical insufficiency, refers to the dilatation and 
shortening of the cervix in the absence of contractions of labour due to the defect of the 
cervical sphincter (Romero et al., 2006). Cervical incompetence has been recognized as a 
cause of repeated mid-trimester spontaneous miscarriage. The clinical presentation is the 
consequent membrane protruding eventually leading to membrane rupture. Several methods 
have been proposed for its diagnosis, including the reduction in cervical resistance index in 
the nonpregnant state and the reduction in sonographic cervical length to less than 25mm 
with funnel sign in mid-trimester (Anthony et al., 2007, Feingold et al., 1984). Women with 
cervical incompetence may benefit from cervical cerclage to prevent miscarriages.   
 
vii. Infections 
The role of infection in RM is not clear. A number of micro organisms have been suggested 
to be associated with spontaneous miscarriage, including Chlamydia trachomatis, Listeria 
monocytogenes, Toxoplasma gondii, rubella, herpes simplex virus (HSV). Bacterial 
vaginosis (BV) seems to be associated with premature rupture of membranes resulting in mid 
trimester loss and preterm labour more than early pregnancy losses (Nelson et al., 2007). The 
association between chlamydia trachomatis and RM had been highlighted in one study 
(Kishore et al., 2003) but later this was refuted. A study examined 504 women with RM and 
154 controls without RM and found that the occurrence of Chlamydia in RM patients was not 
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significantly different to that of controls (Sugiura-Ogasawara et al., 2005). Therefore, the role 
of Chlamydia in RM is still not clear.   
 
1.3 Paternal Factors  
The association between the morphology and function of sperm and RM is not certain yet due 
to the paucity of studies in this area. Some preliminary studies suggest that abnormal integrity 
of sperm DNA may increase the risk of miscarriage (Check et al., 2005, Carrell et al., 2003). 
However these studies focus more on sporadic miscarriages rather than RM. A study assessed 
sperm functional parameters, such as hypo-osmotic swelling (HOS), acrosomal status (AS), 
and nuclear chromatin decondensation (NCD) in vitro between men of partners with 
unexplained RM and men who had recently conceived a child. They found a significant 
reduction in sperm function in the case group compared with the control group (Saxena et al., 
2008), suggesting that impaired sperm function may play a role in RM. Carrell et al also 
found a significant increase of sperm chromosome aneuploidy, apoptosis, and abnormal 
sperm morphology in men with partners having a history of RM (Carrell et al., 2003). 
 
2 Fetal Factors 
Chromosomal anomaly is the commonest fetal cause of RM. Aneuploidy is the most 
prevalent chromosomal abnormalities of abortuses in RM (Carp et al., 2001). Evidence from 
preimplantation genetic diagnosis (PGD) has shown that women with RM had a higher 
incidence of chromosomally abnormal embryos after aneuploidy screening than those without 
RM (Rubio et al., 2005, Rubio et al., 2003).This finding is consistent with those from other 
previous studies that couples with RM had significantly higher rates of chromosomally 
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abnormal embryos in IVF treatment (Pellicer et al., 1999, Simon et al., 1998), suggesting that 
fetal chromosomal anomaly may be the cause of RM. However, some studies have described 
contradictory findings that fetal aneuploidy occurred less in women with RM and with the 
increase in the numbers of repeated miscarriages the occurrence of normal chromosomal 
abortuses increased in women with RM (Sullivan et al., 2004, Ogasawara et al., 2000). 
Therefore, more research is needed to clarify this issue. Interestingly, Carp et al found that 
patients with karyotypically abnormal abortuses had better pregnancy outcomes in their 
subsequent pregnancies than those with karyotypically normal miscarried fetuses (Carp et al., 
2001). Ogasawara et al also found that RM women with a previous karyotypically normal 
abortus were more likely to miscarry in the subsequent pregnancies than those with an 
karyotypically abnormal abortus (Ogasawara et al., 2000) The exact explanation for this 
observation is not known yet. 
 
3 Environmental Factors 
Caffeine consumption and smoking have been implicated in increasing the risk of 
miscarriage.  Recent studies have shown that women who are homozygous for CYP1A2*1F 
alleles (an enzyme responsible for caffeine metabolism) had a high risk of RM with a dose 
dependent effect of daily caffeine intake (Sata et al., 2005). Other studies have shown that 
women exposed to environmental tobacco smoke had a high risk of spontaneous miscarriage  
in combination with caffeine and alcohol consumption (Windham et al., 1999). 
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4 Psychological Factors 
4.1 The impact of stress on reproduction 
Recently, the impact of psychological stress on RM has received more attention. Studies have 
suggested that stress may play a role in RM through maternal neuro-endocrine-immune 
network response (Andalib et al., 2006). Stress, namely pressure or tension, has been defined 
as a form of psychological, physiological and behavioural transaction between people and 
environment, ie. person-environment fit. In this definition the external environmental 
stimulus is regarded as a stressor and the psychological response to the external stimulus is 
termed as stress (Ogden, 2007). Two types of stress are differentiated including acute stress 
and chronic stress. Acute stress is a response to an immediate threat, such as an exam or a 
public presentation. Chronic stress is a response to a prolonged or frequent stimulus, such as 
job stress or poverty (McGonagle and Kessler, 1990). It suggests that a good person 
environment fit may cause no or a low level of stress whereas a poor fit may result in a high 
level of stress. The effect of stress may be beneficial to enable fight or flight adaptive 
response to escape from the harmful situation and the homeostasis may still be resumed. 
However, effect of stress may be detrimental by mediating a series of physiological responses 
resulting in adverse somatic consequences, including impaired cognition, abnormal 
metabolism, impaired immune function and impaired reproduction.   
 
There are an increasing number of studies that reported on the adverse impact of stress on 
reproductive performances, causing premenstrual pain, loss of libido, sexual dysfunction, 
functional hypothalamic amenorrhea, anovulation, infertility, miscarriage, still birth, low 
weight birth and postpartum morbidity (Donadio et al., 2007, Lechner et al., 2007, Botros et 
al., 2006, Diego et al., 2006, Lopez-Gatius et al., 2005, Xiao et al., 2002). Pregnancy is a 
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special physiological and psychological transaction in women with increased sensitivity and 
anxiety. This transaction could be a form of stress causing a negative impact on a woman’s 
wellbeing with a consequent deleterious effect on pregnancy. An adverse pregnancy outcome 
could also be a form of stressor, mediating negative psychological responses such as grief, 
mourning, anxiety, depression, coping, loss of self-esteem and frustration (Kersting et al., 
2004, Nikcevic et al., 1998). Recently the link between negative prenatal psychological stress 
and adverse pregnancy outcome has been highlighted. For example, in IVF treatment it has 
been found that high stress levels are associated with poor biological responses to treatment 
and low pregnancy rates (Boivin and Schmidt, 2005). In a prospective study in women who 
planned their first pregnancies, during a period of 6-month follow-up it was observed that 
women with higher distress scores had lower pregnancy rates and higher early miscarriage 
rates than those with lower distress scores (Hjollund et al., 1999). Studies have also shown 
that both in rat models and in humans stress induces repeated pregnancy loss by up-regulating 
Th1 family cytokines (Knackstedt et al., 2003). In women with RM it has been found that a 
high stress level is associated with an increased risk of subsequent pregnancy loss (Sugiura-
Ogasawara et al., 2002, Andalib et al., 2006). 
 
4.2 The mechanism of stress effect on RM 
Stress stimulation can trigger a series of physiological adaptive responses. The systems that 
respond to stress are the hypothalamo-pituitary-adrenal (HPA) axis and the sympathoadrenal 
system. Stress can affect the secretion of the parvocellular neurons (PVN) in the 
hypothalamus and the release of neuropeptides, corticotrophin releasing hormone (CRH) and 
arginine vasopression (AVP). The interaction of these mediators affects the secretion of 
adrenocorticotrophic hormone (ACTH) in the anterior pituitary gland, which in turn increases 
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the synthesis of glucocorticoids in the adrenal cortex. Simultaneously glucocorticoids have a 
negative feedback on the hypothalamo-pituitary axis, regulating the secretion of CRH and 
ACTH. It is also known that stress can trigger the release of catecholamines and 
noradrenaline via the sympathetic nervous system. Therefore, these increased neurohormones 
and sympathetic factors can activate a series of physiological responses, disrupting 
homeostasis and causing a range of adverse somatic changes, consequently damaging 
pregnancy (Tilbrook and Clarke, 2006, Tilbrook et al., 2006, Ferin, 1999, Chorusos et al., 
1998).  
 
It has been suggested that stress may play a role in pregnancy loss via the interaction between 
psycho-neuroendocrine-immune networks. Overt or latent stress may alter steroidgenesis by 
activating the HPA axis and neuropeptides through the sympathoadrenal system. The 
interaction of these stress-related mediators, such as glucocorticoids, CRH, ACTH, AVP, 
PVN, endogenous opioid peptides and catecholamines, may modify the synthesis and 
secretion of gonadotropin releasing hormone (GnRH) from the hypothalamus and 
gonadotropins from the pituitary. The regulation of GnRH on gonadotropins and the negative 
feedback of gonadal steroids to GnRH could also be modulated by stress-related mediators 
(Tilbrook and Clarke, 2006, Ferin, 1999, Parker and Douglas, 2010). Therefore, stress may 
interfere with the gonadal axis, resulting in adverse pregnancy via neuro-endocrine pathways. 
In addition, it is possible that stress may also interfere with reproductive immunity. Stress 
may alter cytokine profiles which are responsible for the maternal immunity adaption to 
tolerate the semi-allograft embryo during pregnancy, thus adversely affecting implantation 
and trophoblastic invasion, consequently resulting in early pregnancy loss (Glaser, 2005, 
Glaser and Kiecolt-Glaser, 2005, Parker and Douglas, 2010).  
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RM as a part of pregnancy failure shares the common mechanism with pregnancy loss 
resulting from stress. Recently, there are an increasing number of studies exploring the 
relationship between stress and RM. Because many of the psychological concepts are 
subjective and difficult to define precisely, individuals may be uncertain as to how to classify 
themselves into the response ranking categories. In addition, the perception of stress may 
vary between individuals. Some events which are stressful to some individuals may be not to 
others. Therefore, stress scores derived from individual’s self-reports may not reflect the real 
stress status. 
 
Recently, the correlation between psychological stress and some biochemical stress markers, 
including endocrine and immune factors, has been emphasized. Some hormones and immune 
cells responsive to stress, such as cortisol and NK cells, have been examined in studies on the 
relationship between stress and adverse pregnancy outcome (Diego et al., 2006, Andalib et 
al., 2006). Therefore, investigation of biochemical stress markers may provide an objective 
physiological pathway to evaluate the role of stress in RM. However, most of the current 
studies look at the effect of a single stress mediator on RM. So far there is no comprehensive 
study examining the role of stress with regard to the interaction between stress mediators. 
From current literature the possible mechanism of the effect of stress mediators on RM is 
detailed below. 
 
i. Cortisol 
Cortisol is widely recognized as a stress hormone due to its sensitivity and responsiveness to 
stress stimulation. Studies have shown that peripheral cortisol levels are elevated under 
stressful circumstances (Schlotz et al., 2004, Aardal-Eriksson et al., 1999) and cortisol 
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elevation is positively correlated with stress scores (Diego et al., 2006). In pregnant women it 
has been found that prenatal psychosocial stress may increase cortisol secretion (Diego et al., 
2006, Wadhwa et al., 1996). High levels of cortisol have been found to have a negative effect 
on pregnancy. In IVF treatment it has been observed that women who failed in IVF had 
higher cortisol concentrations than those who had successful pregnancies (Demyttenaere et 
al., 1992). In a prospective study high levels of cortisol have been found to be associated with 
an increased risk of miscarriage, suggesting that cortisol elevation may contribute to 
miscarriage (Nepomnaschy et al., 2006).  
 
It is unclear how high cortisol levels affect pregnancy. It has been suggested that high levels 
of cortisol may interfere with gonadal steroid production. In the follicular phase cortisol 
concentrations have been found to be negatively correlated with the concentrations of FSH, 
progesterone and β-HCG (Demyttenaere et al., 1992). Cortisol increase also has the effect of 
suppressing progestin secretion (Nepomnaschy et al., 2004). These inhibitory effects of 
cortisol elevation on gonadal-steroid production may consequently affect pregnancy, 
resulting in miscarriage. However, studies have shown that only sustained elevation of 
cortisol may have this effect. Repeated transient elevation of cortisol does not appear to have 
a similar effect (Turner et al., 1999a, Turner et al., 1999b). It is therefore possible that chronic 
stress, which is more likely to induce sustained increase of cortisol, has a more profound 
deleterious effect on pregnancy than acute stress. 
 
ii. Prolactin  
Stress has been found to have the effect of increasing plasma prolactin secretion. These 
stressful circumstances include war, negative life events and academic examinations (Sonino 
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et al., 2004, Sabioncello et al., 2000, Armario et al., 1996). Studies also found that women 
who underwent IVF treatments had higher anxiety levels and plasma prolactin concentrations 
than fertile controls, suggesting that anxiety may increase plasma prolactin concentrations 
through the HPA activation (Csemiczky et al., 2000). The increase of prolactin in response to 
stress often occurs in parallel with cortisol elevation. Yet to date the exact physiological 
pathway of how stress may increase prolactin secretion is not understood.  
 
Plasma prolactin elevation has been previously related to infertility and RM. For example, 
Csemiczky et al. (2000) have found that infertile women had significantly higher 
concentrations of plasma prolactin throughout the menstrual cycle than fertile women 
(Csemiczky et al., 2000). Some previous studies have reported on the high prevalence of 
hyperprolactinaemia in women with RM (Hirahara et al., 1998, Bussen et al., 1999) and 
improved pregnancy outcomes after treatment of hyperprolactinaemia with bromocriptine 
(Hirahara et al., 1998), suggesting that hyperprolactinaemia may be a possible aetiological 
factor of RM. However, contrary to the above findings, our earlier study showed that 
hyperprolactinaemia rarely occurs in women with RM (Li et al., 2000). Recent studies have 
also shown high levels of plasma prolactin may have a beneficial role in pregnancy and lack 
of expression of prolactin and its receptors in endometrium is associated with RM (Gåfvels et 
al., 1992, Gonen and Casper, 1989, Ozaki et al., 2001). Therefore, it is still unclear whether 
high prolactin levels are associated with miscarriage. Further discussion on the relationship 
between prolactin and RM will be further discussed in the relevant chapter of this thesis as 
appropriate.  
 
iii. Natural Killer Cells 
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It has been found that natural killer (NK) cells may be altered in numbers and activities under 
stress stimulations. In women with RM pre-conceptional stress has been found to have the 
effect of altering peripheral NK (pNK) cells (Hori et al., 2000, Andalib et al., 2006). Of the 
various types of stress, depression appears to have the greatest effect on increasing pNK cell 
cytotoxicity (Hori et al., 2000, Andalib et al., 2006, Shakhar et al., 2006). The alteration of 
pNK cells has been found to be associated with RM (Fukui et al., 2008, Emmer et al., 2000, 
King et al., 2010). Uterine NK (uNK) cells have also been found to be associated with RM. 
Some studies have shown that uNK is elevated in women with RM compared with fertile 
women (Tuckerman et al., 2007, Clifford et al., 1999, Quenby et al., 2005) and the increase 
of uNK cells is positively correlated with the number of previous miscarriages of RM 
(Tuckerman et al., 2004), suggesting that uNK cells play a role in RM. The relationship 
between NK cells and RM will be elaborated in the relevant chapter of this thesis as 
appropriate.  
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Chapter II: Hypotheses to be explored in this thesis 
Hypotheses  
1. Women with RM have higher stress levels than fertile women without miscarriage 
 
 2. ‘Tender loving care’ in the form of clinical consultation, explanation and reassurance from 
the medical staff at the dedicated clinic may reduce stress levels of women with RM 
 
3. Stress may have a prognostic value on subsequent pregnancy outcomes in women with RM 
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Chapter III: Materials and methods 
As several studies are presented in this thesis, in this section only materials and methods 
which are common to all studies will be described. Details of the specific materials and 
methods of each individual study will be described in the relevant sections as appropriate. 
 
I. Health and Safety 
All biological specimens, materials and reagents were handled according to the health and 
safety regulations. Laboratory coats and gloves were worn during specimen or reagent 
handling. Any biological specimens or chemical reagents producing toxic fumes were 
handled in safety cabinets. All recommendations as required by COSHH (Control of 
Substances Hazardous to Health), or in correspondence to the safety data sheets of each 
reagent, were followed. 
 
II. Ethics 
Ethical approval for the recruitment of participants was obtained from the South Sheffield 
Research Ethics Committee (08/H1308/80) in October 2008 (Appendix I). R & D approval 
was granted in July 2009 (Appendix II). Each participant was provided with an information 
sheet describing the nature of the study (Appendix III). All the patients who took part in the 
study were seen by the researcher for consent and to further explain details about the study. 
Instructions with regard to the time and methods of sample collections were delivered to the 
participants once written consent forms were obtained.  
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Data regarding clinical profiles of the patients were collected from the medical notes. The 
collected data was input in a pre-designed chart for research purposes (Appendix IV). The 
chart sheets were kept in a locked cabinet in a secure office where was only accessible to the 
authorized persons. The data was processed anonymously into SPSS software by the 
researcher for the subsequent analyses. The computer where the data was input was secured 
and password protected. 
 
III. Study Setting  
This study was conducted at the Recurrent Miscarriage Clinic in Jessop Wing for Women, 
Royal Hallamshire Hospital, Sheffield Teaching Hospital. The laboratory work was 
conducted in the biomedical laboratories on level 4 in the Academic Unit of Reproductive 
and Developmental Medicine in the Jossop Wing hospital for Women and the flow cytometry 
department on floor D in the Medical School of the University of Sheffield.  
 
IV. Materials 
1 Cases 
Women with a history of recurrent miscarriages, who were referred to the Recurrent 
Miscarriage Clinic, were recruited at their first clinical attendance. Recruitment began in 
November 2008. Due to the long term nature of the study period for each participant 
according to the study protocol, recruitment was ended in September 2009 so that the follow-
up of the participants could be completed within the time frame. We adhered strictly to the 
inclusion criteria during recruitment and therefore excluded a significant number of patients 
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who attended the RM clinic during the study period. There were a total of 52 patients eligible 
to the study during the recruitment period and 45 of them agreed to participate in the study.  
 
Among these 45 recruits, two patients were diagnosed with depression during the study 
period and were referred to psychiatric treatment by their GPs; one patient declined treatment 
at the RM clinic after consent; two patients conceived promptly after consent; four patients 
withdrew from the research due to the distance reason. Therefore, they were excluded from 
the study. The remaining 36 patients completed the research investigations on two occasions 
in accordance with the study protocol.  
 
1.1 Inclusion Criteria 
Women with unexplained RM, who were fertile and ovulatory, were eligible for this study. 
The definition of RM was defined as three or more consecutive spontaneous miscarriages. 
RM without the presence of previous live births was categorized as primary RM and RM 
with the presence of previous live births was categorized as secondary RM. All the patients 
underwent investigations in accordance to an established protocol (Li, 1998), including 
parental chromosomal analysis, thrombotic study, antiphospholipid antibody screen, thyroid 
function and thyroid antibody test, FSH, LH, estradiol, prolactin, free androgen index, 
transvaginal ultrasonography and hysterosalpingography. Hysteroscopy was only performed 
if a uterine abnormality was suspected on pelvic ultrasound or hysterosalpingography. 
Unexplained RM fulfilled the criteria of normal parental chromosomal analysis, absence of 
endocrinological abnormalities, tested negative for antiphospholipid antibody screens, normal 
coagulation studies, pelvis ultrasonography and hysterosalpingography which shows no 
evidence of structural uterine anomaly.  
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1.2 Exclusion Criteria 
Women who had pituitary disorders, psychiatric illnesses and who had depression on anti-
depressants were excluded from this study. 
 
2 Controls 
 Thirty female volunteers aged between 20 to 40 years, who had no history of miscarriage, 
infertility, pituitary diseases, psychiatric disorders and depression, were recruited from the 
Gynaecology Outpatient Unit and the University Department. Parity was not taken into 
account as an inclusion criterion for controls as only the history of miscarriage or infertility 
was considered as the factor which may affect the level of fertility-related stress. 
 
V. Methods  
1 Study Design  
1.1 Case study 
Women with RM, who were referred to the Recurrent Miscarriage Clinic, were approached 
on their first visits at the clinic. There were approximately two new referrals in each clinic 
per week. New referrals were interviewed by the specialist nurses before the clinical 
consultation with regard to the history of their previous miscarriages. Eligible candidates 
were identified after the interview and the investigator was introduced to the potential recruits 
by the specialist nurses. The patients were then seen by the investigator and the information 
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sheets about the purpose of the study were delivered to them. Women who were interested in 
the study were further explained the details of the study, which included the number of the 
visits, the types of samples required from them and the invasive procedures involved for 
these investigations.  They were reassured regarding the anonymity and confidentiality of 
their data and their right of withdrawal from the study at any time. The written consent forms 
were obtained after patients fully understood the entire study.  
 
i. Procedure 
1 Baseline assessment: 
1.1 First visit:  
At the first visit in the study, patients were asked to complete questionnaires to identify 
baseline stress levels. The pre-designed flow chart (Appendix V) outlining subsequent 
research visits was provided to the patient. Patients were required to use barrier contraception 
during the study period until all of the baseline tests were completed. 
 
1.2 Dexamethasone Suppression Test (DST) visit: 
The participant was required to contact Dr Wei Li on day 1 of her next menstrual cycle. The 
appointment was arranged for the serum cortisol measurement at 8:30 am on day 3 to5 of the 
menstrual cycle. On the day prior to the blood test a saliva sample was collected by the 
patient at 11pm at home. A dexamethasone tablet at the dose of 1mg was administrated orally 
after the collection of the saliva sample. At 8:30am the following morning a 5ml blood 
sample was obtained for the serum cortisol estimation. A saliva sample was collected 
simultaneously for salivary cortisol estimation. 
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1.3 Biopsy visit: 
Patients were asked to do daily urine ovulation test with the ovulation test sticks (Clearblue, 
UK) from day 10 of the cycle onwards. They were required to contact Dr Wei Li once 
positive results for ovulation were identified. Their appointments for the LH timed 
endometrium biopsy for uterine nature killer (uNK) cell measurements were arranged on day 
7 to 9 after LH surge. The blood samples for peripheral natural killer (pNK) cell 
measurements were obtained simultaneously with the endometrial biopsies. The sequence of 
the biopsy visit and the DST visit may vary depending on the day they fell in the cycle on 
their first visits.  
 
2. Follow-up assessment 
According to the established protocol of clinical investigations, approximately 3 months 
afterwards patients were offered appointments to discuss the results of their investigations. 
Patients who participated in the research were seen by the investigator again. They were 
required to complete the same questionnaires in order to compare the change of their stress 
levels during this period. Simultaneously a blood sample was obtained from them for pNK 
cell measurements.  
 
Participants were then followed up across the study period until they conceived again after 
the recruitment. The data regarding their pregnancy outcomes and the information of their 
clinical profiles were collected from the medical records for the analysis. Participants who 
did not conceive within a six-month period after the second assessment were asked to 
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complete the study. They were categorized into the non-pregnant group in the analysis and 
the data regarding their clinical information was also collected from the medical records. 
 
1.2 Control study 
Female volunteers were approached in the Gynaecology Outpatient Unit and the University 
Department in the Jessop Wing. They were informed about the purpose of the study with the 
poster. After giving written consent, they were asked to do daily urine dipstick tests 
(Clearblue, UK) from day 10 of the cycle onwards with a view to detecting the LH surge. On 
day 7 to10 after the LH surge a blood sample was obtained for pNK cell measurements. They 
were asked to complete the same questionnaires to identify their stress levels. 
 
1.3 Outcome measures 
1.3.1 Clinical measures 
The conception outcome was defined as the outcome of the first conception within a six-
month period after the second assessment. The pregnancy outcome was measured as the 
outcome of the first pregnancy during the study period. Miscarriage was defined as the 
spontaneous loss of pregnancy following a pregnancy test, including biochemical 
pregnancies, pregnancies with the presence of a sac on ultrasound scan and pregnancies with 
the presence of fetal cardiac activity in the first trimester. 
 
First trimester spontaneous miscarriages occur in 15% of all pregnancies and are most 
frequently due to abnormal embryos or fetuses, particularly aneuploidies like trisomy 21, 18, 
or 13 (Donoso et al., 2007). Spontaneous miscarriage can be classified as threatened, delayed, 
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inevitable, complete or incomplete. In threatened miscarriage, the embryo or fetus is viable 
but there is vaginal bleeding with a closed cervical os. In delayed miscarriage, the fetus with 
a minimum crown-rump length of 6 mm is either non-viable or an empty gestation sac 
measures more than 20mm in average diameter. In delayed miscarriage, there may or may not 
be associated vaginal bleeding. Inevitable miscarriage is often characterised by a dilating 
cervical os and abdominal pain. In this thesis we did not take into account threatened 
miscarriage in the study analysis.  
 
No treatment was given to the study subjects apart from tender loving care. ‘Tender loving 
care’ was defined as clinical consultation, explanation and reassurance by a team of dedicated 
staff in the RM clinic. RM women who were referred to the Recurrent Miscarriage Clinic 
were interviewed by the two specialist staff nurses regarding the past history of repeated 
pregnancy losses and the relevant medical history. A series of investigations were then 
performed according to an established protocol (Li, 1998) in the clinic as described in the 
preceding context. The questions asked by the patients regarding the causes of RM and 
available treatments were explained explicitly and patiently as appropriate by the dedicated 
clinicians at the clinic. The patients were reassured of a likely profound improvement in 
pregnancy outcomes after treating the identified causative factor of RM and the likelihood of 
a subsequent successful pregnancy in women with unexplained RM condition regardless of 
the past unsuccessful pregnancies. They were offered a fast track to access to appointment for 
their cycle timed investigations by direct telephone contact with the two specialist nurses at 
the clinic.  
 
1.3.2 Laboratory measures 
Psychometric measures 
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The psychological stress status was defined as the scores of the validated questionnaires 
predesigned for this thesis. 
 
Biochemical measures 
The biochemical stress status was defined as the results of biochemical stress markers 
measured in both peripheral blood samples and endometrial or salivary samples, including 
natural killer cells, prolactin and cortisol. 
2 Laboratory Equipments 
2.1 Heating equipment 
Heating blocks and waterbath were from Techne (Duxford, Cambridge, UK). A Panasonic 
microwave oven was also used for the heating antigen retrieval procedure in 
immunohistochemistry. 
 
2.2 Light microscope 
A standard light microscope (Zeiss, Germany) was used for microscopic observation of 
immunostaining. A haemometre was used for microscopic calculation of cells isolated from 
the blood samples for flow cytometry.  
 
2.3 Measuring equipment 
All amounts were weighed by using a Mettler PM 4000 balance (Mettler-Toledo Ltd, 
Leicester, UK). PH was measured with a Jenway pH metre3020 (Thermo orion, Beverly, 
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USA). Fluid volumes were dispensed with Eppendorfs pipettes with tips of P10, P100 and 
P1000 as appropriate. 
 
2.4 Moist chamber 
A plastic chamber with suitable platform inside was used to incubate sections with reagents 
for immunohistochemistry at the appropriate incubation temperature. 
 
2.5 Storage equipment  
A laboratory cold refrigerator at +4℃ (Lec) and a -20℃ freezer (Sparkfree Lab Freezer) were 
used for storage of agents and for overnight incubation of sections with antibodies for 
immunohistochemistry.  
 
2.6 Centrifuge equipment 
A Beckman GS-6R centrifuge machine was used for the centrifugation of samples. 
 
2.7 Flow cytometry facility 
A four-colour fluorescence capable flowcytometer (BD FACSCalibur
TM
 system, UK) was 
employed for the flow cytometry experiment. 
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Chapter IV: The impact of psychological stress on RM 
I. Introduction 
Definition of stress 
Stress, namely pressure or tension, describes experiencing events which can produce 
psychological consequences (Smith et al., 2003, Atkinson and Hilgard, 1996). Stress occurs 
when the threats are beyond an individual’s ability to cope. There are two types of stress, 
namely eustress and distress. Eustress which is positive and motivating enables individuals to 
fight or flee. For example, in a racing competition eustress exerts excitement and mobilizes 
the muscles to accomplish the competition. Distress which is negative and harmful alters 
emotional or physical homeostasis due to failure in coping with the threats (Selye, 1975, 
Carstens and Moberg, 2000). The events which can cause stress are referred to as stressors 
(Atkinson and Hilgard, 2000). There are two types of stressors, namely acute stressors which 
are short term events such as hungry and a car accident; and chronic stressors which are long 
term events such as poverty or physical health (Ogden, 2007). 
 
The reactions triggered by stress are termed as stress responses (Atkinson and Hilgard, 1996). 
The psychological responses to stress include anxiety, anger and aggression, apathy and 
depression and cognitive impairment. The physiological reactions to stress can include 
increased metabolic rate, increased heart rate, dilations of pupils, high blood pressure, tensing 
of muscles, increased secretion of neural and endocrine hormones and elevated blood sugar 
(Atkinson and Hilgard, 2000). However, not only the stressful events determine the 
individual’s stress responses but also the way how an individual perceives stress affects stress 
responses. So far several stress response models have been proposed by researchers. An 
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essential model of stress responses is the ‘fight-flight’ which was first described in 1932 by 
Walter Cannon. It describes the arousal and mobility of the body in response to stress 
stimulus via activation of the sympathetic nervous system and the endocrine system. This 
arousal may be protective by facilitating confrontation or flight from the threat. On the other 
hand, it may be harmful because it causes psychosomatic symptoms over time (Cannon, 
1932).  
 
Another widely recognized stress response model is ‘general adaptation syndrome’ which 
describes a series of physiological changes in stress responses. It consists of three phases. In 
the first phase of alarm, the body expends resources and lowers resistance to confront a threat 
by activating sympathetic nervous system. In the second phase of resistance, the body 
increases its resistance and actively confronts the threat by fleeing or fighting it. In the third 
phase of ‘exhaustion’ the body depletes its physical resources resulting in decompensation, 
leading to illness (Selye, 1975). 
 
 Lazarus and colleagues (1984) have proposed an ‘interaction’ theory which emphasizes the 
interaction between the individual and environment in stress responses. In this theory an 
individual’s internal factors such as attitudes, personality and lifestyle, and environmental 
factors interact with stressors, reducing or increasing a person’s susceptibility to stressors. 
Stress responses are associated with the coping methods adopted by the person and past 
experiences with the stressors (Lazarus and Folkman, 1984) . Therefore, stress is the 
consequence of a person’s appraisal process of the stressful events. Individuals may feel less 
stress when they feel their resources adequate to deal with the stressors whereas an individual 
may feel more stress when they feel resources inadequate (Ogden, 2007).  
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Difficulties in measuring stress 
The cause of stress varies between individuals. Some events which are stressful and 
overwhelming to some individuals may be not to others. Individuals may deal with stressors 
differently based on their own experiences and resources. Therefore, stress measurements 
have been inherently difficult. Several confounding factors, such as gender, age, social status 
and education, can also affect stress measurements (Fortuny et al., 1988). To date a wide 
variety of methods have been employed to measure stress, including self-report 
questionnaires; behavioral measures, such as task performances under stress; physiological 
measures, such as heart rates and blood pressure; and biochemical measures, such as cortisol 
and catecholamines (Lovallo, 1997). However, each type of measurement has its own bias. 
For example, cortisol secretion is affected and interacts with a variety of neuro-endocrine 
factors other than those enhanced by stress (Tilbrook and Clarke, 2006). Self-report measures 
are subject to the variation of stress perception and responses between individuals (Suzumori 
and Sugiura-Ogasawara, 2010). Behavioral measurements are subject to multiple 
explanations. Performance decline may be due to decline in motivation, fatigue or cognitive 
strain (Pilcher et al., 2007). Therefore, bias may be produced in stress measurements by using 
a single stress measure. The possibility of obtaining a good measurement of stress may be 
increased by combining several measurements. In this thesis we combined both self-report 
questionnaire measurements and biochemical measurements to comprehensively assess stress 
in women with RM. 
 
Stress and miscarriage 
A long term arousal of the sympathetic or the neuro-immune-endocrine systems exposed to 
stress stimulation can increase a person’s susceptibility to disease or illness (Ogden, 2007). 
This overarousal has a negative effect on arteries, immune and endocrine systems causing 
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health problems (Smith et al., 2003). It has been widely recognized that stress may play a role 
in some disease causation, such as asthma, stomach ulcer and cardiac diseases. Recently the 
relationship between stress and miscarriage has been paid more attention. 
 
Stress following miscarriages 
For many couples pregnancy and childbirth are desired outcomes of their relationship. 
However, approximately 15% to 20% of pregnancies result in spontaneous miscarriages 
(Darroch et al., 1999, Henshaw, 1998). Couples who suffer miscarriages often describe the 
experience as stressful. The symptoms of the psychological distress caused by miscarriages 
are often referred to as grief, mourning, guilt, anxiety, depression, coping, loss of self-esteem 
and frustration (Andalib et al., 2006, Kersting et al., 2004, Nikcevic et al., 1998, Nishikawa et 
al., 1991, Dingle et al., 2008). Although there is an increasing body of studies examining the 
occurrence of psychological distress following miscarriages, the incidence of psychological 
morbidity after miscarriages varies between studies (see table IV-1). The reason for this 
variation may be due to the lack of consensus on stress measurements used in current studies. 
Although questionnaires are the most widely used instruments to measure stress, there is no 
consensus on the psychometric measures used to assess fertility-related stress, which should 
be sought in the questionnaire based study. Different authors employed different 
questionnaires measuring different psycho-parameters in their studies. For example, some 
studies measured anxiety and depression as the principal symptoms of the fertility-related 
stress whereas others examined generic personality disorder and health concerns (Sham et al., 
2010, Stallman et al., 2010, Lok et al., 2010, Obi et al., 2009, Dingle et al., 2008, Cumming 
et al., 2007). Therefore, the results obtained from different questionnaires varied 
significantly. Table IV-1 illustrates the variation in the instruments used to measure the 
impact of miscarriage on women’s psychological wellbeing.
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Table IV 1. Studies which have assessed psychological morbidity in women who have experienced miscarriages 
Author Assessment time Sample size Instruments Items Psychological morbidity 
Sham et al (2010) 3 months after miscarriage 161 General Health Questionnaire (GHQ) 
The Structured Clinical Interview for DSM-IV 
Axis Disorder 
12 
 
? 
10% of depressive disorder 
1.2% of anxiety disorder 
0.6% of obsessive compulsive disorder 
0.6% of posttraumatic disorder  
Stallman et al (2010) 3 months post-miscarriage 117 The Kessler 10 10 81.2% of distress 
Lok et al (2010) Immediately after miscarriage 
3 months after miscarriage 
6 months after miscarriage 
12 months after miscarriage 
280 General Health Questionnaire (GHQ) 
Beck Depression Inventory (BDI) 
 
12 
 
21 
55%  scored high on GHQ and 26.8% high on BDI 
25% high on GHQ and 18.4% on BDI 
17.8% high on GHD and 16.4% high on BDI 
10.8% high on GHD and 9.3% high on BDI 
Obi et al (2009) 1~3 months after miscarriage 202 Zung Self-Rating Depression Scale 20 74.3% had minimal depressive symptoms 
3% had moderate depressive symptoms 
13.9% had sever depressive symptoms 
Dingle et al (2008) Previous miscarriages in 
lifetime 
82 women at age 21 Composite International Diagnostic Interview 
computerised version 2.1 
 
?  53.7% of anxiety and 43.2% for affective 
Cumming et al 
(2007) 
1 month after miscarriage 
6months after miscarriage 
13 months after miscarriage 
400 women  in the 1st 
assessment 
317 women in 2nd assessment 
275 women in 3rd assessment 
The Hospital Anxiety and Depression Scales 14 28.3% for anxiety and 10% for depression in the first assessment 
20% for anxiety and 4% for depression in the 2nd assessment 
17% for anxiety and 2% for depression in the 3rd aseessment 
Nishikawa et al., 
1991 
Within a period of 13 months 
of a miscarriage at 10 to 14 
weeks of gestation 
204 women  The Hospital Anxiety and Depression Scales 
The Expanded Texas Inventory of Grief 
14 
17 
45% of anxiety and 15% of depression 
? authors did not describe the numbers of items containing in the instruments 
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Stress causing miscarriages 
Recently, there are an increasing number of studies exploring the effect of stress on 
miscarriage. Stress may activate the HPA axis affecting the establishment of pregnancy 
through the interaction of the psycho-neuro-endocrine-immune network. The physiological 
mechanism of stress effect on pregnancy has been discussed in chapter I. 
 
In animal studies it has been shown that sound stress induces miscarriages in mice by up-
regulating inflammatory factors, such as TNF-α (Knackstedt et al., 2003). In humans it has 
been reported that stress reduces the conception probability and high levels of stress are 
associated with an increased risk of miscarriage (Buck Louis et al., 2010, Ebbesen et al., 
2009, Sugiura-Ogasawara et al., 2002, Andalib et al., 2006, Arck et al., 2001) . For example, 
Boivin et al (2005) conducted a prospective epidemiological study with a large cohort of 818 
couples who underwent fertility treatments. They found that both men and women with 
higher levels of fertility stress were less likely to conceive than those with lower levels of 
stress. In addition, they found that this effect was more significantly pronounced in women 
than in men (Anthony et al., 2007).  Arck et al (2008) also examined a large cohort of 1098 
women and found that high stress levels were associated with an increased risk of subsequent 
miscarriages in the first trimester of pregnancy (Arck et al., 2008). Another large 
epidemiological study based on UK population investigated 603 women with a recent 
miscarriage in the first trimester compared with 6116 women without a recent miscarriage. 
They found that stress is a risk factor of miscarriage (Maconochie et al., 2007), confirming 
that stress plays a role in miscarriage. 
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However, in contrast to the above studies, there are some studies which found a negative 
association between stress and miscarriage. For example, a prospective study investigating 
783 women found that anxiety and depression had no impact on pregnancy rates in IVF 
treatment (Lintsen et al., 2009). Studies also found that psychological stress had no effect of 
increasing the risk of miscarriage in a subsequent pregnancy (Nelson et al., 2003b, Nelson et 
al., 2003a). Furthermore, one study showed that high stress levels were associated with a 
better pregnancy outcome rather than miscarriage (Cooper et al., 2007).   
  
The reason for the above conflicting findings may be due to the variation in the psychometric 
measures used to assess stress. To address this issue, we searched for the relevant articles on 
the association between stress and miscarriage in Pubmed, using a combination of the 
following search terms: stress and miscarriage, stress and pregnancy loss, emotion and 
miscarriage/pregnancy loss and psychology and miscarriage/pregnancy loss. Table IV-2 
shows the psychological instruments employed in current studies to examine the relationship 
between stress and miscarriage. 
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Table IV 2. Studies on the association between stress and miscarriage 
Authors Study population Controls  Psycho-parameters measured Findings  
Cooper et al., 
2009 
783 women in their first IVF or 
ICSI 
No Dutch version of the State Anxiety Inventory 
the Beck Depression Index for primary care 
Dutch version of The State–Trait–Anxiety Inventory 
Neither anxiety nor depression affected the ongoing pregnancy rates.  
Arck et al., 
2008 
55 women with a subsequent 
miscarriage between 4 to 12 
weeks of gestation 
809 women with a 
progressing pregnancies 
beyond 20 weeks of gestation 
PSQ short version 
The Quality of Life 
The Short Form 12 
Depressive symptoms 
Social Support (SOZU) 
Women who subsequently miscarried perceived higher levels of stress than those who had 
successful pregnancies. 
Maconochie 
et al., 2007 
603 women with a recent 
miscarriage in the first trimester 
6116 women with a 
pregnancy beyond 12 weeks 
Interviews on social demographic factors and behavioural factors Feeling stressed  is associated with a high risk of miscarriage 
Cooper et al., 
2007 
129 couples undergoing their first 
IVF 
No  Fertility Problem Inventory Women who had a live birth (defined as >20 weeks) scored significantly higher in the 
negative view of a child-free lifestyle scale and the need for parenthood scale than those 
who miscarried. High stress is associated with a better pregnancy outcome rather than 
miscarriage.  
Nelson et al., 
2003 
98 women with a spontaneous 
miscarriage  
228 pregnant women Perceived Stress Scale 
Prenatal Social Environment Inventory 
Index of Spousal Abuse 
High levels of psychological stress are not associated with risks of miscarriage. The 
influence of stress on miscarriage is not clear.  
Nelson et al., 
2003 
174 women experienced a 
spontaneous miscarriage 
798 women with ongoing 
pregnancies >22 weeks 
using the Center for Epidemiologic Studies Depression Scale 
the Life Oriented Test-Revised 
There was no association between depression and optimism and miscarriage.  
Arck et al., 
2001 
94 women with a miscarriage in 
the first trimester 
No  German version of Perceived Stress Questionnaire 
WHO-Quality of Life 
Social Support (SOZU K22) 
Women with miscarriage who had higher stress scores were associated with higher 
numbers of immunocompetent cells such as MCT+, CD8+ T cells and TNF α cells. Stress 
may modulate immunological factors which cause miscarriage 
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Stress and RM 
Recurrent miscarriage (RM) is a particularly frustrating condition, causing pronounced 
psychological distress in couples who desire to have children. Studies have shown that apart 
from having grief, depression and low self-esteem symptoms, couples also reported changes 
in sexuality and communication difficulties after RM (Serrano and Lima, 2006). It has been 
found that approximately 32% of women also develop depression and anxiety following RM 
(Klock et al., 1997).  
 
Although there are an increasing number of studies reporting on the impact of stress on 
miscarriage, few studies have been published examining the association between stress and 
RM. We searched on Pubmed for all the relevant articles using a combination of the 
following search terms: stress and recurrent miscarriage, stress and repeated pregnancy loss, 
emotion and recurrent miscarriage, and stress and habitual miscarriage. The articles related to 
the searched papers were also searched to avoid missing any relevant reference. Only six 
relevant studies were identified in Pubmed. However, among these six papers, two of them 
were written in German and one of them was written in French. Therefore, the remaining 
three studies were obtained. Table IV-3 illustrates the psychological measurements used in 
these three studies to assess stress in women with RM. Among these three studies, one study 
examined both the psychological and physiological risk factors of RM and found that 
psychological factors were less important than pathological abnormalities in the cause of RM. 
In their study pathological abnormalities showed a more significant association with 
miscarriages than psychological factors (Bergant et al., 1997).  Another study critically 
examined the role of stress in RM combining both psychological measurements and 
biochemical measurements. They found that women with RM had higher stress scores than 
fertile women and high stress scores were associated with an elevated activity of peripheral 
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natural killer cells, suggesting that psychological stress may contribute to RM through the 
effect of modulating immunological functions (Andalib et al., 2006). This finding was 
supported by a prospective study which showed that depression was associated with a high 
risk of miscarriage in a subsequent pregnancy in women with RM, suggesting that stress is a 
contributory factor of RM (Sugiura-Ogasawara et al., 2002). However, due to the paucity of 
studies in this area, whether or not stress is a cause of RM is still not clear. 
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Table IV 3. The psychological measurements used in studies on the relationship between stress and RM 
Authors Study population Control population Psychological instruments Findings 
Andalib et al., 2006 45 women with three or more 
previous miscarriages 
45 multi-parous women without a 
history of miscarriage 
Life Change Units 
the Beck Depression Inventory 
Women with RM had significant higher scores in 
depression scale than controls. 
Bergant et al., 1997 
 
 
 
36 women with more than two 
previous consecutive miscarriages 
36 controls without RM and 
matched for age and occupation 
The State–Trait–Anxiety Inventory 
The ‘Giessener Beschwerdebogen’ 
The Life Satisfaction Questionnaire 
The Beck Depression Inventory 
No significant difference in the stress measurements was 
found between study population and controls. 
Psychological factors is less importance as a cause for RM. 
Sugiura-Ogasawara et 
al., 2002 
60 couples with more than two 
previous consecutive miscarriages 
No Symptom Checklist-90 Revised 
The NEO Five Factor Index 
Semi-structured Interviews 
High scores in depression is associated with an increased 
risk of a subsequent miscarriage. 
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Although researchers have endeavored to study the relationship between stress and 
miscarriage, there have been few efforts engaged on developing a specific questionnaire to 
measure miscarriage-related stress. To date most studies examined miscarriage-related stress 
with a variety of standard psychological instruments which measured personality, anxiety, 
depression and health status, etc (see table IV-1). There was no standardized psychological 
instrument with the advantage of reliability, validity and sensitivity in measuring specific 
stress related with miscarriage.  
 
Concerning this issue, a few studies have been conducted with the aim of developing a valid, 
sensitive and reliable questionnaire to measure stress related to fertility problems (Newton et 
al., 1999, Lok et al., 2004, Lee et al., 1997). Newton et al (1999) conducted a prospective 
study sampling 1,153 women and 1,149 men with infertility problems in order to develop a 
reliable instrument to assess infertility-related stress. They found that the Fertility Problem 
Inventory (FPI) was a reliable and sensitive self-report instrument which could identify an 
individual’s global level of infertility-related stress (Newton et al., 1999).  
 
46 items were selected to construct the FPI with good reliability and responsiveness. These 
questions typically addressed marital relationships, social relationships, sexual relationships, 
parenthood, childfree view, general quality of life, anxiety and depression, etc. This 
multidomain questionnaire comprised five relevant independent scales, measuring five 
psychometric domains of social concern, sexual concern, relationship concern, the need for 
parenthood and rejection of a childfree lifestyle. Furthermore, a comprehensive score 
summing across all five scales was used as a global measure of the level of perceived 
infertility-related stress. All five scales and the composite total scale showed high internal 
consistency (Social concern=0.87, Sexual concern=0.77, Relationship concern=0.82, 
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Rejection of childfree lifestyle=0.80, Need for parenthood=0.84 and Global stress=0.93), 
suggesting that each of the scales was composed of a relatively homogeneous set of items 
which yield producible and consistent results. The Test-retest reliability of FPI was 0.83 for 
women and 0.84 for men, indicating the greater reliability of responsiveness over time. The 
discriminant validity of FPI was 0.45 and the convergent validity of FPI was significant 
(ρ<0.01), suggesting that the questionnaire was measuring separate but related dimensions of 
fertility-related stress. Currently, the FPI inventory is widely used as a reliable instrument in 
the assessment of fertility-related stress. In the present study we employed FPI as the 
principal psychometric measure to assess the stress status in women with unexplained RM. 
 
Although there is an increasing body of studies on the relationship between stress and 
miscarriage, few efforts have been made to examine the association between stress and RM. 
Due to the paucity of studies in this area it is still not clear whether stress is a consequence of 
RM or a cause of RM. Therefore, we conducted this prospective study in a cohort of women 
with unexplained RM. The aim of the present study was to i) examine the role of stress in 
RM by comparing the stress levels between women with unexplained RM and fertile 
controls; ii) examine the effect of Tender Loving Care on stress reduction by comparing the 
change of stress levels before and after clinical care; iii) examine the prognostic value of 
stress on the subsequent conception and pregnancy outcome. 
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II. Materials and Methods 
1 Subjects 
A total of 36 women with unexplained RM (case group) and 30 female fertile volunteers 
(control group) were included in this study. They all met the inclusion criteria of the study. 
The case group was assessed with a questionnaire package on two occasions during the study 
period in accordance with the study protocol. The first assessment was measured at the time 
of initial recruitment (baseline assessment). After the clinical consultation, explanation and 
reassurance by a team of dedicated staff, the participants were assessed again with the 
identical questionnaire package at a follow-up visit (follow-up assessment) prior to 
conception. The control group was assessed with the same questionnaire package only once 
at the time of recruitment. 
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2 Methods 
A comprehensive questionnaire package (Appendix VI) was used in this study to measure the 
psychological stress levels in the case group and control group. To prevent data invalidation 
associated with missing data, the investigator double checked the questionnaire answers on 
obtaining it from the participants to ensure that each of the questions was answered and the 
answer was interpretable. The pre-designed questionnaire package consisted of three 
validated individual instruments, including the Fertility Problem Inventory (FPI), the 
Perceived Stress Scale (PSS) and the Positive and Negative Affect Schedule (PANAS). The 
questions in these questionnaires were brief, clear, easily understood and easy to response. 
The validity, reliability and sensitivity of these instruments have been testified through a 
large body of research (Newton et al., 1999, Cohen et al., 1983, Watson, 1988). The 
copyright permissions were obtained from the authors and the authorized organizations 
(Appendix VII).  
 
• The Fertility Problem Inventory (FPI)  
FPI was developed by Newton et al to evaluate fertility problem stress. It had 46 items and 
comprised five constructs including Social Concern, Sexual Concern, Relationship Concern, 
Need for Parenthood, and Rejection of Childfree Lifestyle. Each of the five scales was 
composed of a relatively homogeneous set of items measuring the intended psychometric 
domain. A 6-point ordinal scale was referred in the scoring of FPI, categorizing the response 
from ‘1= strongly disagree’ to ‘6 = strongly agree’. The scale score was obtained from 
reversing the scores on some items and summing up each raw score of the multiple items in 
each scale. The composite measure of the global stress of FPI was also obtained by summing 
across all five scales. High scores in the psychometric domain of Social Concern were 
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interpreted as more sensitivity to reminders, comments and questions about infertility, 
feelings of alienation or isolation from peers and difficult in social activities. High scores in 
the domain of Sexual Concern were interpreted as loss of sexual enjoyment, feeling pressure 
to schedule sex and loss of sexual self-esteem. High scores in the scale of Relationship 
Concern were interpreted as having communication difficulties about infertility problems and 
future relationship concerns. High scores in the domain of Rejection of Childfree Lifestyle 
were interpreted as having negative view of childfree lifestyle or status. High scores in the 
scale of Need for Parenthood reflected a close identification with the role of parent. High 
scores of global stress reflected high levels of perceived infertility-related stress. The FPI has 
demonstrated a good reliability, sensitivity and validity (Newton et al., 1999). 
 
• The Perceived Stress Scale (PSS)  
PSS was developed by Cohen et al to evaluate the stressfulness of the situations in the past 
month of individuals’ lives. It is an empirically established index of general stress appraisal 
and is a most widely used psychological instrument for measuring the perception of stress. It 
was a 10-item self report questionnaire and relatively free of content to any population group. 
The items were designed to reflect how unpredictable, uncontrollable and overloaded that the 
respondents found their lives (Cohen et al., 1983). A 4-point scale rating from ‘0= never’ to 
‘4= very often’ was referred to rank the successive degrees of each item. The scale score was 
obtained from reversing the scores on some items and then summing the scores across all 10 
items. High scores of PSS indicated a high level of stress.  
 
• The Positive and Negative Affect Schedule (PANAS)  
PANAS was developed by Watson et al to briefly measure independent mood factors of the 
positive and negative affects which related to personality states and traits. It consisted of 10 
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positive affects (interested, excited, strong, enthusiastic, proud, alert, inspired, determined, 
attentive and active) and 10 negative affects (distressed, upset, guilty, scared, hostile, 
irritable, ashamed, nervous, jittery and afraid) (Watson, 1988). PANAS measured the extent 
to which the respondents had experienced these different emotions and feelings within the 
past week. The reliability of PANAS instrument was 0.89, suggesting that it was composed 
of a relatively homogeneous set of items (Crawford and Henry, 2004). A 5-point scale was 
referred in the scoring of PANAS, rating from 1 to 5 increasingly. PANAS was scored by 
simply summing up the raw scores of each scale. Respondents with a sum-score above 25 in 
the Positive Affects scale were suggested to be more optimistic and those with scores above 
25 in the Negative Affects scale were suggested to be more pessimistic.  
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III. Statistical Analysis 
Statistical analyses were performed using the SPSS (Statistical Package for the Social 
Sciences) version 16. Differences in the scores of the stress measurements intergroup and 
intragroup were analyzed by independent t tests. The comparison of the scores of stress 
measurements between the two assessments were analyzed by paired t tests. The correlation 
between the scores of psychometric measurements and plasma prolactin concentrations was 
analyzed by Pearson correlation coefficient test. Statistical significance was set at p value 
<0.05. 
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V. Results 
1. The demographic characteristics of the study population 
A total of 36 women with unexplained RM were included in the study population. They all 
completed two questionnaires at the time of baseline assessment and the follow-up 
assessment respectively. The demographic characteristics of these 36 women are shown in 
table IV-4. No significant correlation between the psychometric measurements and the age or 
the number of previous miscarriages was found in these 36 cases (ρ>0.05) (table VI-5). There 
was also no significant association between plasma prolactin measurements and the results of 
psychometric parameters (ρ>0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
Table IV 4. Demographic characteristics of the 36 women with unexplained RM 
Women with unexplained RM 
n = 36 
Age (years) 35.9 ± 4.6 
No. of previous miscarriages (n) 
(median, range) 
 
4 (3-8) 
BMI (kg/cm
2
) 25.8 ± 4.7 
FSH (IU/l) 6.5 ± 2.3 
LH (IU/l) 5.1 ± 2.2 
Oestradiol (pmol/l) 174.3 ± 58.3 
Progesterone (nmol/l) 40.6 ± 15.3 
FAI 2.8 ± 2.0 
Prolactin (mIU/l) 191.9 ± 121.7 
Type of RM 
( n, % )  
Primary RM 24 (66.67%) 
Secondary RM 12 (33.33%) 
Family history of RM 
( n, % ) 
yes 8 (22.2%) 
no 28 (77.8%) 
All values are shown in the form of mean ± SD unless otherwise specified. 
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Table IV 5. The correlation between psychometric measures and the demographics of the 36 cases 
 Age (years) No. of previous miscarriages 
Infertility Problem Inventory 
global scores 
 
ρ = 0.95 
 
ρ = 0.13 
 
 
Subscales 
Relationship Concern ρ = 0.72 ρ = 0.07 
Sexual Concern ρ = 0.65 ρ = 0.11 
Need for Parenthood ρ = 0.71 ρ = 0.19 
Rejection of Childfree Lifestyle ρ = 0.72 ρ = 0.69 
Social Concern ρ = 0.85 ρ = 0.68 
Perceived Stress Scale ρ = 0.43 ρ = 0.47 
PANAS Positive Affect ρ = 0.61 ρ = 0.25 
PANAS Negative Affect ρ = 0.61 ρ = 0.25 
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2. The differences in stress measurements between cases and controls 
 The scores of stress measurements of the 36 cases and 30 controls are shown in table IV-6. 
Cases had significantly higher global scores of the Fertility Problem Inventory than controls 
(p<0.05). The same pattern was shown in its subscales of Sexual Concern, Need for 
Parenthood, Rejection of Childfree Lifestyle and Social Concern (p<0.05). Cases also had 
significantly higher scores in the Perceived Stress Scale and the PANAS Negative Affect 
scale, and significantly lower scores in the PANAS Positive Affect scale than controls 
(p<0.05).   
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Table IV 6. Differences in the scores of psychometric measurements between cases and controls 
 case group 
N=36 
Control group 
N=30 
P value 
 
Age (years) 
 
35.9 ± 4.6 
 
34.0  ± 6.1 
 
ρ >0.05 
Infertility Problem Inventory 
global scores 
 
162.0 ± 35.2 
 
137.2  ± 35.2 
 
ρ <0.05* 
 
 
Subscales 
Relationship Concern 28.4 ± 10.6 27.6  ± 9.1 ρ >0.05 
Sexual Concern 24.5 ± 8.8 19.0  ± 9.5 ρ <0.05* 
Need for Parenthood 43.6 ± 9.4 36.7  ± 7.5 ρ <0.05* 
Rejection of Childfree Lifestyle 31.1 ± 8.7 26.4  ± 7.1 ρ <0.05* 
Social Concern 34.5 ± 11.7 27.4  ± 10.3 ρ <0.05* 
Perceived Stress Scale 21.2  ± 7.5 16.56  ± 4.2 ρ <0.05* 
PANAS Positive Affect  29.4  ± 9.9 36.8  ± 5.3 ρ <0.05* 
PANAS Negative Affect 25.1  ± 9.7 18.4  ± 5.0 ρ <0.05* 
All the values are in the form of mean ± SD. 
* significant 
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3. The association between stress and conception outcomes 
Of the 36 cases, 26 of them subsequently conceived during the study period and 10 of them 
did not conceive. Table IV-7 shows the results of stress measurements of these two 
subgroups in the two assessments. There was no significant difference in the stress scores 
between the pregnant group and the non-pregnant group in the baseline assessment or in the 
follow-up assessment (p>0.05). No significant difference in the numbers of previous 
miscarriages was found between the pregnant group and non-pregnant group (p>0.05).  Age 
was the only significant factor associated with conception outcomes. Women who conceived 
again were younger than those who did not, as we expected (p<0.05).  
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Table IV 7. Differences in the demographics and the scores of psychometric measurements between cases 
with different conception outcomes 
 Pregnant group 
N=26 
Non-pregnant group 
N=10 
P value 
 
Age (years) 
(mean ± SD, range) 
 
34.9 ± 4.7 
(34-42) 
 
38.6 ± 2.9 
(25-42) 
 
ρ <0.05* 
No. of previous miscarriages 
(median, range) 
4.0 (3-6) 4.0 (3-8) ρ >0.05 
Baseline assessment 
Infertility Problem Inventory 
global scores  
 
164.5 ± 37.6 
 
155.4  ± 28.5 
 
ρ >0.05 
 
 
Subscales 
 
Relationship Concern 29.0 ± 11.7 26.6  ± 7.2 ρ>0.05 
Sexual Concern 24.5 ± 9.2 24.4  ± 8.2 ρ >0.05 
Need for Parenthood 43.3 ± 8.4 44.1  ± 12.1 ρ >0.05 
Rejection of Childfree Lifestyle 31.3 ± 8.9 30.4  ± 8.5 ρ >0.05 
Social Concern 36.3 ± 10.5 29.9  ± 13.8 ρ >0.05 
Perceived Stress Scale 21.8  ± 7.6 19.5  ± 7.2 ρ >0.05 
PANAS Positive Affect 28.4  ± 9.8 31.8  ± 10.4 ρ >0.05 
PANAS Negative Affect 25.8  ± 8.4 23.3  ± 12.9 ρ >0.05 
Follow-up assessment 
Infertility Problem Inventory 
global scores 
162.6 ± 18.0 161.5 ± 33.6  
ρ >0.05 
 
 
Subscales 
Relationship Concern 30.4 ± 7.1 31.6 ± 5.6 ρ >0.05 
Sexual Concern 22.7 ± 5.1 26.0 ± 9.7 ρ >0.05 
Need for Parenthood 43.4 ± 5.8 41.9 ± 10.2 ρ >0.05 
Rejection of Childfree Lifestyle 31.4 ± 5.9 31.9 ± 7.3 ρ >0.05 
Social Concern 34.7 ± 5.6 30.1 ± 11.8 ρ >0.05 
Perceived Stress Scale 19.8 ± 4.0 17.5 ± 5.1 ρ >0.05 
PANAS Positive Affect 30.9 ± 5.8 32.2 ± 5.6 ρ >0.05 
PANAS Negative Affect 24.8 ± 6.3 22.1 ± 9.5 ρ >0.05 
All the values are shown in the form of mean ± SD unless otherwise specified. 
*significant 
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4. The association between stress measurements and pregnancy outcomes 
Among the 26 cases who subsequently conceived, 22 of them conceived spontaneously and 4 
of them conceived through the assisted conception techniques. Of these 26 pregnancies, 18 
(69.2%) of them were live births and 8 (30.8%) of them resulted in miscarriage again.  The 
results of stress measurements of these two subgroups are shown in table IV-8. There was no 
significant difference in the age and the number of previous miscarriages between the two 
subgroups. The significant factors associated with pregnancy outcomes were the scores of the 
PANAS Positive Affect scale and the Perceived Stress Scale. In the baseline assessment the 
live birth group had significantly lower scores in the PANAS Positive Affect Scale and 
significantly higher scores in the Perceived Stress Scale than the miscarriage group (p<0.05). 
In the follow-up assessment the live birth group also had significantly lower scores in the 
PANAS Positive Affect Scale than the miscarriage group (p<0.05). No significant difference 
in the scores of the Fertility Problem Inventory was found between the two subgroups in the 
two assessments. 
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Table IV 8. A comparison of the results of stress measurements of 26 cases with different pregnancy 
outcomes 
 Live birth group 
N=18 
Miscarriage group 
N=8 
P value 
Age (years) 35.0 ± 4.6 34.5 ± 5.3 ρ > 0.05 
No. of previous miscarriages (n) 
(median, range) 
4.0 (3-6) 4.0 (3-8) ρ > 0.05 
Baseline assessment 
Infertility Problem Inventory 
global scores 
166.6 ± 30.6 159.9  ± 52.4 ρ > 0.05 
 
 
Subscales 
 
Relationship concern 29.0 ± 10.6 29.1  ± 14.6 ρ > 0.05 
Sexual concern 24.3 ± 7.9 25.0  ± 12.3 ρ > 0.05 
Need for parenthood 44.1 ± 7.5 41.8  ± 10.6  ρ > 0.05 
Rejection of childfree 
lifestyle 
31.5 ± 8.5 31.0  ± 10.5 ρ > 0.05 
Social concern 37.8 ± 8.0 33.0  ± 14.8 ρ > 0.05 
Perceived Stress Scale 23.8  ± 6.1 17.5  ± 9.3 ρ < 0.05* 
PANAS Positive Affect 25.0  ± 7.1 36.1  ± 11.1 ρ < 0.05* 
PANAS Negative Affect 26.7  ± 7.2 24.0  ± 10.9 ρ > 0.05 
Follow-up assessment 
Infertility Problem Inventory 
global scores 
164.1 ± 16.6 159.2 ± 21.8 ρ > 0.05 
 
 
subscales 
Relationship concern 30.2 ± 7.3 30.9 ± 7.1 ρ > 0.05 
Sexual concern 24.3 ± 4.7 19.0 ± 4.4 ρ > 0.05 
Need for parenthood 43.5 ± 5.3 43.0 ± 7.0 ρ > 0.05 
Rejection of childfree life style 31.9 ± 6.2 30.5 ± 5.4 ρ > 0.05 
Social concern 34.1 ± 4.7 35.9 ± 7.5 ρ > 0.05 
Perceived Stress Scale 19.5 ± 4.1 20.5 ± 3.8 ρ > 0.05 
PANAS Positive Affect 29.0 ± 4.5 35.1 ± 6.6 ρ < 0.05* 
PANAS Negative Affect 24.5 ± 6.4 25.5 ± 6.4 ρ > 0.05 
All the values are shown in the form of mean ± SD unless otherwise specified. 
*significant 
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5.  The stress status of the 36 cases before and after ‘tender loving care’ 
The results of the stress measurements of the 36 cases in the baseline assessment and in the 
follow-up assessment are shown in table IV-9. No significant difference in the stress scores 
of each psychometric parameter was found between the two assessments in this group of 
women. Table IV-10 shows the results of stress measurements at the baseline assessment and 
the follow-up assessment of the 36 cases with different conception outcomes. There was no 
significant difference in stress measurements of the pregnant group and the non-pregnant 
group between the two assessments.  
 
Table IV-11 shows the results of stress measurements of the 26 cases with different 
pregnancy outcomes at the two assessments. In the live birth subgroup of 18 cases, there were 
significant differences in the scores of Perceived Stress scale and Social Concern scale 
(p<0.05) between the two assessments. The levels of perceived stress and social relationship 
concerns in live birth subgroup reduced significantly after receiving ‘tender loving care’ 
whereas no stress reduction was found in the miscarriage subgroup after receiving ‘tender 
loving care’. 
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Table IV 9. The results of psychometric measurements of the 36 cases at the baseline assessment and the 
follow-up assessment 
 Baseline stress assessment 
N=36 
Follow-up stress assessment 
N=36 
P value 
Infertility Problem Inventory 
global scores 
 
162.0 ± 35.1 
 
162.3  ± 22.9 
 
ρ >0.05 
 
 
Subscales 
 
Relationship concern 28.4 ± 10.6 30.8  ± 6.6 ρ >0.05 
Sexual concern 24.5 ± 8.8 23.6  ± 6.7 ρ >0.05 
Need for parenthood 43.6 ± 9.4 43.0  ± 7.1 ρ >0.05 
Rejection of childfree lifestyle 31.1 ± 8.7 31.5  ± 6.2 ρ >0.05 
Social concern 34.5 ± 11.7 33.4  ± 7.9 ρ >0.05 
Perceived Stress Scale 21.2  ± 7.5 19.2 ± 4.4 ρ >0.05 
PANAS Positive Affects 29.4  ± 10.0 31.2  ± 5.7 ρ >0.05 
PANAS Negative Affects 25.1  ± 9.7 24.0  ± 7.2 ρ >0.05 
All the values are shown in the form of mean ± SD. 
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Table IV 10. The results of stress measurements of the 36 cases with different conception outcomes at the baseline assessment and the follow-up assessment 
 Pregnant group 
(n=26) 
Non-pregnant group 
(n=10) 
Baseline assessment Follow-up assessment P value Baseline assessment Follow-up assessment P value 
Infertility Problem Inventory 
global scores 
 
164.5 ± 37.6 
 
162.6  ± 18.0 
 
ρ >  0.05 
 
155.4 ± 28.5 
 
161.5 ± 33.6 
 
ρ >  0.05 
 
 
Subscales 
 
Relationship concern 29.0 ± 11.7 30.4  ± 7.1 ρ >  0.05 26.6 ± 7.2 31.6 ± 5.6 ρ >  0.05 
Sexual concern 24.5 ± 9.2 22.7  ± 5.1 ρ >  0.05 24.4 ± 8.2 26.0 ± 9.7 ρ >  0.05 
Need for parenthood 43.3 ± 8.4 43.4  ± 5.8 ρ >  0.05 44.1 ± 12.1 41.9 ± 10.2 ρ >  0.05 
Rejection of childfree lifestyle 31.3 ± 8.9 31.4  ± 5.9 ρ >  0.05 30.4 ± 8.5 31.9 ± 7.3 ρ >  0.05 
Social concern 36.3 ± 10.5 34.7  ± 5.6 ρ >  0.05 29.9 ± 13.8 30.1 ± 11.8 ρ >  0.05 
Perceived Stress Scale 21.8  ± 7.6 19.8 ± 4.0 ρ >  0.05 19.5 ± 7.2 17.5 ± 5.1 ρ >  0.05 
PANAS Positive Affect 28.4  ± 9.8 30.9  ± 5.8 ρ >  0.05 31.8 ± 10.4 32.2 ± 5.6 ρ >  0.05 
PANAS Negative Affect 25.8  ± 8.4 24.8  ± 6.3 ρ >  0.05 23.3 ± 12.9 22.1 ± 9.5 ρ >  0.05 
All the values are shown in the form of mean ± SD. 
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Table IV 11. The results of stress measurements of the 26 cases with different pregnancy outcomes at the baseline assessment and the follow-up assessment 
 Live birth group 
(n=18) 
Miscarriage group 
(n=8) 
Baseline assessment Follow-up assessment P value Baseline assessment Follow-up assessment P value 
Infertility Problem Inventory 
global scores 
 
166.6 ± 30.6 
 
164.1  ± 16.6 
 
ρ >  0.05 
 
159.9 ± 52.4 
 
159.2 ± 21.8 
 
ρ >  0.05 
 
 
Subscales 
 
Relationship concern 29.0 ± 10.6 30.2  ± 7.3 ρ >  0.05 29.1± 14.6 30.9 ± 7.1 ρ >  0.05 
Sexual concern 24.3 ± 7.9 24.3  ± 4.7 ρ >  0.05 25.0 ± 12.3 19.0 ± 4.4 ρ >  0.05 
Need for parenthood 44.1 ± 7.5 43.5  ± 5.3 ρ >  0.05 41.8 ± 10.6 43.0 ± 7.0 ρ >  0.05 
Rejection of childfree lifestyle 31.5 ± 8.5 31.9  ± 6.2 ρ >  0.05 31.0 ± 10.5 30.5 ± 5.4 ρ >  0.05 
Social concern 37.8 ± 8.0 34.1  ± 4.7 ρ <  0.05* 33.0 ± 14.8 35.9 ± 7.5 ρ >  0.05 
Perceived Stress Scale 23.8  ± 6.1 19.5 ± 4.1 ρ <  0.05* 17.5 ± 9.3 20.5 ± 3.8 ρ >  0.05 
PANAS Positive Affect 25.0  ± 7.1 29.0  ± 4.5 ρ >  0.05 36.1 ± 11.1 35.1 ± 6.6 ρ >  0.05 
PANAS Negative Affect 26.7  ± 7.2 24.5  ± 6.4 ρ >  0.05 24.0 ± 10.9 25.5 ± 6.4 ρ >  0.05 
All the values are shown in the form of mean ± SD. 
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VI. Discussion 
The relationship between stress and RM 
Whether stress is a cause or a consequence of miscarriage has always been debated. Some 
studies have found evidence that stress levels in women with miscarriages are higher than 
women without miscarriages. In addition, high stress levels are found to be associated with a 
poor chance of conception and an increased risk of miscarriage, suggesting that stress is a 
causative factor of miscarriage (Buck Louis et al., 2010, Ebbesen et al., 2009). In this study 
we examined the stress status in women with unexplained RM in which other identifiable 
causes of RM had been excluded to allow stress as the factor affecting RM. We found that 
women with unexplained RM had higher levels of overall fertility-related stress and 
perceived stress and were more pessimistic than fertile women, supporting the notion that 
stress may be a contributory factor of RM. 
 
The association between stress and conception rate 
Although in this study we found high levels of stress in women with unexplained RM, it is 
still not clear whether high stress levels are a consequence of the previous miscarriages or are 
the causative factor of future adverse pregnancies. Therefore, we further examined the impact 
of stress on subsequent conception rates and pregnancy outcomes in this group of women. In 
this study we found no significant difference in stress levels between pregnant cases and non-
pregnant cases, suggesting that stress has no impact on subsequent conception rates.  
 
Our finding is in contrast with previous studies in which stress has been found to be 
associated with a poor chance of conception (Buck Louis et al., 2010, Klonoff-Cohen et al., 
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2001, Ebbesen et al., 2009). However, there are also some studies which have found a 
negative association between stress and conception chances. For example, one study 
examined a large cohort of 783 women undergoing IVF treatment using the State Anxiety 
Inventory and the Beck Depression Inventory. No significant difference in stress levels were 
found between women who conceived following IVF and those who did not, suggesting that 
psychological stress had no impact on pregnancy (Lintsen et al., 2009). Another study also 
found no effect of stress on subsequent conception performance in IVF treatment (Anderheim 
et al., 2005). Our finding is consistent with the findings from the above studies, supporting 
the notion that stress has no influence on conception rates. In our study only age was found to 
be the significant factor associated with conception rates. Younger women with RM had a 
better conception chance than older women, as we expected. Studies have also shown the 
rapid decline in the oocyte quality in IVF treatment and the decrease in conception rates in 
women older than 35 years (Ledger, 2009, Zhang et al., 2008), suggesting that fertility 
declines with advancing age.  
 
The association between stress and pregnancy outcome 
In the subgroup analysis on the association between stress and pregnancy outcomes, we 
found that cases with subsequent live births had higher stress scores in the Perceived Stress 
Scale and the Social Relationship Scale of the FPI than fertile women. Cases with live births 
also had significantly lower scores in the PANAS Positive scale than controls, suggesting that 
women with unexplained RM who are comparatively more stressed and less optimistic are 
more likely to have a better pregnancy outcome.  
 
This finding was unexpected and is contradictory to previous research where a positive 
association between stress and miscarriage was found (Klonoff-Cohen et al., 2001). 
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However, there are some studies which found a reverse association between stress and 
pregnancy outcomes. For example, one study investigated 129 couples in IVF treatment using 
the Fertility Problem Inventory (FPI). They found that both young and old couples with 
higher stress scores in Social Concern and Need for Parenthood scales subsequently had a 
higher pregnancy rate than those with lower stress scores. With regard to the rate of ongoing 
pregnancy (defined as a live birth at > 20 weeks of gestation), the same pattern was shown 
that couples with higher scores in the Fertility Problem Inventory had significantly higher 
ongoing pregnancy rates (Cooper et al., 2007), suggesting that moderate stress may be 
beneficial to successful pregnancy establishment according to the Yerkes-Dondson theory of 
moderate stress resulting in optimal performance (Yerkes and Dodson, 1908). 
 
In this study we also found that high stress levels were more likely to be associated with a 
better pregnancy outcome in women with RM. The discrepancies of the current findings on 
the impact of stress on pregnancy outcomes may be attributed to several factors. Firstly, apart 
from lack of consensus on the psychological instruments used to measure stress, the type of 
stress assessed is an important confounding factor in stress measurements in women with 
RM.  The nonspecific questionnaires used to predict pregnancy outcomes in current studies 
may cause bias. Some studies measured anxiety, relationship concerns or depression to 
examine the impact of stress on pregnancy whereas other studies measured personality, 
mood, generic health status or perceived stress. It is argued that the questionnaires used in the 
current studies may be inadequate to capture specific fertility stress. Studies have shown that 
general psychological characteristics, such as active and passive coping, personality 
characteristics, dependency, self-criticism and intrusiveness, are more important in measuring 
the variability of psychological distress in women with fertility problems than infertility 
specific concerns (Van den Broeck et al., 2010).  It has been proposed that measuring 
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pregnancy specific anxiety of worries or fears about pregnancy, childbirth, the health of the 
infant and future parenting, are more predictive on pregnancy outcomes than measuring 
general anxiety or depression (Huizink et al., 2004). It has also been suggested that stress 
coping strategies adapted by individuals may be a relevant factor in predicting pregnancy 
outcomes rather than stress measurements (Panagopoulou et al., 2006). The fact that a 
significant reduction in stress levels prior to the conception in the subgroup of cases with 
subsequent live births suggests that the coping strategy may have an effect on pregnancy 
outcomes. 
 
Secondly, a limitation of this study is that stress was measured at the time of initial 
recruitment and the follow-up time point before the subsequent pregnancies. The interval 
between the last stress assessment and a subsequent pregnancy varies from 1 month to 6 
months between participants. The stress status of these participants may change during this 
interval and thus may not truly reflect the pre-pregnant stress status. Therefore, stress 
measurements of non-conceptional cycle may be of limited value on predicting subsequent 
pregnancy outcomes. However, it is hardly practical to measure stress in each reproductive 
cycle in a clinical research in order to identify the exact pre-pregnant stress.  
 
Thirdly, the short-term nature of the study follow-up may prevent us from identifying the 
significance of the adverse effect of stress on pregnancy outcomes. In this study only 
pregnancies achieved in a short period of 6 months were taken into account in the study 
analysis. The pregnancies achieved beyond this period were not followed therefore 
pregnancies with poor or good prognosis may be over presented in this study. In a future 
study this bias should be avoided by following a longer period of fertility outcome of at least 
12 months.  
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The effect of ‘tender loving care’ on stress reduction 
In this study we hypothesized that ‘tender loving care’ in the form of clinical consultation, 
explanation and reassurance by the dedicated staff may help to reduce stress levels. However, 
we did not find an obvious effect of this type of tender loving care on stress reduction in 
women with RM. There was no significant stress reduction before and after the tender loving 
care in the whole study population of 36 women with RM. However, in the subgroup of 18 
cases with subsequent live births there was a small but significant stress reduction in the 
perceived stress scale and social concern scale, suggesting that this subgroup of women may 
respond to tender loving care better, which leads to their live births. This finding supports the 
notion that the stress coping strategies adapted by individuals are an important factor in 
predicting pregnancy outcomes rather than stress evaluation. 
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VII. Conclusion  
In this study, we found that women with RM had higher stress levels than fertile women, 
suggesting that high stress levels are associated with RM. The intensity of stress has no 
predictive value on subsequent conception rates. However, RM women who conceived again 
and who have relatively higher stress levels are less likely to miscarry. It is possible that RM 
women with more stress and concerns may adopt coping strategies or reduce their activities, 
leading to a better pregnancy outcome. 
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Chapter V: The relationship between natural killer cells and RM 
I. Introduction 
1 Morphology and phenotype of natural killer cells 
Natural killer (NK) cells are a subset of non-B, non-T peripheral lymphocytes regulating the 
innate immune response (Moretta et al., 1994). NK cells which comprise up to 15% of 
peripheral lymphocytes are the large granular lymphocytes expressing antigen receptors 
capable of recognizing and binding target cells. NK cells can mediate cell contact-dependent 
cytolysis of target cells which can express foreign major histocompatibility complex (MHC) 
molecules. This action can be exerted without prior sensitization and restriction by human 
leukocyte antigen (HLA) (Robertson and Ritz, 1990). The unique cell surface antigens of NK 
cells are CD56 and CD16. CD56 is expressed essentially on all NK cells and a small portion 
of cytotoxic T lymphocytes; CD16 is the receptor responsible for NK-mediated antibody-
dependent cellular cytotoxicity. There are two subsets of NK cells based on the intensity of 
CD56 expression. They are CD56
dim
 with low expression of CD56 and high expression of 
CD16 (CD56+16+); and CD56
bright
 with high expression of CD56 and low or no expression 
of CD16 (CD56+16-) (Cooper et al., 2001b).  
 
2 The role of peripheral NK cells in RM 
In peripheral blood, CD56
dim
 NK cells are predominant and more cytotoxic whereas 
CD56
bright
 cells which compose a small portion of total peripheral NK (pNK) cells are the 
main source of NK released immunoregulatory cytokines (Cooper et al., 2001a, Nagler et al., 
1989).  Studies have shown that the pre-pregnant stress levels may elevate the cytotoxity of 
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peripheral NK cells in women with RM (Andalib et al., 2006). It has also been found that 
increases of pNK cells in numbers and activities are associated with RM. Table V-1 
illustrates the current studies on the relationship between the NK cell alteration and RM. RM 
patients with high pNK activities have been found to have a significantly higher miscarriage 
rate in their subsequent pregnancies (Matsubayashi et al., 2001, Aoki et al., 1995). It has been 
demonstrated that women with RM and implantation failures have a significantly higher ratio 
of CD56
bright
 pNK cells expressing TNFα (tumour necrosis factor-α)/GM-CSF (granulocyte-
macrophage colony-stimulating factor) than fertile controls (Fukui et al., 2008). A 
longitudinal study comparing the pre- and post-conceptional profile of NK cells between 
women with RM and fertile controls, suggested that in preconception the number and 
cytotoxicity of peripheral CD56+/CD16+ NK cells were similar between women with RM 
and fertile controls. However, during early pregnancy, women with RM expressed a higher 
number of CD56+/CD16+ NK cells compared to fertile controls, paralleled with an increase 
in cytotoxicity of NK cells (Emmer et al., 2000), suggesting that the increase in the subset of 
CDdim pNK cells may be the cause of RM. 
 
However, to date it is disputed whether pNK alteration in RM subjects is due to the effect of 
RM or merely a sympathetic response to venipuncture stress. Significant increases in pNK 
number and activity of women with RM have been found immediately after peripheral 
venous cannulation, compared with fertile controls. However, 20 minutes after cannulation 
there was no difference in the pNK measurement between the two groups (Shakhar et al., 
2006), suggesting that high sympathetic responsiveness to venipuncture stress in RM subjects 
may be responsible to the pNK alteration.  
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Table V 1. Studies on the relationship between pNK cells and RM 
Authors RM Criteria Study Group Control Group Diagnostic Definition Results Findings 
King et al.,  
2010 
3 or more 
consecutive 
previous 
miscarriage 
104 non-pregnant 
RM subjects 
33 fertile women 1. NK cells and the CD56dim subset were 
expressed as a percentage of lymphocytes 
as well as absolute number.  
2. The activated CD69+CD56dim subset 
was expressed as a percentage of 
CD56dim cells as well as an absolute 
number 
RM subjects had significantly higher NK percentage and lower 
CD56bright/CDdim ratio than controls. 
 
The percentage of pNK 
increased in RM women, 
especially in women with 
unexplained RM. 
Fukui et al., 
2008 
2 or more 
previous 
spontaneous 
miscarriages 
25 women with RM 20 women with 
implantation 
failures 
15 fertile healthy 
women 
The expression of type-1 cytokines of 
TNFα, IFNγ, GM-CSF and IL-4,5,10 and 
13 were measured to determine the 
cytokine shift in NK cells 
NK cells with  TNFα/GM-CFS expression or  IFNγ expression were 
significantly higher in women with RM or implantation failures than 
fertile controls. 
Increases in type 1 cytokine 
expression on NK cells are 
associated with RM.  
Perricone et al., 
2006 
3 or more 
consecutive 
previous 
miscarriages 
394 non-pregnant 
RM subjects; 187 
pregnant RM 
subjects 
42 fertile non-
pregnant women 
Did not mention 1. Non-pregnant RM subjects had higher absolute numbers of NK cells 
than non-pregnant fertile women 
2. Pregnant RM subjects had significantly higher numbers of NK cells at 
first trimester than fertile pregnant women 
1. Increased NK cells are 
associated with pregnancy loss. 
2. NK levels should always be 
evaluated in women with RM 
Emmer et al., 
2000 
2 or more 
previous 
unexplained 
miscarriages 
43 women with RM 37 fertile women The percentage of NK cell cytotoxicity 
was determined as: 
% lysis= (sample value – spontaneous 
release)/ (maximum release-spontaneous 
release) 
 
 
1. Before pregnancy, levels of NK cytotoxicity and numbers of both 
single CD56+ and CD56+/CD16+ were similar between RM women and 
controls 
2. Women with RM had higher number of CD56+CD16+ paralleled with 
the increases in cytotoxicity during early pregnancy than controls. 
However, single CD56+ numbers decreased in pregnant women with 
RM. 
3. Between RM group, women with NK cells <12% had a positive 
association with a subsequent live birth. 
1. Analysis of pNK cell profile 
is of diagnostic value in RM. 
2. NK cell cytotoxity appears 
promising in RM diagnosis. 
Michou et al., 
2003 
2 or more 
consecutive 
previous 
miscarriages 
25 women with RM; 
30 women with 
sporadic previous 
miscarriages; 33 
infertile women 
11 fertile women 1. Percentage of CD56+/CD16- in the total 
peripheral blood NK cell is given by the 
measurement of the CD3- cells (CD3- are 
estimated by gating on the 
CD56PE/CD16FITC primary lymphocyte 
analysis distribution). 
2. Percentage of uNK cells was counted as 
a fraction of the total NK cell population 
1. Study group had significantly higher CD56+/CD16- fraction than 
fertile controls. 
2. Study group had significantly higher concentration of CD56+/CD16- 
cells than fertile controls. 
3. Women with sporadic miscarriage and infertile women had 
significantly higher NK cell number than fertile controls. 
The fraction of the 
concentration of CD56+/CD16- 
cells in total NK cells could be 
used as an indicator of 
subsequent successful 
pregnancy.  
Yamada et al., 
2003 
2 or more 
previous 
miscarriages 
85 women with RM no Did not mention CD56+ NK cell activities and numbers in RM subjects following a 
subsequent miscarriage (n=26) were higher than those with live birth 
(n=59).  
High activity and number of 
pre-conceptional CD56+ NK 
cells were predictive of 
spontaneous miscarriage 
Aoki et al., 
1995 
2 previous 
unexplained 
miscarriages 
68 women with RM 47 fertile women High level of NK activity was defined as 
the mean + 1SD of NK activity in controls 
1. Women with RM had higher NK activity (39.4%) than controls 
(29.0%) 
2. Women with high level of NK activity had a much higher miscarriage 
rate (71%) than those with normal NK activity (20%) 
Raised NK cell activity may be 
the cause of miscarriage and 
may be used as a predictor of 
pregnancy loss. 
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3 The role of uterine NK cells in RM 
Recently, the importance of the uterine in situ environment in RM has been paid more 
attention. Endometrial leukocytes constitute about 10% of stromal cells in the proliferative 
phase and increase to 20% in the secretory phase; in early pregnancy, they accumulate 
consistently to 30-40% in decidua and implantation sites (King et al., 1991). NK cells 
dominate the endometrial leukocyte population and are referred to as uterine NK (uNK) cells 
(Bulmer et al., 1991). The number of uNK cells changes during the menstrual cycle. They are 
few in the proliferative phase and increase significantly in the secretory phase (Trundley and 
Moffett, 2004). In the first trimester of normal pregnancy up to 70% of decidual lymphocytes 
are NK cell, namely decidual NK (dNK) cells (Moffett-King, 2002). uNK cells accumulate 
around spiral arteries and endometrial glands in the late secretory phase of endometrium and 
early pregnancy decidua. The time and the site of uNK expression suggest that uNK may play 
an important role in immunoregulation and angiogenesis in early pregnancy (Quenby et al., 
2009). Yet to date the precise mechanism of uNK function is not clear. 
 
The CD56+ population constitutes mainly uNK and dNK cells(Moffett et al., 2004). It is 
suggested that uNK may derive from blood CD56
dim
 population, formed from stem cell 
precursors in bone marrow and migrate to endometrium where they proliferate and 
differentiate in situ (Chantakru et al., 2002). Table V-2 shows the phenotypic differences 
between pNK and uNK cells (Dosiou and Giudice, 2005).  
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Table V 2. Expression of surface antigens on NK cells 
Antigen  Peripheral NK (CD56dim) uNK (CD56bright) 
CD2 (early T cell marker) + + 
CD7 (early T cell marker) +  + 
CD18 (integrin) + + 
CD16 (NK marker) + - 
CD45 (hematopoietic cell) + + 
CD56 (NK marker) + + 
CD57 (NK marker) + - 
CD62L (adhesion molecule) +/- - 
CD69 (activation marker) - + 
KIR (NK marker) + + 
c-kit (cytokine receptor) - + 
IL-2Rβ (cytokine receptor) + + 
This table was adapted from ref. (Dosiou and Giudice, 2005) 
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The majority of uNK cells are CD56
bright
 CD16- NK cells with high affinity of IL-2 receptors 
(Rai et al., 2005, Nishikawa et al., 1991). uNK cells also express CD38 and CD69 
phenotypically, but lack expression of CD3, CD4, CD8 and CD57. Among these uNK 
phenotypes, CD56+ and CD38+ cells increase from nonpregnant state of endometrium up to 
75% in the first trimester decidua (Moffett-King, 2002, Bulmer et al., 1991). dNK cells also 
express higher intensities of CD56 markers (Koopman et al., 2003, Hill et al., 1995). Double 
immunohistochemical labelling for decidual CD56+ and CD38+ completely overlaps 
(Bulmer et al., 1991), suggesting  that CD56+ is the predominant NK cell subset of decidua. 
 
3.1 uNK cells in normal pregnancy 
The role of uNK in normal pregnancy is uncertain. A review concluded that there are several 
possible functions of uNK, including the regulation of placental and trophoblast growth, 
implantation, decidual vascularisation via mediating cytokines (GM-CSF, CSF-1) and the 
involvement of trophoblast invasion (Dosiou and Giudice, 2005). It has been demonstrated 
that in nonpregnant endometrium, uNK cells are closely located to stromal cells around 
glands and blood vessels (Quenby et al., 2008). During pregnancy, they are in close 
proximity to the implantation site, close to the infiltrating extravillous trophoblast (Slukvin et 
al., 2004). The accumulation of uNK cells around implantation site during early normal 
pregnancy suggests that they contribute to the establishment of pregnancy (Cooper et al., 
2001a). However the exact mechanism by which semi-allogenic trophoblasts can escape lysis 
from accumulating uNK cells in implantation site is uncertain. It has been suggested that 
uNK cells may participate in local immuno-suppression at the maternal-fetal interface 
through the productin of immunomodulatory cytokines during implantation (Koopman et al., 
2003). uNK CD56 cells may also produce interferonγ in early pregnancy remodelling 
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decidual transformation and spiral artery modification, thus affect pregnancy in this way 
(Ashkar and Croy, 2001). The angiogenesis effect of uNK has been donmenstrated in a study 
which found that uNK immunostaining density was positively correlated with the formation 
of vessels, spiral arteriole smooth muscle differentiation and endometrial oedema; and uNK 
cell measurements were associated with a reduced uterine artery resistance to blood flow in 
women with RM or recurrent implantation failure (RIF), suggesting that uNK may contribute 
to miscarriage due to increased angiogenesis and blood flow during implantation leading to 
excessive oxidative stress (Quenby et al., 2009). 
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3.2 uNK cells in RM 
An increasing number of studies have shown that uNK cells increase in women with RM 
compared with fertile women (Tuckerman et al., 2007, Clifford et al., 1999)  and the number 
of previous miscarriages of RM is associated with uNK increases (Tuckerman et al., 2004), 
suggesting a contributory role of uNK in RM. It has been proposed that the imbalanced 
expression of uNK phenotype with a decrease of CD56+CD16- and an increase of 
CD56+CD16+ may be responsible for RM (Lachapelle et al., 1996). A study investigated the 
immunophenotypic profile of uNK cells in women with RM comparing with fertile women 
using a panel of 14 monoclonal antibodies to immunostain the luteal phase endometrium. 
They found that women with RM had significantly higher expression of CD56+, CD16+, 
CD4+ and CD14+ phenotypes than fertile women. Further comparison of the difference of 
uNK phenotype between RM subjects with different subsequent pregnancy outcomes showed 
that RM women with subsequent miscarriages had higher expression of CD56+, CD16+ 
CD4+, CD8+ and CD14+ than those with subsequent live births (Quenby et al., 1999). This 
suggests that high expression of CD56+CD16+ uNK subset may play an important role in 
RM.  
 
However, in contrast to the above findings, there are some studies which have not found an 
increase of uNK in RM subjects (Shimada et al., 2004, Michimata et al., 2002). There are 
several possible reasons for these conflicting results. Firstly, the sampling of study population 
may be not consistent between studies. Some researchers have strictly included women with 
three or more miscarriages into the study group (Tuckerman et al., 2007, Clifford et al., 1999, 
Quenby et al., 1999) whereas others have also included women with two previous 
miscarriages (see table V3). Secondly, there is no consensus on uNK counting or the normal 
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reference range of uNK in current studies. Some authors have defined the mean number of 
uNK cells as a percentage of CD45+ cells (Michimata et al., 2002, Clifford et al., 1999) 
whereas others have counted the number of uNK cells as a percentage of total stromal cells 
(Tuckerman et al., 2007, Quenby et al., 1999) (see table V3). Finally, the normal variation of 
the number of uNK cells is unclear due to the paucity of epidemiological studies on the 
presence of uNK cell in normal fertile women. So far there is no consensus on the reference 
range of uNK used between centers. Therefore, the results from different studies yield 
conflicting findings. 
 
The aim of this study was i) to examine the role of NK cells in RM by measuring both 
peripheral and endometrial NK cells in women with unexplained RM; ii) to examine the 
prognostic value of NK cell measurements on a subsequent pregnancy outcome in women 
with RM by correlating NK cell measurements with pregnancy outcomes; iii) to examine if 
NK cell measurements in peripheral blood can reflect NK cell changes in endometrium by 
comparing the result of pNK cell measurements with that of  uNK cell measurements
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Table V 3. A summary of studies on the relationship between uNK and RM 
uthors  RM criteria Study Group Control Group Method uNk Counting Results Findings 
Lachapelle et al., 
1996 
≥3 previous 
miscarriages 
20 women with RM 15 fertile women FCfl 
Flow cytometry 
CD56+ cells was counted as 
the percentage of total 
CD45+ cells 
1.uNK CD16-CD56+ subset decreased in RM subjects 
compared with controls 
2.uNK CD16+CD56+ increased in RM subjects compared 
with controls 
uNK cell subset of CDdim 
plays an immunological role 
in RM 
Clifford et at., 
1999 
≥3 previous 
miscarriages 
29  women with RM 10 fertile women IHC The number of positively 
stained cells in 10 non-
overlapping high-powered 
fields was counted 
Women with RM had significantly higher uNK CD56+ than 
controls 
Increases in uNK cells is the 
possible pathogenesis of RM  
Quenby et at., 
1999 
≥3 previous 
miscarriages 
22 women with RM 9 women for 
laparoscopic 
sterilization 
IHC uNKCD56+,CD16,CD14,CD
8,CD4 were counted as a 
percentage of total stromal 
cells 
1.uNK CD56CD16CD14CD4 was significantly higher in 
women with RM than controls 
2.RM women who subsequently miscarried had significantly 
higher uNK CD56CD16CD8CD4 than those had live birth or 
controls 
 Women with RM have a 
different population of 
leucocyte in the pre-
implantation endometrium 
compared with fertile 
controls 
Quack et al., 
2001 
≥3 previous 
miscarriages 
38  women with RM 20 women with 
elective  termination 
of pregnancy 
IHC CD56+ cells were counted in 
the ratio of CD56+ cells to 
CD45+ cells 
1. CD56+ NK cells decreased in women with RM compared 
with controls 
2. Unexplained RM subjects with normal male karyotype had 
significantly more activated leukocytes than those unexplained 
RM subjects with a trisomy 16 (n=21) and controls 
Cellular immunity with 
increased number of 
leukocytes may be involved 
in RM 
Michimata et al., 
2002 
≥2 previous 
miscarriages 
17 women with RM 15 women with solely 
male infertility 
IHC uNK CD56+ , CD16+, 
CD3+, CD8+  cells were 
counted as a percentage of 
CD45+ cells 
1. No significant difference of uNK CD56, CD16, CD45 and 
CD3, CD8 was found between women with RM and controls. 
2. No significant difference in numbers or ratios of lymphocyte 
subsets were found between cases with subsequent miscarriage 
and those with live birth 
uNK cells have no predictive 
value for subsequent 
pregnancy outcomes in 
women with RM  
Quenby et al., 
2005 
≥3 previous 
miscarriages 
85 women with 
unexplained RM 
18 women for 
sterilization 
IHC uNK CD56+ cells were 
counted as a percentage of 
total stromal cells 
1. Women with RM had significantly more uNK cells than 
controls 
2. Prednisolone significantly reduced the number of uNK cells 
from 14% to 9%. 
1. The presence of uNK cells 
is high in peri-implantation 
endometriumof women with 
RM. 
2. Prednisolone has a 
therapeutic effect in reducing 
high uNK cells in RM 
Tuckerman et al., 
2007 
≥3 previous 
miscarriages 
87 women with RM 10 women with 7 of 
them with proven 
fertility 
IHC uNK CD56+ cells were 
counted as a percentage of 
total stromal cells 
1. The number of uNK cells was significantly higher than that 
in controls. 
2. No significant difference in uNK numbers was found 
between RM women who subsequently miscarried and those 
who had live births. 
3. No correlation was found between the presence of uNK cells 
and the numbers of previous miscarriages. 
uNK has the diagnostic value 
in RM but has no prognostic 
value on a subsequent 
pregnancy outcome 
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II. Materials and Methods 
1 Subjects 
Cases 
A total of 36 women with unexplained RM were recruited in this study. Of these 36 recruits, two 
patients declined endometrial biopsy procedures on their consent; we failed to obtain sufficient 
endometrial tissue in one patient and later she withdrew from the study following her referral to 
the assistant conception unit (ACU) for further fertility treatment; two patients neglected to use 
contraception in the biopsy cycle and later declined the study due to time pressure; two patients 
were not accessible to any contact means during the biopsy cycle and later were withdrawn from 
this study. 
 
The remaining 29 patients underwent an endometrial biopsy for uterine NK cell measurements 
and two blood tests for peripheral NK cell measurements on two occasions in correspondence 
with the study protocol. Among these 29 patients, the blood sample of one patient was incorrectly 
stored in a tube without heparin and another blood sample was spoiled due to unexpected 
disruption of the electricity supply during the centrifugation procedure for cell isolation. These 
two patients were withdrawn from the peripheral NK cell measurements. Therefore, a total of 29 
patients were included in uNK cell measurements and 27 of them were included in pNK cell 
measurements  
 
Controls 
A total of 30 fertile female volunteers were recruited in this study. Among them, 21 of them 
agreed to give blood samples for pNK cell measurements in the mid-luteal phase of the cycle. 
Therefore, these 21 fertile women were used as controls for pNK cell measurements in this study. 
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2 Methods 
2.1 Procedure 
a Endometrial biopsy 
A LH-timed endometrial biopsy during the peri-implantation window was conducted to measure 
natural killer cells in endometrium. Participants were required to test ovulation with dip sticks 
from an ovulation test kit (Clearblue, UK ) provided by the researcher from day 7 of the menstrual 
cycle onwards to precisely indentify LH surge. They were required to contact Dr Wei Li once 
positive ovulation test was detected. An appointment for LH-timed biopsy was then arranged on 
Ward G1 in the mid-luteal phase between day 7 and day 9 after ovulation. An endometrium 
biopsy was performed as an outpatient procedure without prior dilatation of the cervix or any form 
of analgesia. The procedure was operated with a pipelle sampler (Prodimed, France) induced 
through the cervical canal and the endometrium tissue was obtained by creating a negative suction 
pressure. The samples were then fixed in formalin and wax embedded in the Histology 
Department for future immunohistochemistry. Slides were cut for research and sent to the 
laboratory in the Academic Unit of Reproductive and Developmental Medicine.  
 
b. Peripheral blood tests 
The first blood test for pNK cell measurements was conducted concurrently with the endometrial 
biopsy in accordance with the research protocol. Another blood test for pNK cell measurements 
was conducted at a follow-up clinical attendance prior to conception. A 5ml blood sample was 
obtained in a green top tube with heparin (EDTA tube) from the patients in each assessment. The 
samples were conveyed immediately to the laboratory in the Academic Unit of Reproductive and 
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Developmental Medicine. All samples were processed within 4 hours after sampling for the flow 
cytometry experiment. 
 
2.2 Flow cytometry for pNK cell measurements 
a. The principle of flow cytometry 
Standard flow cytometry techniques were used to determine the expression of pNK cells within 
plasma samples from women with unexplained RM and fertile controls. The protocol was 
optimized to determine the best conditions for maximal fluorescence labelling with the target 
cells. The phenotypes of CD56 and CD16 were detected as the surface markers to peripheral NK 
cells in flow cytometry with four-colour fluorescence capable FACSCalibur
TM
 system (BD, 
Oxford, UK). Mouse anti-human CD56 and CD16 antibodies were used for fluorescent labelling 
NK cells. Because T cells and platelets, which have the same density with NK cells, could not be 
eliminated from the isolation solution of NK cells from the plasma, mouse anti-human CD3 
antibody which specifically conjugates with T cells; and CD45 antibody which conjugates with 
leucocytes but not with platelets were used to exclude these two types of cells. Only cells with 
positive of CD45+CD56+CD16+/- expression and negative of CD3 expression were identified as 
NK cells in this study. The results of pNK cell measurements of controls were used as the 
reference for determination. 
 
Flow cytometry measures and then analyzes the property of each individual cell from 0.2 to 150 
micrometres as they flow in a fluid steam through a beam of laser light of a single wavelength. 
The single cells either scatter or absorb and then re-emit (fluorescence) the light when they pass 
through the light beam one in a line. The light signals emitted by the particles are detected by a 
number of detectors: one in line with the light beam (Forward Scatter or FSC) and several 
perpendicular to it (Side Scatter or SSC). FSC correlates with the cell volume and SSC correlates 
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with the inner complexity of the particle (i.e., shape of the nucleus, the amount and type of 
cytoplasmic granules or the membrane roughness). This combination of scattered and fluorescent 
light is collected by the detectors and various types of information about the properties of each 
individual cell are generated. The properties of the cells measured include the size of the particles, 
relative granularity or internal complexity, and relative fluorescent intensity.  
 
b. Flow cytometry technique 
A 5ml blood sample was obtained in a tube with heparin (EDTA tube) and was diluted with equal 
volume of PBS. 10ml of the diluted sample was then layered over 5ml of Lymphoprep (1.077) 
gently and centrifuged at 600g for 30minutes without brake. After centrifugation, the 
mononuclear cells which banded at the interface were removed by pipette. Mononuclear cells 
were then washed in 10ml of PBS and centrifuge at 500-600g for 5 minutes with brake setting up 
at rate 3. The suspension was decanted and the cells were re-suspended with 10ml PBS and 
centrifuged for 5 minutes again twice. Then the suspension was decanted and the cells were re-
suspended with 1ml PBS. Cells were counted on a haemocytometer and 1X10
6
 cells were 
transferred into each microtube. 20ul of appropriate antibodies or isotypes were added into each 
tube as appropriate. The agents applied were as follows: 
 
Tube-a: sample only (unstained control) 
Tube-b: sample + CD56 antibody (APC Mouse Anti-Human CD56, BD Pharmingen
TM
) 
Tube-c: sample + CD 16 antibody (PE Mouse Anti-Human CD16, BD Pharmingen
TM
) 
Tube-d: sample + CD 45 antibody (FITC Mouse Anti-Human CD45, BD Pharmingen
TM
) 
Tube-e: sample + CD 3 antibody (PreCP Mouse Anti-Human CD3, BD Pharmingen
TM
) 
Tube-f: sample + all antibodies (CD56 antibody, CD16 antibody, CD45 antibody and CD3 
antibody, BD Pharmingen
TM
) 
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Tube-g: sample + all isotype controls (CD56 IgG1 k, CD16 IgG1 k, CD3 IgG1 k and CD45 IgG1 
k, BD Pharmingen
TM
) 
 
After applying reagents, the samples were incubated on ice in the dark for 30 minutes. After 
incubation 0.5ml of flow buffer was added into each tube and the cells were washed twice by 
centrifugation for 5 minutes at 500g. Then the cells were re-suspended in 0.5ml flow buffer and 
fixed with cellfix solution (100ul/tube) (BD, UK). The samples were processed by the flow 
cytometer after connecting the password protected computer to the FACSCalibur
TM
 machine (BD, 
UK). The voltage and compensation was adjusted for each sample to achieve the maximal 
detection of the target cells. The computer then converted light analogue signals into digital data 
and generated the results for the future analysis. 
 
2.3 Immunohistochemistry for uNK cell determination 
a. The principle of immunohistochemistry 
Standard immunohistochemistry techniques were used to measure uNK cells within endometrium 
tissue from women with unexplained RM. The protocol was optimized to determine the best 
conditions for maximal immunostaining with minimal background staining. Phenotype CD56 was 
detected as the surface marker of natural killer cells in the immunohistochemistry measurement. 
Monoclonal mouse anti Human CD 56 at a dilution of 1:50 (Serotec, UK) was used as the primary 
antibody within this study. 
 
An indirect staining method where a biotin labelled secondary antibody raised against the IgG of 
the primary antibody was used. As avidin has four binding sites for biotin, the signal of end 
products was further amplified through the biotinylated secondary antibody reacted with the pre-
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formed avidin-biotin complexes on the primary antibody. This tertiary signal amplification 
increased the sensitivity of staining techniques and helped to reduce unwanted background 
staining. To visualize the areas of antibody-antigen binding, enzyme-substrate reactions was 
employed to convert colourless chromagens into coloured end products. Chromagen solution 
(Diaminobenzidine, DAB) was used to produce brown staining to visualize the target antigen.  
 
The key technique of the immunohistochemistry was antigen retrieval method. When aldehyde-
based fixatives (eg. formalin) were used during tissue preparation, inter- and intra-molecular cross 
links were produced masking certain structural proteins of tissue antigens. This adverse effect was 
caused by the formation of methylene bridges between reactive sites on tissue proteins. The 
degree of masking of the antigenic sites depended upon the length of fixation time, temperature, 
concentration of fixatives and the availability of other nearby proteins able to undergo cross-
linkage. In order to expose these hidden antigenic sites, heat mediated antigen retrieval technique 
was employed in the current study.  The heat mediated antigen retrieval techniques included 
microwave oven irradiation, combined microwave oven irradiation and proteolytic enzyme 
digestion, pressure cooker heating, autoclave heating, waterbath heating, steam heating and high 
temperature incubation. We used microwave oven irradiation for heating mediated antigen 
retrieval due to the advantages of having a digital timer for precise time adjustment, a turntable 
platform for uniform heating of the retrieval solution and an ideal working power ranged from 
700W to 1000W. 
 
b. The technique of immunohistochemistry 
Immunohistochemistry was performed on de-waxed and re-hydrated 5 mm tissue sections. The 
majority of procedures were carried out at room temperature. The exceptions were antigen 
unmasking which was carried out in a microwave oven and incubation with the primary antibody 
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which was performed overnight at +4°C. All sections were quenched in 0.3% hydrogen peroxide 
in methanol for 20 min prior to antigen unmasking. Unmasking was performed in an 800 W 
microwave oven in 10 nmol/l boiling citrate buffer at pH 6.0. The slides were incubated for 12 
minutes at medium heat and then left to cool in the buffer for 20 minutes. Then slides were 
blocked for 1 hour in the blocking buffer (Universal Elite ABC kit, Vector Laboratories, UK) 
which contained avidin and then incubated overnight with primary antibody (Monoclonal Mouse 
anti Human CD 56 1:50; Serotec, UK). The next day slides were incubated with the secondary 
antibody (Universal Elite ABC kit, Vector Laboratories, UK) for 30 minutes at room temperature. 
Then slides were incubated with peroxidase substrate DAB (Diaminobenzidine) for 8 minutes 
(Vector Laboratories, UK). Slides were then washed in distilled water for 5 minutes and stained 
with 10% haematoxylin for 15 minutes. After slides were differentiated, dehydrated, cleared and 
mounted, the number of endometrial CD56+ NK cells was counted as the percentage of CD56+ 
cells over total endometrial stromal cells in 10 random selected microscopic fields at 
magnification of X400. Only cells positive for CD56 staining in stroma were counted as uNK 
cells. Glandular epithelial cells were not counted as stroma cells in this thesis. Only cells with 
clear nuclei in the clumps were counted as effective cells. The inter and intra observer errors were 
1. 5(±1.2)% and 2.6(±2.2)% respectively. The normal reference of the expression of natural killer 
cells in endometrium was defined from 2.2% to 13.9% (Tuckerman et al., 2007).  
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III. Statistical Analysis 
Statistical analyses were performed using the SPSS (Statistical Package for the Social Sciences) 
version 16. Differences in the results of natural killer cell measurements intergroup and intragroup 
were analyzed with independent T tests. The comparison of the results of peripheral natural killer 
cell measurements between the baseline assessment and the follow-up assessment were analyzed 
with paired T tests.  The correlation between NK cell measurements and psychometric 
measurements, and pNK cell measurements and uNK cell measurements were analyzed with 
Pearson correlation coefficient tests. Statistical significance was set at p value <0.05. 
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IV. Results 
1. Peripheral NK (pNK) cell measurements 
A total of 27 cases and 21 controls had pNK cell measurements with flow cytometry. Figure V-1 
(a, b) shows the representative density plot graphs of pNK cell measurements by flow cytometry. 
The demographic characteristics of the 27 cases are shown in table V-4. The mean (± SE) age of 
the 27 cases was 36.0 ± 0.9 years. The mean (± SE) age of the 21 controls was 34.1 ± 1.2 years. 
There was no significant difference in the mean age between cases and controls (p>0.05). No 
significant difference in the results of pNK cell measurements was found between cases and 
controls (p>0.05) (table V-5). 
 
Figure V-2 (a, b) shows the comparison of pNK cell measurements of the 27 cases between the 
baseline assessment and the follow-up assessment. No significant differences in the measurements 
of the two subsets of pNK CDdim and pNK CDbright were found between the two assessments.  
 
Figure V-3(a, b) shows the comparison of pNK cell measurements at the baseline assessment and 
the follow-up assessment between the 27 cases with different conception outcomes. There were 
no significant differences in pNK cell measurements of the two assessments between cases who 
subsequently conceived and those who did not (p>0.05).  
 
Figure V-4 (a,b) shows the comparison of pNK cell measurements at the two assessments between 
18 cases with different pregnancy outcomes. In the baseline assessment no significant difference 
in the pNK cell measurements was found between cases who had subsequent live births and those 
who miscarried again (p>0.05). However, in the follow-up assessment a significant difference in 
the results of pNK CDdim cells was found between the live birth group and the miscarriage group 
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(p<0.05). Cases who miscarried again had significantly higher pNK CDdim cells than those who 
had live births. No significant difference in pNK CDbright cell measurements was found between 
the live birth group and miscarriage group in the follow-up assessment (p>0.05).  
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Figure V 1 (a, b). Representative density plot graphs of peripheral NK cell measurements with flow cytometry. 
FL4 axis represents CD56 expression and FL2 axis represents CD16 expression.  
(a) A representative density plot graph of pNK measurements of cases 
 
 
(b) A representative density plot graph of peripheral NK cell measurements of controls 
 
 
CDdim  
CDbright  
CDdim  
CDbright  
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Table V 4. Demographics of 27 cases with peripheral NK cell measurements 
 
Age 
(years) 
 
pNK CDdim 
% 
 
pNK CDbright 
% 
 
No. of previous miscarriages 
(median, range) 
type of RM 
primary RM 
(n, %) 
secondary RM 
(n, %) 
36.0 ± 0.9  23.4 ± 3.0 1.8 ± 0.1 4 (3-8) 19 (70.4%) 8 (29.6%) 
All the values are shown in the form of mean ± SE unless otherwise specified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
 
Table V 5. A comparison of peripheral NK cell measurements between cases and controls 
 Cases 
N=27 
Controls 
N=21 
ρ value 
Age (yrs) 36.0 ± 0.9 34.1 ± 1.2 ρ =0.19 
pNK CDdim% 23.4 ± 3.0 21.9 ± 3.0 ρ =0.72 
pNK CDbright% 1.8 ± 0.1 1.5 ± 0.3 ρ =0.29 
All the values are shown in the form of mean ± SE. 
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Figure V 2 (a, b). The comparison of peripheral NK cell measurements of the 27 cases between the baseline 
assessment and the follow-up assessment. 
 
(a) The comparison of pNK CDbright cell measurements of the 27 cases between the two assessments 
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(b) The comparison of pNK CDdim cell measurements of the 27 cases between the two assessments 
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Figure V 3 (a, b). The comparison of peripheral NK cell measurements of 27 cases with different conception 
outcomes in the baseline assessment and the follow-up assessment 
 
(a) A comparison of pNK cell measurements of the 27 cases with different conception outcomes at the baseline assessment 
 
 
(b) A comparison of pNK cell measurements of the 27 cases with different conception outcomes at the follow-up assessment 
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Figure V 4 (a, b). The comparison of peripheral NK cell measurements of cases with different pregnancy 
outcomes in the baseline assessment and the follow-up assessment 
 
(a) A comparison of pNK cell measurements of the 18 cases with different pregnancy outcomes at the baseline assessment 
 
 
(b) A comparison of pNK cell measurements of the 18 cases with different pregnancy outcomes at the follow-up assessment 
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2. Uterine NK (uNK) cell measurements 
A total of 29 women with unexplained RM had uNK cell measurements with the LH timed 
endometrial biopsies. Figure V-5 shows the immunohistochemical staining for CD56+ NK cells in 
the endometrium of the mid-luteal phase. uNK CD56+ cells were present as clumps of cells 
around the glands or vessels in stroma. The demographic characteristics of these 29 cases are 
shown in table V-6. Of these 29 endometrial biopsies, one had a high result of uNK cells of 20.2% 
(figure V-6). The results of uNK cell measurements for the rest 28 samples were all within the 
normal range (defined as the range from 2.2% to 13.9%) (Tuckerman et al., 2007). There was no 
significant difference in the results of uNK cell measurements between cases with different 
conception outcomes or different pregnancy outcomes (p>0.05). Figure V-7 and 8 show the 
results of uNK measurements of cases with different conception outcomes and pregnancy 
outcomes.  
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Figure V 5 (a, b). Immunohistochemical staining of CD56 cells in endometrium tissue of women with 
unexplained RM. Magnification X400. 
(a) CD56+ cells were present as clumps of cells in stroma around the glands.  
 
 
 
(b) CD56+ cells were present as clumps of cells in stroma around the vessels.  
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Figure V 6. Image of immunohistochemical staining of the endometrium tissue of women with unexplained RM 
with a high value of uNK CD56 cell measurement. Magnification X400.  
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Table V 6. Demographic characteristics of 29 cases with uNK cell measurements 
 
cases 
 
age 
 
uNK 
 
No. of previous miscarriages 
(median, range) 
type of RM 
primary RM 
(n, %) 
secondary RM 
(n, %) 
n= 29 35.9 ± 0.8 yrs 7.1 ± 0.73 4 (3-8) 21 (72.4%) 8 (27.6%) 
All the values are shown in the form of mean ± SE unless otherwise specified. 
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Figure V 7. Results of uNK CD56 cell measurements of 29 cases with different conception outcomes 
 
 
Figure V 8. Results of uNK CD56 cell measurements of 20 cases with different pregnancy outcomes 
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3. Correlation between pNK cell measurements and uNK cell measurements 
A total of 27 matched blood and endometrial samples were obtained from the same individual and 
at the same time in the mid-luteal phase for the uNK cell and pNK cell measurements.  No 
significant correlation was found between the results of uNK cell measurements and the results of 
pNK CDdim or CDbright measurements (ρ>0.05). Figure V-9 shows the association between the 
measurements of uNK cells and pNK CDdim cells in the 27 matched samples. Figure V-10 shows 
the association between the measurements of uNK cells and pNK CDbright cells in the 27 
matched samples. There was also no association between the peripheral and uterine NK cell 
measurements and the demographics (table V-7).  
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Figure V 9. No correlation between uNK cell measurements and pNK CDdim cell measurements 
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Figure V 10. No correlation between uNK cell measurements and pNK CDbright cell measurements 
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Table V 7. The correlation between peripheral and uterine NK cell measurements and the demographics 
 Age  No. of previous miscarriages 
uNK measurements 
n=29 
ρ =0.08 ρ =0.93 
pNK CD dim measurements  
n=27 
ρ =0.65 ρ =0.07 
pNK CD bright measurements 
n=27 
ρ =0.30 ρ =0.38 
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4. Correlation between NK cell measurements and psychometric measurements 
Table V-8 shows the correlation between the NK cell measurements and psychometric 
measurements. There was a significant inverse correlation between the results of pNK CDbright 
cells and the scores of fertility problem stress. Women with higher levels of fertility problem 
stress had significantly lower expression of pNK CDbright cells (ρ <0.05) (figure V-11).  
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Table V 8. The relationship between NK cell measurements and psychometric measurements in women with 
unexplained RM 
 NK cell measurements 
pNK CDdim% 
n=27 
pNK CDbright% 
n=27 
uNK% 
n=29 
Fertility Problem Inventory ρ =0.64 ρ =0.04* ρ =0.94 
Perceived Stress Scales ρ =0.37 ρ =0.09 ρ =0.49 
PANAS Positive Affect ρ =0.96 ρ =0.37 ρ =0.91 
PANAS Negative Affect ρ =0.42 ρ =0.13 ρ =0.24 
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Figure V 11. An inverse correlation between the results of pNK CDbright cell measurements and FPI scores 
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V. Discussion 
Natural killer cells, which are part of innate immune system, have been found in both peripheral 
blood and endometrium. Recently, there has been an increasing body of studies reporting on the 
increases in the number of peripheral NK cells or endometrial NK cells in women with RM, 
suggesting that NK cell elevation either in peripheral blood or in endometrium may be a causative 
factor of RM. However, the lack of clarity of the relationship between pNK and uNK 
measurements makes interpretation of these results difficult. Measurements of peripheral NK cells 
by flow cytometry are considerably less invasive compared to uNK measurements with an 
endometrial biopsy. Flow cytometry can also precisely detect subsets of pNK cells such as CDdim 
and CDbright separately, which are postulated to play different roles in reproductive processes 
(Kwak-Kim and Gilman-Sachs, 2008, Laird et al., 2003). Therefore, measurements of pNK cells 
may act as a surrogate for uNK cell measurements in studies on RM if pNK cell measurements 
reflect the results of uNK cell measurements. We conducted this study measuring NK cells in both 
peripheral blood and endometrium in matched samples obtained at the same time from the same 
individual in a group of women with unexplained RM in order to examine the role of NK cells in 
RM and the relationship between pNK cell measurements and uNK cell measurements in RM. 
 
The relationship between pNK measurements and RM 
 Current studies on the relationship between pNK cells and RM have yield conflicting results. 
Some studies have found the evidence of the increases of pNK cells in both numbers and activities 
in women with RM or RIF (recurrent implantation failure) (King et al., 2010, Prado-Drayer et al., 
2008, Yamada et al., 2003)  and the achievement of live births in women with RM or RIF by 
treating high pNK cells with prednisolone or immunoglobulin G (Stricker et al., 2000, van den 
Heuvel et al., 2007, Coulam and Goodman, 2000), suggesting that increased pNK cells may be an 
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immunological factor of RM. However, there are also studies which found a negative association 
between pNK cell measurements and RM. For example, a study comparing 85 RM women with 
27 fertile controls found that there was no significant difference in pNK cell numbers between 
women with RM and controls, suggesting that pNK cell measurements have no diagnostic value 
on RM  (Wang et al., 2008). Another study also suggests that enumeration of pNK cells including 
the counting of total number of pNK CD56+ and the two subsets of CDdim and CDbright cells 
has no predictive value on pregnancy outcomes (Thum et al., 2005). In our study we found no 
differences in the numbers of pNK cell measurements between women with RM and fertile 
controls. 
 
There are several factors which may contribute to the current conflicting findings. Firstly, there is 
no consensus on the antibodies used to measure pNK cells with flow cytometry. Some studies 
labeled pNK cells with CD56, CD16 and CD69 antibodies (Thum et al., 2004) whereas others 
labeled pNK cells only with CD56 antibody (Wang et al., 2008). It is well known that T cells 
which contaminate in the NK cell isolation from blood samples also express CD56 antigen apart 
from its unique antigen of CD3. Therefore, it is likely that different subsets of monocytes are 
measured in studies with different methods of antibody labeling, which lead to the conflicting 
results. In our study we employed four antibodies of CD56, CD16, CD3 and CD45 to define pNK 
cells. Only cells with expression of CD56+CD16+/- CD45+CD3- were defined as pNK cells.  
 
Secondly, the setting of the gate and the compensation of the fluorescent chromosone spectrum on 
the flow cytometer is quite arbitrary and need to be adjusted from sample to sample in each 
experiment. Therefore, the results derived from different experiments and operated by different 
researchers may vary and lead to different conclusions.  
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Thirdly, it is possible that the increase of pNK cells found in RM studies is the result of 
sympathetic responses to the stressful venipuncture. A study has observed the change in the 
numbers of pNK cell measurements in women with RM between the first blood samples obtained 
by venipuncture and the second blood samples obtained 20minutes after cannulation, suggesting 
that high sympathetic responsiveness to venipuncture stress in RM subjects may be responsible to 
the pNK cell increase (Shakhar et al., 2006).  
 
The association between pNK cell measurements and subsequent pregnancy outcomes 
Although we did not find a significant difference in pNK cell measurements between women with 
RM and fertile controls, we found that RM women who had miscarriages in a subsequent 
pregnancy had higher numbers of pNK CDdim subset prior to conception than those who had live 
births. This finding suggests that the elevation of pNK CDdim cells prior to conception is a risk 
factor of subsequent miscarriage in women with RM. The exact mechanism of how pNK CDdim 
adversely affects pregnancy is not known. It will be of interest to examine the cytotoxity of pNK 
CDdim cells in women with RM in future studies. However, due to the limitation of the numbers 
of women with pNK measurements, this finding needs to be verified in a future study.  
 
The effect of ‘tender loving care’ on pNK cell measurements in women with RM 
In this study we hypothesized that ‘tender loving care’ in the form of clinical consultation, 
explanation and reassurance by a team of dedicated staff may help to reduce the stress level in 
women with RM. No significant change in the measurements of pNK cells was found after’ tender 
loving care’, suggesting that this kind of ‘tender loving care’ has no effect on reducing the results 
of stress marker measurements. This finding is consistent with the result from the psychometric 
measurements where no evidence of the effect of ‘tender loving care’ on psychological 
measurements was found. 
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However, interestingly we found a small but significant inverse association between the results of 
pNK measurements and psychometric measurements. High fertility stress was associated with a 
decrease in pNK CDbright cells in women with RM. The exact mechanism of how fertility 
specific stress affects the pNK CDbright cells is yet not known. Previous studies have reported on 
stress increasing the cytotoxicity of peripheral NK cells in women with RM (Andalib et al., 2006) 
and found a negative association between stress levels and the number of peripheral NK cells 
(Arck et al., 2001). Due to the paucity of studies in this area, it is still not clear how stress may 
affect the number of pNK cells. 
 
The relationship between uNK cell measurements and RM 
uNK cells, which are the most predominant leucocyte in the endometrium, are present adjacently 
to the trophoblast cells in implantation site. uNK cell expression is maximal in the mid-to late-
luteal phase of the cycle and increases in early pregnancy. The site and the time of uNK cell 
expression suggest that uNK cells are involved in implantation. Recently, the role of this 
endometrial factor in RM has been a focus of research interest. Previous studies have found the 
positive association between raised uNK cells and RM, and the reduction in uNK cell numbers 
achieved by prednisolone treatment in women with RM (Clifford et al., 1999, Tuckerman et al., 
2007, Larciprete et al., 2007, Quenby et al., 2005), suggesting that the increase of uNK cells is a 
contributory factor of RM. In this prospective study, we did not find an obvious association 
between uNK cell measurements and RM or pregnancy outcomes in women with RM. Due to the 
small number of cases examined in this study, the relationship between uNK cells and RM still 
need to be investigated in future studies. 
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The correlation between peripheral NK cell measurements and endometrial NK cell 
measurements 
Peripheral and endometrial NK cells are in contact with trophoblasts in different areas. The 
peripheral NK cells bath the trophoblast cells through the circulation whereas endometrial NK 
cells are in contact with the trophoblast cells in the implantation sites. Peripheral blood NK cells 
are part of the innate immune system and are involved in the maternal immunological regulation 
to adapt the semi-allograft embryo in the early pregnancy. The precise role of uNK cells in the 
implantation process is still not very clear. Research has proposed several functions of uNK 
including direct interaction with MHC molecules on the invading trophoblast, production of 
chemokines and cytokines, angiogenesis and spiral artery remodeling (Bulmer et al. 2010; Bulmer 
and Lash 2005; Quenby et al. 2009).  
 
The majority of pNK cells are CDdim (CD56+16+) whereas the majority of uNK cells are 
CDbright (CD56+16-). Studies have found considerable differences in the cell surface markers 
between pNK and uNK, suggesting they are different phenotypically and functionally 
(Schallhammer et al., 1997). This raises a question whether the measurement of pNK reflects uNK 
measurements in studies on RM. Up to date only one published study has examined the 
association between endometrial NK cells and peripheral NK cells in women with RM (Park et 
al., 2010). In the study of Park et al, they examined numbers of NK cells in decidual tissue and 
peripheral blood in matched samples obtained at the same time from 21 women with more than 2 
previous miscarriages. They found that there was a positive correlation between the numbers of 
NK cells measured in the decidual tissue and those measured in the peripheral blood. Therefore, 
they concluded that peripheral NK cell changes reflected endometrial NK cell alteration in women 
with RM and pNK measurements can be a surrogate for uNK cell measurements in the diagnosis 
of RM with the advantage of less invasive procedure.  
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However, we should note that this study investigated the presence of NK cells in decidual tissue 
of early pregnancy comparing with the results of peripheral NK cells. The presence of endometrial 
NK cells varies significantly in different phases of the menstrual cycle and during pregnancy. 
They increase from the proliferative phase reaching maximum in the secretory phase (King et al., 
1991). In the first trimester of pregnancy,  endometrial NK cells dominantly form70% of 
leucocytes in the decidua (Moffett-King, 2002). However, the number of pNK cells increases in 
the luteal phase (Lee et al., 2010) and does not change throughout the pregnancy (Southcombe et 
al., 2010). In addition, studies revealed a decrease in the total number of lymphocytes in the third 
trimester associated with a suppressed regulatory effect on maternal immunity to tolerate the 
semi-allograft fetus (Mahmoud et al., 2001). Therefore, the dynamic change of NK cells in 
decidua of the early pregnancy may be not synchronized with the change of NK cells in 
circulation and thus pNK measurements in early pregnancy may not reflect the measurements of 
NK cells in decidua. In addition studies have shown that peripheral NK cells can be artificially 
increased by the stress of venipuncture (Shakhar et al., 2006). Therefore, the significance picked 
up in the above study may be a type II error. 
 
In our prospective study we investigated the numbers of NK cells in the peripheral blood and 
endometrium in the matched samples obtained at the same time from the same individual in a 
group of women with unexplained RM. In this study we found no correlation between pNK 
measurements and uNK measurements in RM women in the pre-conceptional state. Our study is 
the first study to investigate the association between uNK and pNK measurements in pre-
conceptional state in women with RM. The limitation of the study is that it was carried out in 
women with RM. A control study in fertile women would also be of interest to further examine 
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the association between pNK and uNK measurements with simultaneously obtained blood and 
endometrial samples. 
 
The negative association between pNK cell results and uNK cell results found in this study raises 
the question about the role of pNK cell measurements in RM.  The finding that the pNK cell 
measurements are not related to uNK cell measurements suggests that it may be inappropriate to 
extrapolate results from peripheral blood to interpret changes in the endometrium. Therefore, the 
role of peripheral NK cell measurements in RM remains to be ascertained. 
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VI. Conclusion 
In the present study we found that the increase in numbers of pNK CDdim cells is associated with 
an increased risk of a subsequent miscarriage in women with RM. The exact pathogenesis of how 
increased pNK CDdim cells adversely affect pregnancy is not clear. In this study we also find no 
correlation between the measurements of NK cells in peripheral blood and those in endometrium 
in women with RM, suggesting that pNK cell measurements do not reflect uNK cell 
measurements.  
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Chapter VI: The relationship between plasma prolactin 
concentrations and RM 
I. Introduction 
Recurrent miscarriage (RM) is a heterogeneous condition in which 50% of the cases remain 
unexplained. To date several aetiological factors of RM have been identified, including parental 
chromosomal anomalies, uterine pathology, haematological abnormalities, immunological factors 
and endocrinological disorders. However, most previous studies in relation to the endocrine 
abnormalities of RM have focused on the luteal phase deficiency (LPD) and PCOS (polycystic 
ovarian syndrome) (Cocksedge et al., 2009, Palomba et al., 2006, Nardo et al., 2002). Less 
attention has been paid to the role of prolactin in RM.  
 
Prolactin is a polypeptide hormone synthesized by the lactotroph cell in the anterior pituitary 
gland and in extrapituitary sites such as mammary gland, placenta and uterus (Goffin et al., 2002, 
Eyal et al., 2007, Reis et al., 2002). Apart from the lactation and endocrine effects, prolactin may 
have the luteotrophic function by potentiating the effect of luteinizing hormone (LH) on 
steroidgenesis in granulosa-luteal cells and inhibiting the 20α-hydroxysteroid dehydrogenase 
enzyme which inactivates progesterone (Freeman et al., 2000, Kanuka et al., 1997, Richards and 
Williams, 1976). Therefore, prolactin plays an important role in maintaining corpus luteum 
function and progesterone secretion, with potential impact on establishment of pregnancy. The 
exact mechanism of the luteotrophic effects of prolactin is still unclear.  
 
Recently the role of prolactin in RM has attracted more attention. Several studies have reported a 
high prevalence of hyperprolactinaemia in the follicular phase in women with RM and described 
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the suppression of prolactin secretion with bromocriptine to improve pregnancy outcome 
(Hirahara et al., 1998, Csemiczky et al., 2000, Bussen et al., 1999), suggesting that high plasma 
prolactin levels may be a possible aetiological factor of RM. However, our earlier study showed 
that hyperprolactinaemia rarely occurs in women with RM  (2.5%, 3/122)  (Li et al., 2000). In 
some studies it has been suggested that an adequate level of plasma prolactin is essential to 
maintain corpus luteum function (Gåfvels et al., 1992) and establish a successful pregnancy (Oda 
et al., 1991). In IVF treatment it has been observed that transient hyperprolactinaemia is 
associated with a better chance of successful pregnancy outcomes (Ozaki et al., 2001). The 
inadequate expression of prolactin and its receptor in endometrium during the implantation 
window has been found to cause premature luteolysis and subsequent infertility or recurrent 
miscarriages (Garzia et al., 2004). Therefore, this raises the question of whether or not a high 
plasma prolactin level is associated with an increased risk of recurrent miscarriage. Due to the 
paucity of the studies in this area, the relationship between the plasma prolactin level and RM is 
still unclear. The aim of this retrospective study was to investigate the relationship between 
plasma prolactin concentrations and the pregnancy outcomes in a large cohort of women with 
unexplained RM.  
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II. Materials and Methods 
Subjects 
A series of 174 consecutive women with unexplained RM, who had plasma prolactin 
concentrations measured in the early follicular phase from January 1999 to September 2009, were 
identified from the clinical database and were included in this study. All the patients who 
conceived again after the referral were offered telephone pregnancy counselling service as part of 
‘tender loving care’ throughout their subsequent pregnancies. No other treatment was given to this 
group of women.   
 
Outcome measures 
Pregnancy outcome was defined as the outcome of the first pregnancy after referral. In patients 
who conceived more than once during the study period, only the first pregnancy was considered. 
 
Prolactin measurement 
Blood samples for plasma prolactin measurements were taken in the early follicular phase. 
Prolactin assay was performed by automated microparticle enzyme-immunoassay (Abbott Axsym 
Analyser, Abbott Diagnostics) at the Clinical Chemistry Department, Royal Hallamshire Hospital. 
The intra-and inter-assay coefficient of variation for prolactin measurement was 3.7% and 11.5%. 
The presence of hyperprolactinaemia was defined as plasma prolactin concentration > 660 mIU/l. 
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III. Statistical Analysis 
Results were expressed as numbers, mean ±SE, range and percentages as appropriate. Normal 
distribution of prolactin value was tested with Kolmogorov-Smirnov test. Differences in plasma 
prolactin concentrations between women who subsequently miscarried and those who had a live 
birth were analysed with T test. The difference in the miscarriage rate between the two subgroups 
was analysed with Pearson x
2
 test. Statistical significance was set at p value <0.05 and analysis 
were performed using SPSS (Statistical Package for the Social Sciences) version 16. 
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IV. Results 
A total of 174 women with unexplained RM had their plasma prolactin measured. The mean age 
(±SE) was 32.2 (± 0.4) years; the median number of previous miscarriages was 4 (ranged from 3 
to14). The mean (±SE) prolactin concentration was 226 (±9.3) mIU/l. Among those 174 women 
with unexplained RM, 40 of them did not conceive and 9 of them were lost to follow-up. The 
remaining 125 women with unexplained RM conceived again after the referral. The differences in 
clinical profile between women who conceived (n=125) and those who did not conceive (n=40) 
are shown in table VI-1. As expected, women who did not conceive were older than those who 
conceived (P< 0.05). Women who conceived again had higher mean prolactin concentrations than 
those who did not conceive. However, the difference was not significant.  
 
Among those 125 women with unexplained RM who conceived again, 2 women had ectopic 
pregnancies, 3 women had mid-term miscarriages due to cervical incompetence, 3 women had 
mid-term terminations of pregnancies due to fetal deformation and 8 women lost follow-up of 
their pregnancy outcomes. Therefore, they were excluded from the study analysis. A total of 109 
women with subsequent pregnancies were included in the study analysis. The mean age was 31.9 
(±0.6) years. The median of the numbers of previous miscarriages was 3 (ranged from 3 to 7). The 
mean (±SE) concentration of prolactin was 278 (±13.1)mIU/L. 
 
In the 109 subsequent pregnancies, 49 (45%) pregnancies resulted in the first trimester loss again 
whereas 60 (55%) pregnancies resulted in live birth. Women with a subsequent live birth had 
significantly (ρ=0.01) higher prolactin concentrations (308± 12.2mIU/l) than those with a 
subsequent miscarriage (240±16.8mIU/l) (Figure VI-1).  
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These 109 women were further divided into two subgroups according to the mean value of the 
prolactin measurements. 45 women with prolactin concentrations above the mean level were 
allocated into high normal prolactin group and 64 women with those below the mean level were 
allocated into low normal prolactin group (Table VI 2). The miscarriage rate in women with high 
normal prolactin (15/45, 33.3%) was significantly lower (p<0.05) than that in women with low 
normal results (34/64, 53.1%). 
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Table VI 1. The differences in demographics between 125 women with unexplained RM who conceived again 
and 40 women with unexplained RM who did not conceive 
 Women who conceived 
(n=125) 
Women who did not conceive 
(n=40) 
 
ρ value 
Age (years) 31.0  ± 0.6 32.6  ± 0.5 ρ = 0.02* 
No. of previous miscarriages 
(median, range) 
 
4 (3-10) 
 
4 (3-14) 
ρ = 0.47 
Prolactin concentrations (mIU/l) 234.5  ± 12.6 196.3  ± 9.9 ρ = 0.26 
All the values are shown in the form of mean ± SE unless otherwise specified. 
* Significant 
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Figure VI 1. Prolactin concentrations of women with unexplained RM who had a subsequent live birth and 
those who miscarried again 
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Table VI 2. The differences in the miscarriage rates between the two subgroups 
  
High normal prolactin subgroup 
(prolactin≥278mIU/l) 
n=45 
 
Low normal prolactin subgroup 
(prolactin<278mIU/l) 
n=64 
 
 
 
p value 
 
Age (years) 31.5 ± 0.8 32.1 ± 0.7 ρ >0.05 
No. of previous miscarriages 
(median, range) 
3 (3-6) 3 (3-7) ρ >0.05 
No. of miscarriages 
(n, %) 
15 (33.3%) 34(53.1%) ρ <0.05* 
Prolactin concentration (mIU/l) 415 ± 17.9 181 ± 7.0 ρ <0.05* 
All the values are shown in the form of mean ± SE unless otherwise specified. 
*significant 
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V. Discussion 
The role of prolactin in RM is controversial. Some studies have reported a high occurrence of 
hyperprolactinaemia in women with RM and a positive association between hyperprolactinaemia 
and adverse pregnancy outcomes (Bussen et al., 1999, Csemiczky et al., 2000, Hirahara et al., 
1998). However, evidence from observational studies in IVF shows that women with high 
prolactin concentrations have a better pregnancy rate and live birth rate, indicating high prolactin 
may benefit pregnancy (Ozaki et al., 2001). This conclusion is supported by other studies in which 
a lack of endometrial expression of prolactin was found to be associated with an increased risk of 
miscarriage (Garzia et al., 2004). These contradictory findings failed to resolve the question as to 
whether prolactin is detrimental or beneficial in pregnancy. Therefore, we conducted a study to 
examine the role of plasma prolactin in RM. 
 
In this study the role prolactin in RM was examined in a large cohort of 174 women with 
unexplained RM using patient data taken from the clinical database. We only included women 
with unexplained RM in whom other possible causes of RM have been excluded to enable 
prolactin concentration to be the only factor affecting pregnancy. In this study we found that 
women with plasma prolactin concentrations in the lower end of the physiological range had an 
increased risk of miscarriage, suggesting that adequate concentrations of plasma prolactin 
participate in the maintenance of pregnancy. 
 
The adverse effect of low prolactin concentration on pregnancy outcome found in this study is 
consistent with some previous studies where the relationship between the plasma prolactin 
concentration and the outcome of assisted conception treatment were examined. Ozaki et al 
(2001) compared plasma prolactin concentrations between women who had subsequent live births 
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following IVF treatment and those who had early pregnancy losses. They found that women with 
successful pregnancies had significantly higher prolactin levels than those with early losses 
(Ozaki et al., 2001). In a study by Gonen and Casper (1989) transient hyperprolactinaemia 
following ovarian stimulation was found to be associated with a better chance of pregnancy 
following IVF treatment. Before HCG administration, there was no significant difference in the 
basal prolactin level between women who subsequently conceived and those who did not conceive 
(11.1±0.6ug/l vs 10.1±0.4ug/l). After HCG administration, the prolactin level in the pregnant 
group was significantly higher than that in nonpregnant group (20.8±1.6ug/l vs 16.0±0.9ug/l) 
(Gonen and Casper, 1989). It is not yet understood why in assisted conception women with high 
prolactin levels had better pregnancy outcomes. It has been observed that women with higher 
prolactin concentrations had significantly higher fertilization rates and cleavage rates of oocytes in 
IVF treatment than those with low prolactin concentrations (Oda et al., 1991).  
 
While some studies reported that high prolactin levels had an inhibitory effect on GnRH release 
and HCG-induced ovulation, and a negative regulatory function on endometrial decidualization in 
pregnancy (Milenković et al., 1994, Liu et al., 1997, Eyal et al., 2007), other studies have reported 
a beneficial effect of prolactin on pregnancy. Plasma prolactin was found to have a beneficial 
effect on maintaining corpus luteum in early pregnancy via modulation of luteinizing 
hormone/chorionic gonadotropin  (LH/CG) receptors (Gåfvels et al., 1992). LH/CG receptors are 
expressed in corpus luteum tissue and chorionic villous macrophages after implantation (Sonoda 
et al., 2005, Saint-Dizier et al., 2004). In a rat model it has been demonstrated that inhibition of 
plasma prolactin secretion with bromocriptine during early pregnancy deceased LH/CG receptors 
and led to premature luteolysis, subsequently resulting in miscarriage. This effect can be reversed 
by prolactin supplementation after implantation (Gåfvels et al., 1992, Chan et al., 1980), 
suggesting that adequate prolactin secretion is of protective to pregnancy. 
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The relationship between the prolactin concentration and the outcome of spontaneous pregnancy, 
especially in women with a history of recurrent pregnancy loss has not been previously studied. In 
our study, we found women who subsequently miscarried had a lower plasma prolactin 
concentration than those who had a live birth. We also found that plasma prolactin level appears 
to have a prognostic value on the outcome of pregnancy in women with RM, with low 
physiological levels having a worse outcome than high levels. Thus our data supports the notion 
that low prolactin level is associated with an adverse pregnancy outcome. 
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VI. Conclusion 
In conclusion, we found that in women with unexplained RM a low prolactin level is associated 
with an increased risk of miscarriage. The exact reason for the observation is unclear but it seems 
likely that an adequate level of prolactin concentration is needed for the maintenance of successful 
pregnancies. It will be of interest to further examine the expression prolactin and its receptor in 
the endometrium to ascertain the mechanism of RM in association with low prolactin 
concentrations. 
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Chapter VII: The expression of endometrial prolactin receptor in 
RM 
I. Introduction 
The success of pregnancy relies on two aspects, namely uterine receptivity and embryo 
development. It is crucial that the endometrium undergoes a series of morphological changes and 
tissue remodeling in the decidualization process of early pregnancy to facilitate the invasion and 
implantation of the proliferating trophoblast cells. It is well recognized that a number of growth 
factors, cytokines and protein hormones are involved in the initiation and development of 
decidualization.  
  
Prolactin is a polypeptide hormone and is synthesized and secreted by lactotroph cells in the 
anterior pituitary gland (Freeman et al., 2000). Prolactin is a reproductive hormone and regulates 
lactation. The extra-pituitary expression of prolactin and its receptors in the glandular epithelial 
cells of secretory endometrium and in the decidua of early pregnancy has been identified (Jones et 
al., 1999). Endometrial prolactin increases steadily after implantation, reaching a peak at about 
20-25 weeks of pregnancy and declines towards term (Wu et al., 1995). Endometrial prolactin 
RNA transcript is longer than pituitary prolactin. Endometrial prolactin has been considered to be 
distinct from pituitary prolactin structurally, chemically, immunologically and biologically 
(Gellersen et al., 1989, Gellersen et al., 1994). Endometrial prolactin may have a role in 
decidualization and embryo implantation through modifying the expression of adhesion and 
proteolytic molecules which facilitate trophoblast cell invasion following extracellular matrix 
degradation of the endometrium (Starzyk et al., 1999, Ormandy et al., 1997, Horseman et al., 
1997).  
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The biological functions of prolactin are mediated by interaction with its receptors of long or short 
isoforms (Binart et al., 2010, Bole-Feysot et al., 1998). Studies have found prolactin induced up-
regulation of prolactin receptor expression in the corpus luteum during pregnancy (Telleria et al., 
1997). Prolactin receptors are transmembrane cytokine receptors that initiate kinase signaling 
pathways such as JAK/STAT (Bachelot and Binart, 2007, Jabbour et al., 1998). The expression of 
endometrial prolactin receptor has been found to be upregulated during the secretory phase of the 
menstrual cycle and influence glandular epithelial and stromal proliferation and gene transcription 
of the mitogenic and differentiative effect of hormones (Jabbour et al., 1998). The target 
hormones activated by prolactin receptor in endometrium is still not clear. The time and site of its 
expression in endometrial tissue suggest a crucial role for prolactin and its receptor in 
establishment and maintenance of early pregnancy. In human endometrium prolactin receptor has 
been found to regulate the decidualization via autocrine pathway (Eyal et al., 2007). 
 
Prolactin receptors have also been identified in uterine natural killer (NK) cells (Gubbay et al., 
2002). The distinctive presence of uterine CD56
bright
 NK cells around trophoblast cells during 
implantation suggests that they may play an important role in angiogenesis and immunoregulation 
between the fetal-maternal interface in early pregnancy (Quenby et al., 2008).  Therefore, 
prolactin may also affect uterine NK cells function or differentiation with mitogenic effect 
through ERK phosphorylation pathway (Gubbay et al., 2002) and thus affect implantation in this 
way. 
  
The aim of this study was to examine the relationship between endometrial prolactin receptor and 
RM by comparing the expression of prolactin receptor in endometrium between women with 
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unexplained RM and fertile women; and correlating the expression of prolactin receptor with the 
subsequent pregnancy outcome in women with unexplained RM. 
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II. Materials and Methods 
1 Subjects 
1.1 Cases 
A total of 22 endometrial biopsies from cases with unexplained RM were used for prolactin 
receptor measurements. The LH timed endometrial tissues were obtained with a pipelle sampler 
(Prodimed, France) on LH day 7 to 9. The LH surge was detected with daily urine dipsticks 
(Clearblue, UK) from day 10 of the cycle onwards until LH surge was identified. The details of 
the endometrial biopsy collection procedure has been described in Chapter V. Samples were fixed 
in formalin and wax embedded in the Histology Department for immunohistochemistry. Slides 
were cut from these biopsy samples and sent to the laboratory in the Academic Unit of 
Reproductive and Developmental Medicine. The mean (±SE) age of these cases is 35.7 (±1.0) 
years. 
 
1.2 Controls  
Nine endometrial samples from healthy women of proven fertility were retrieved from the 
Pathology Department of the Royal Hallamshire Hospital. The endometrial biopsies were 
collected in the mid luteal phase from LH day 7 to 9. The endometrial tissue was fixed in formalin 
and wax embedded in the Histology Department. Slides were cut from these biopsy samples and 
sent to the laboratory in the Academic Unit of Reproductive and Developmental Medicine. The 
mean (±SE) age of these controls is 34.3 (±0.8) years. 
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2 Methods 
Technical optimization of the immunohistochemical procedure 
Standard immunohistochemistry techniques were used in this study to identify the expression of 
prolactin receptor in endometrium from women with unexplained RM and healthy fertile women. 
The principle of immunohistochemistry has been discussed in the previous relevant chapter. The 
protocol was optimized to determine the best conditions for the best immunostaining with 
minimal background staining in the laboratory in the Academic Unit of Reproductive and 
Developmental Medicine. The monoclonal mouse anti human prolactin receptor antibody 
(AbCam, UK) was used as the primary antibody to determine the expression of prolactin receptor 
in this study. The antibody was tested with the positive control tissue of breast carcinoma to verify 
the specificity of the antibody. A series of dilutions of the prolactin receptor antibodies were 
prepared at the concentrations of 1:250, 1:500, 1:750, 1:1000, 1:1250 and 1:1500 respectively 
with PBS solution as the diluent. The optimal dilution of prolactin receptor antibodies was 
determined when a clear product colour with a minimal background tissue staining was achieved 
at the end of the immunohistochemistry procedure. The optimal concentration of antibody dilution 
was confirmed at the ratio of 1: 500 after several pilot experiments. The preferred antigen retrieval 
method for prolactin receptor immunostaining was established with heat induced enzymatic 
procedure where sections were unmasked with 0.5% pepsin solution for 30mins in a waterbath 
under the temperature of 37°C. The detail of the procedure was illustrated as below. 
 
The paraffin embedded endometrial sections were dewaxed in the xylene twice and then 
rehydrated in the alcohol solution in descending concentrations three times. The sections were 
then washed in the tap water and quenched in the fresh made 3% of hydrogen peroxidise in 
methanol for 20 minutes to eliminate the endogenous nonspecific antigens. The sections were then 
washed again and digested with the 0.5% pepsin in hydrogen chloride in a moisture chamber for 
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30 minutes in a waterbath at 37°C. After antigen retrieval, the sections were blocked with the 
horse serum for 30 minutes at room temperature and then incubated with the prolactin receptor 
antibody at the dilution of 1:500 for 1 hour at room temperature. The biotinylated secondary 
antibody was applied for 30 minutes at room temperature after the sections were washed with the 
TBS buffer. Vectorstain was performed for 30 minutes followed by DAB application to colour the 
end products for 10 minutes. The sections were then counter stained with haematoxylin for 30 
seconds and dehydrated in the alcohol solution and rewaxed in the xylene solution respectively. 
The slides were then mounted and observed under the light microscopy. 
 
Quantification of immunohistochemical staining 
The immunostaining intensity in the tissue sections was graded and scored using H Scoring 
system (Lessey et al., 1996a, Lessey et al., 1996b) following the equation: 
H-score = ∑ Pi ( i + 1), where I = staining intensity (1= weak, 2 = moderate, 3 = strong) and Pi = 
percentage of cells stained at each intensity (0-100%). The expression of prolactin receptor was 
assessed separately in the luminal and glandular epithelium and in the stroma in mircroscopic 
fields at X10 magnification. The numbers of stromal cells with positive prolactin receptor 
expression were counted and expressed as the average of the cell numbers in ten fields at X400 
magnification.   
 
The scoring was conducted by two independent observers (SML and WL) both blinded to the 
status of the slides. In the case of a large discrepancy in the results between the two observers, the 
slides were reanalyzed in the presence of both observers until the final agreement in the scoring 
was reached. The results were determined by taking the average of the results from each 
individual observer. The staining procedure for prolactin receptor was performed and scored twice 
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to verify the reproducibility and the reliability of the results. The final results for the expression of 
prolactin receptor were obtained by using the average of each individual study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 157 
 
III. Statistical Analysis 
Statistical analyses were performed using the SPSS (Statistical Package for the Social Sciences) 
version 16. As the data of the H-scores of prolactin receptor was non-parametric, Mann Whitney 
U test was chosen for the statistical analysis to compare the differences in prolactin receptor 
measurements between groups. The correlation between prolactin receptor measurements and 
demographic features or psychometric measurements was analyzed with Spearman’s correlation 
coefficient test. Statistical significance was set at p value <0.05. 
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IV. Results  
1. The results of endometrial prolactin receptor measurements  
A total of 22 endometrial biopsies from women with unexplained RM and 9 endometrial biopsies 
from the fertile controls were used for prolactin receptor measurements. The 
immunohistochemical staining of prolactin receptor was identified in glands of breast carcinoma 
tissue from the positive control slides (figure VII-1). Positive immunostaining of prolactin 
receptor was identified in the luminal epithelium, glandular epithelium and stroma both in the 
endometrial tissue from women with RM and that from fertile controls. The pattern of the 
prolactin receptor expression in the endometrium of fertile women was seen with the strongest 
intensity of staining in the luminal epithelium, moderate to weak intensity in the glandular 
epithelium and very weak or no staining in the stoma (figure VII-2a). Women with unexplained 
RM were found to have a similar pattern of endometrial prolactin receptor expression (figure VII-
2b). 
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Figure VII 1 (a, b). Immunohistochemical staining for prolactin receptor in positive control slides (breast 
carcinoma tissue). Magnification X100 
 
(a) 
 
 
 
(b) 
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Figure VII 2 (a, b). Immunohistochemical staining for prolactin receptor in the endometrium of fertile women 
and women with unexplained RM. Magnification X100. Prolactin receptor was stained strongly in the luminal 
epithelium, moderately in glandular epithelium and weakly in stroma. The black arrow points to the positive 
staining cells for prolactin receptor. 
 
(a). The expression of prolactin receptor in the endometrium of fertile women in the mid luteal phase 
 
 
 
(b). The expression of prolactin receptor in the endometrium of women with unexplained RM in the mid luteal phase 
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2. The comparison of the scores of endometrial prolactin receptor between cases and 
controls 
Table VII-1 shows the results of prolactin receptor H-scores in each compartment of the 
endometrium of the 22 cases and 9 controls and the positive cell counting in stroma between the 
two groups. No significant difference was found in the endometrial prolactin receptor expression 
between cases and controls (p>0.05). When comparing the difference in prolactin receptor 
expression between cases with different conception outcomes or different pregnancy outcomes, no 
significant difference was seen between the subgroups with different conception outcomes or 
pregnancy outcomes (p>0.05) (table VII-2, 3).  
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Table VII 1. A comparison of the H scores of the immunohistochemical staining of prolactin receptor in each 
compartment of the endometrial tissue between cases and controls 
 Women with unexplained RM 
N=22 
Fertile women 
N=9 
 ρ  value 
Luminal epithelium 223.8 (55-300) 220 (135-312.5) ρ = 0.54 
Glandular epithelium 165.0 (0-255) 200 (50-300) ρ = 0.19 
Stroma 20.0 (0-80) 25 (0-60) ρ = 0.71 
Cell counting 1.0 (0.35-1.85) 1.1 (0.7-2.1) ρ = 0.59 
All the values are shown in the form of median and range. 
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Table VII 2. A comparison of the H scores of the immunohistochemical staining for prolactin receptor in each 
compartment of endometrium between 22 cases with different conception outcomes 
 Pregnant group 
N=16 
Non-pregnant group 
N=6 
 
ρ value 
Luminal epithelium 240 (55-300) 228.8 (140-292.5) ρ =0.77 
Glandular epithelium 160 (0-255) 180 (80-225) ρ =0.44 
Stroma 16.3 (0-70) 32.5 (0-80) ρ =0.32 
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Table VII 3. A comparison of the H scores of immunohistochemical staining for prolactin receptor in each 
compartment of endometrium tissue between 16 cases with different pregnancy outcomes 
 Live birth group 
N=7 
Miscarriage group 
N=9 
 
ρ value 
Luminal epithelium 205 (55-262.5) 240 (100-300) ρ =0.61 
Glandular epithelium 170 (0-255) 150 (40-245) ρ =0.53 
Stroma 5 (0-70) 35 (0-52.5) ρ =0.23 
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3. The correlation between the endometrial prolactin receptor measurements and the 
demographics, plasma prolactin measurements and the psychometric measurements 
Spearman’s correlation analysis shows that there was a significant correlation between prolactin 
receptor expression in the luminal epithelium and the numbers of previous miscarriages (p <0.05) 
(figure VII-4). Women with unexplained RM who had more previous miscarriages had higher 
expression of prolactin receptor in endometrium. No significant correlation was found between 
plasma prolactin measurements and the prolactin receptor measurements in various compartments 
of the endometrium tissue (p >0.05) (table VII-4). Table VII-5 shows the correlation between 
endometrial prolactin receptor expression and the results of psychological measurements in the 22 
cases. No significant correlation was found between endometrial prolactin measurements and 
psychometric measurements.  
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Table VII 4. The correlation between the H scores of endometrial prolactin receptor and the demographics and the plasma prolactin concentrations 
  prolactin receptor expression in luminal 
epithelium 
 
prolactin receptor expression in glandular 
epithelium 
prolactin receptor expression in 
stroma 
Age (years) 
 
ρ =0.24 ρ =0.43 ρ =0.65 
No. of previous 
miscarriages 
ρ =0.03* ρ =0.12 ρ =0.91 
Plasma prolactin 
concentrations 
ρ =0.11 ρ =0.18 ρ =0.19 
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Figure VII 3. A positive correlation between the H scores of prolactin receptor in luminal epithelium and the 
numbers of previous miscarriages 
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Table VII 5. Correlation between psychometric measurements and the expression of prolactin receptor in each 
compartment of endometrium in women with unexplained RM 
 FPI PSS PANAS Positive Affect PANAS Negative Affect 
prolactin receptor in luminal epithelium 
n=22 
ρ =0.16 ρ =0.32 ρ =0.62 ρ =0.65 
prolactin receptor in glandular epithelium 
n=22 
ρ =0.46 ρ =0.23 ρ =0.84 ρ =0.91 
prolactin receptor in stroma 
n=22 
ρ =0.22 ρ =0.06 ρ =0.14 ρ =0.20 
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V. Discussion 
The expression of endometrial prolactin receptor in RM 
In the preceding chapter we demonstrated a reverse association between plasma prolactin and 
pregnancy outcomes in women with unexplained RM. In this chapter we extended our study to the 
endometrial level to examine the relationship between the endometrial prolactin receptor and RM. 
In this present study we examined the expression of prolactin receptor in each endometrial 
compartment including luminal epithelium, glandular epithelium and stroma. 
Immunohistochemical localization revealed that endometrial prolactin receptor is strongly 
expressed in the epithelium of lumina and glands and weakly expressed by the stroma. This 
finding is consistent with previous studies which showed strong expression of endometrial 
prolactin receptor in epithelium layers of lumina and glands either in the mid to late luteal phase 
of endometrium or in deciduas (Jones et al., 1998, Garzia et al., 2004). In addition, we also found 
some individual cells which expressed prolactin receptor in the stroma of the mid-luteal phase of 
endometrium. In previous studies double immunofluorescence using antibodies against both 
prolactin receptor and CD56 showed that the prolactin receptor positive cells in stroma were also 
positive for CD56, suggesting that prolactin receptor was expressed in the uNK CD56 cell 
population in endometrial stroma (Gubbay et al., 2002). Therefore, the individual brown stained 
cells found in this study may be a subpopulation of uNK cells. 
 
In this study we did not find any significant difference in the expression of the endometrial 
prolactin receptor between women with RM and fertile women. However, we found that the 
numbers of previous miscarriages was correlated with the expression of prolactin receptor in 
luminal epithelium.  
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Our finding is in contrast with a previous study in which a significant reduction of prolactin 
receptor expression in the endometrium was observed in women with RM (Garzia et al., 2004). In 
the study of Garzia et al, the quantity of the expression of endometrial prolactin receptor was 
examined by RT-PCR method and the localization of its expression in endometrium was 
examined by immunohistochemistry method.  In our study we immunolocalized the pattern and 
site of endometrial prolactin receptor expression in women with RM and employed H-score to 
quantify the significance. H-score is a semi-quantitative calculation method which takes into the 
consideration of the staining intensity in conjunction with the percentage of positive stained cells. 
The results of H-score are subject to a variety of subjective factors, such as observers and quality 
of the staining. Therefore, different observers may produce different results based on their own 
judgment upon the extent of the staining. In the present study we also found discrepancy in the 
results of H-score of several slides between the two observers who conducted the scoring. We 
overcame this problem by identifying the disputed slides and double checking the results with the 
presence of both observers until the agreement was reached. Therefore, the finding of no 
significant differences in the expression of endometrial prolactin receptor in RM in this study with 
H-score method needs to be verified in a future study. In the future it will be of interest to 
combine both qualitative PCR and quantitative immunohistochemistry methods to further identify 
the expression of prolactin receptor in women with RM. 
 
The relationship between endometrial prolactin receptor and pregnancy outcomes in women 
with RM 
We examined the impact of endometrial prolactin receptor expression on pregnancy outcome in 
women with RM. So far this is the first study examining the relationship between endometrial 
prolactin receptor and pregnancy outcomes. In this study we did not find a significant association 
between prolactin receptor expression and pregnancy outcomes. Apart from the limitation of H-
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score method we used in this study, it worth to note that the small numbers of cases included in 
this part of study may limit the power to detect a significant difference. Therefore, a future 
prospectively designed study with a larger sample size may be necessary to verify whether or not 
there is an association between prolactin receptor expression and pregnancy outcome in women 
with RM. 
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VI. Conclusion 
In this study we identified the pattern and site of the expression of the prolactin receptor in the 
endometrium tissue in women with RM. We did not find a significant difference in the expression 
of the endometrial prolactin receptor expression between women with RM and fertile controls. 
Instead we found RM women with more previous miscarriages had significantly higher 
expression of prolactin receptor in the luminal epithelium. The exact mechanism for this 
observation is not clear. It will be of interest to employ both qualitative and quantitative methods 
in the future study to further examine the relationship between the expression of endometrial 
prolactin receptor and RM. 
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Chapter VIII: Measurement of cortisol in the evaluation of the 
relationship between stress and RM 
I. Introduction 
Cortisol is synthesized from cholesterol in the adrenal cortex and is the end product of the HPA 
(Hypothalamic-pituitary-adrenal) axis activation. Recently the measurement of cortisol as a 
biomarker in the evaluation of the HPA response to the psychological stress and related mental 
health disorders has been paid more attention. One of the prominent physiological changes in 
response to stress stimulation is the activation of the HPA system and the subsequent increased 
release of cortisol from the adrenal cortex into peripheral blood. Excessive secretion of 
glucocorticoids under stress exerts multiple metabolic effects and subsequently compromises 
homeostasis, thereby impairing pregnancy.  
 
There is increasing evidence showing that psychosocial stress in the antenatal period may cause 
serum cortisol elevation (Diego et al., 2006, Demyttenaere et al., 1992, Wadhwa et al., 1996). For 
example, one study examined 54 women prior to 28 weeks gestation and found that the stress 
scores in these women were positively correlated with the serum cortisol elevation (Wadhwa et 
al., 1996). It has been suggested that high cortisol levels may have a negative effect on the 
establishment of pregnancy. For example, a study examined 40 women undergoing IVF treatment 
and found that women with higher concentrations of cortisol had poorer pregnancy rates following 
IVF than those with lower concentrations of cortisol (Demyttenaere et al., 1992). In a prospective 
study Nepomnaschy and colleagues measured peripheral serum cortisol concentrations in 22 
pregnant women during the first three weeks after conception and found that women whose 
pregnancies subsequently miscarried (n=13) had significantly higher mean serum cortisol 
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concentrations than those whose pregnancies resulted in live births (n=9) (Nepomnaschy et al., 
2006). In the same study population, they also found that women with high serum cortisol levels 
(n=12) were 2.7 times more likely to miscarry in their subsequent pregnancies than those with 
normal cortisol levels (n=10), suggesting that high levels of cortisol may contribute to 
miscarriage. However, the exact physiological mechanism of the adverse effect of high cortisol on 
pregnancy outcome is yet unknown.  
 
 The measurement of cortisol in the evaluation of the HPA function may be affected by various 
factors. Cortisol secretion has a circadian rhythm, usually peaking between 07:00 and 11:00 hours 
and declining across the day such that lower levels are present in the circulation between 21:00 
and 00:00 hours (Nomura et al., 1997). In most studies the level of serum cortisol in the morning 
has been measured to evaluate the pituitary and adrenal function at the time of maximal secretion 
(Dickerson and Kemeny, 2004). Serum cortisol (hydrocortisone; 11β, 17α, 21-trihydroxy-4-
pregnane-3, 20-dione) may be free or bound to corticosteroid-binding globulin (CBG) and 
albumin in the circulation (figure IV-1). Approximately 75~80% of cortisol in circulation is bound 
to CBG and 15% of cortisol is bound to albumin (Brien, 1981). Free cortisol which is the unbound 
portion is biologically active and measured as an index of cortisol concentration (Gozansky et al., 
2005, Morineau et al., 1997).  
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Figure VIII 1. Structure of corticosteroid-binding globulin in complex with cortisol. This work has been 
released into the public by its author I, Lijealso. This applies worldwide. 
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Recently, studies have reported the measurement of serum cortisol in the evaluation of HPA 
dysregulation and the escape of cortisol suppression in the HPA function test in women with 
psycho-psychiatric disorders (Fountoulakis et al., 2004, Wingenfeld et al., 2007, Gaab et al., 
2003). The Dexamethasone Suppression Test (DST) has been widely used to assess pituitary and 
adrenal function. In normal subjects dexamethasone suppresses ACTH (Adrenocorticotrophic 
Hormone) and therefore cortisol secretion. Significantly impaired adrenocortical responsiveness 
following the DST was found in subjects with depression or borderline personality disorder, 
compared with healthy subjects (Wingenfeld et al., 2007, Fountoulakis et al., 2004). Half of the 
patients with a depressive syndrome were found to be the non-DST suppressors and DST results 
were shown to be a useful measure of depression rather than symptomatology (Fountoulakis et al., 
2004). It was suggested that DST non-suppression in women with distress was due to the 
development of a reversible glucocorticoid resistance with compromise of the inhibitory feedback 
of exogenous cortisol on the HPA axis after the DST (Wingenfeld et al., 2007, Stokes and Sikes, 
1988, Herman and Cullinan, 1997). In addition, significant menstrual cycle changes in cortisol 
suppression after dexamethasone administration have been found. Tandon et al conducted a study 
in 25 hospitalized women with major depression who had weekly DST measurements. They 
found that cortisol suppression were lowest at 3.84 μg/dl during menstrual period, rose to 4.94 
μg/dl in the follicular phase, reached a peak at 7.61 μg/dl in the periovulation period and declined 
in the luteal phase to 5.00 μg/dl (Tandon et al., 1991). This finding suggests that the phase of the 
menstrual cycle is an important confounding variable in the interpretation of the result of the DST 
in women. There is likely to be less suppression with DST in women in the luteal phase than in 
the follicular phase. Therefore, cortisol suppression in women is usually assessed in the follicular 
phase to precisely reflect the pituitary-adrenal function. Other factors that may cause false positive 
responses in the DST test include malabsorption of dexamethasone, drugs that increase the hepatic 
clearance of dexamethasone and oestrogen therapy or pregnancy (Newell-Price, 2008).  
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The alteration of HPA function in response to stress is modulated by several other factors. The 
sampling of serum cortisol involves venipuncture which can act as an acute stressor to increase 
HPA activity and therefore potentially giving a false positive result of HPA activation. It is not 
practical to perform a series of blood collections throughout normal daily activity to assess the 
HPA function in routine clinical practice. Recently studies have provided evidence that urinary 
and salivary cortisol can be used as surrogates for plasma cortisol with the advantage of non-
invasive sample collection and ease of repetition (Gozansky et al., 2005, Nakamura et al., 2008). 
It has been found that 24-hour urinary cortisol value has a positive and significant correlation with 
plasma cortisol (Nelson et al., 2002). Urinary cortisol increased in response to stress and its 
increases were associated with the intensity of the stress (Smitha and French, 1997). 
 
Recently the advantage of the measurement of salivary cortisol as a surrogate to serum cortisol in 
the study of the HPA axis has received more attention (Perogamvros et al., 2010b, Perogamvros et 
al., 2009). Salivary cortisol at 23:00 hours has been proposed to replace serum midnight cortisol 
due to its sensitivity and specificity in diagnosis for the presence of subtle cortisol excess 
(Putignano et al., 2001, Gozansky et al., 2005, Perogamvros et al., 2010b, Perogamvros et al., 
2009). Salivary cortisol reflects the bioactive fraction of serum free cortisol and is not affected by 
changes in cortisol-binding globulin (Perogamvros et al., 2010b). Salivary cortisol as a practical 
surrogate to serum free cortisol has been found to be increased under stress stimulation 
(Federenko et al., 2004) and its elevation is positively correlated with the stress scores (Ng et al., 
2003). Studies compared the utility of salivary cortisol and serum cortisol in the measurement of 
psychological dysfunction of the HPA axis and concluded that saliva is a sensitive and reliable 
medium for cortisol measurement (Deutschbein et al., 2009, Baghai et al., 2002). In studies 
comparing salivary cortisol with simultaneously obtained serum cortisol in assessing the dynamic 
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HPA axis activity, salivary cortisol demonstrated a higher sensitivity and specificity in the HPA 
function test than serum cortisol (Gozansky et al., 2005, Perogamvros et al., 2010a), suggesting 
that measurement of salivary cortisol may replace serum cortisol with the advantage of non-
invasive sample collection and free of cortisol-binding globulin influence.  
 
The immunoassay for the measurement of salivary cortisol is affected by variable cortisol 
interferences. The enzyme 11β-hydroxysteriod dehydrogenase type2 (11β-HSD2) expressed in the 
parotid glands is capable of converting active cortisol into inactive cortisone, which causes the 
cross-reactivity of cortisone in the determination of cortisol concentration with immunoassays 
(Smith et al., 1996). To address this limitation, Perogamvros et al conducted a series of studies to 
develop a novel, robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for 
the combined measurement of salivary cortisol and salivary cortisone (Perogamvros et al., 2009). 
They compared the value of salivary cortisol measurement of LC-MS/MS assay with serum free 
cortisol measurement in the HPA function test and found that salivary cortisol measurement is 
superior to serum cortisol measurement with a higher sensitivity and specificity (Perogamvros et 
al., 2010b). In the present study we employed this accurate assay to precisely measure salivary 
cortisol in the stress assessment of women with unexplained RM. 
 
The aim of this study was to determine if RM was associated with the feedback dysregulation of 
the HPA axis by measuring cortisol suppression in serum and saliva following the Dexamethasone 
Suppression Test and basal midnight salivary cortisol. 
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II. Materials and Methods 
1 Subjects 
Among 36 participants who were recruited in the stress and RM project, six of them declined the 
Dexamethasone Suppression Test (DST) due to concerns about the side effects of steroid 
administration; four of them canceled the DST after they were prescribed the dexamethasone due 
to time pressure; one of them could not attend the scheduled appointment for the blood test after 
the dexamethasone administration due to heavy snow.  
 
The remaining 25 participants had blood samples taken for the morning serum cortisol 
measurement following the DST. 19 of them had primary RM and 6 of them had secondary RM. 
They all met the inclusion criteria of unexplained RM and none of them had the pituitary 
disorders, psychiatric illnesses or depression. They were informed of the nature of the study with a 
patient information leaflet and gave the written consent before the commencement of the cortisol 
measurement. The study was approved by the South Sheffield Research Ethics Committee 
(08/H1308/80).  
 
Among these 25 participants who underwent serum cortisol measurements following DST, three 
of them reported omitting saliva collection and thus did not collect saliva samples; three of them 
forgot to collect saliva samples with DST.  Therefore, a total of 19 participants collected saliva 
samples on two occasions in correspondence to the study protocol for the salivary cortisol 
measurements. 
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2 Procedure 
2.1 Serum Cortisol Measurement 
All the eligible participants were given an instruction leaflet on the Low Dose Overnight 
Dexamethasone Suppression Test (DST) for serum cortisol measurement at the RM clinic.  The 
DST was explained in detail by the investigator. They were reassured that no side effect would 
occur with the administration of a single low dose of exogenous glucocorticoid. They were 
required to take a tablet of Dexamethasone at the dose of 1mg at 23:00 hours on day 3, 4 or 5 of 
the menstrual cycle. At 9:00 hours the next morning a blood sample was obtained for serum 
cortisol measurement by the specialist nurse on the ward G1 in the Royal Hallamshire Hospital. 
The samples were analyzed in the Clinical Chemistry department of the Royal Hallamshire 
Hospital using the serum cortisol assay. 
 
2.2 Salivary Cortisol Measurement 
Salivary cortisol was measured during the DST. Participants were given sample collectors 
(Salivette, SARSTEDT, UK) to collect the midnight saliva samples at 23:00 hours at home prior 
to dexamethasone administration. Patients were instructed to refrain from brushing their teeth, 
smoking, eating or drinking anything but water for at least 60 minutes prior to sampling. The 
saliva sample was obtained by chewing the cotton wool swab which contained citrate acid to 
simulate the saliva flow. A sufficient volume of saliva was achieved when the swab was fully wet. 
The participants were required to store the samples in the freezer at home and return them back to 
the investigator the next morning on their visit for the blood tests. A second saliva sample was 
collected simultaneously with the collection of a blood test for the morning serum cortisol 
measurement as part of the dexamethasone suppression test. The saliva fluid was recovered from 
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the swab by spinning the container at 1000g for 5 minutes in the centrifuge and was stored at -20 
°C in the freezer for later analysis in batches in the University of Manchester.  
 
3  Methods 
3.1 Serum Cortisol Measurement 
Serum cortisol was measured by the Clinical Chemistry Department in the Royal Hallamshire 
Hospital with Bayer Advia Centaur automated immunoassay (Bayer, Newbury, UK).  The 
interassay coefficient of variation (CV) was 7% at 200nmol/l and 8% at 1050nmol/l. The 
intraassay CV was 4% at 28ng/l. The laboratory reference of the 1mg Dexamethasone 
Suppression Test is set at the suppression of the morning serum cortisol to less than 50nmol/l.  
 
3.2 Salivary Cortisol Measurement 
Salivary cortisol was measured with a liquid chromatography-tandem mass spectrometry (LC-
MS/MS) assay in the Department of Biochemistry in the University of Manchester with a lower 
limit of quantitation at 0.39nmol. The intra-assay CVs was 9.3% and inter-assay CVs was 9.7% at 
1.8-52.2 nmol/L of salivary free cortisol. The cut-off value for the midnight salivary cortisol 
estimation was recommended as 4nmol/l in LC-MS/MS assay with no blood contamination in the 
samples (Newell-Price, 2009). 
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III. Statistical Analysis 
Statistical analyses were performed using the SPSS (Statistical Package for the Social Sciences) 
version 16. Differences in the concentration of cortisol measurements between cases with 
different conception outcomes or different pregnancy outcomes were analyzed with independent T 
test. The correlation between cortisol measurements and case demographics was analyzed with 
Pearson Correlation coefficient test. The correlation between cortisol measurements and 
psychometric measurements was analyzed by Spearman’s rank correlation coefficient test.  
Statistical significance was set at p value <0.05. 
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IV. Results  
3.1 Serum cortisol measurements 
Among 25 patients who underwent the morning serum cortisol measurements following DST, 20 
of them had primary RM and 5 of them had secondary RM. The demographics of these 25 
patients are shown in table VIII-1. There was no significant difference in cortisol suppression 
between cases who subsequently conceived and those who did not, or between cases who had 
subsequent live births and those who had miscarriages again (ρ>0.05) (figure VIII-2, 3). 
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Table VIII 1. Demographics of the 25 cases with serum cortisol measurements 
Cases with serum cortisol measurements 
N=25 
Age (years) 35.7 ± 0.9 
No. of previous miscarriages 
median (range) 
 
4 (3-8) 
Serum cortisol suppression (nmol/l) 23.5 ± 4.3 
All the values are shown in the form of mean ± SE unless otherwise specified.  
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Figure VIII 2. A comparison of the resluts of serum cortisol suppression between 25 cases with different 
conception outcomes 
 
 
 
 
Figure VIII 3. A comparison of the results of serum cortisol suppression between 18 cases with different 
pregnancy outcomes 
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3.2 Salivary cortisol measurements 
Among the 19 cases with salivary cortisol measurements, 14 of them had primary RM and 5 of 
them had secondary RM. Table VII-2 shows the demographics of these 19 cases. There was no 
significant difference in the mid-night basal salivary cortisol measurements between cases with 
different conception outcomes or different pregnancy outcomes (p>0.05). The same pattern was 
seen in the morning salivary cortisol suppression where no significant difference was seen 
between cases with different conception outcomes or different pregnancy outcomes (p>0.05) 
(Table VII-3,4). 
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Table VIII 2. Demographic characteristics of 19 cases with salivary cortisol measurements 
Cases with salivary cortisol measurements 
N=19 
Age (years) 36 ± 1 
No. of previous miscarriages 
median (range) 
 
4 (3-8) 
Mid-night salivary cortisol (nmol/l) 2.5 ± 0.9 
Morning salivary cortisol (nmol/l) 1.9 ± 0.7 
All the values are shown in the form of mean ± SE unless otherwise specified.  
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Table VIII 3. The comparison of mid-night salivary cortisol concentrations and morning salivary cortisol 
suppression between 19 cases with different pregnancy outcomes 
 Pregnant group 
N=13 
Non-pregnant group 
N=6 
 
ρ value 
Mid-night salivary cortisol 
(nmol/l) 
 
1.2 ± 0.4 
 
5.2 ± 2.9 
 
> 0.05 
Morning salivary cortisol 
(nmol/l) 
 
1.7 ± 0.9 
 
2.3 ±1.5 
 
> 0.05 
All the values are shown in the form of mean ± SE. 
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Table VIII 4. The comparison of the mid-night salivary cortisol concentrations and morning salivary cortisol 
suppression between 13 cases with different pregnancy outcomes 
 Live birth group 
N=7 
Miscarriage group 
N=6 
 
ρ value 
Mid-night salivary cortisol 
(nmol/l) 
 
0.8 ± 0.4 
 
1.7 ± 1.0 
 
> 0.05 
Morning salivary cortisol 
(nmol/l) 
 
2.4 ± 1.6 
 
0.8 ± 0.1 
 
> 0.05 
All the values are shown in the form of mean ± SE. 
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3.3 The correlation between serum cortisol and salivary cortisol 
There was a significant positive correlation between the morning serum cortisol suppression 
following DST and morning salivary cortisol suppression (p=0.05) (figure VII-5). No significant 
association was seen between serum cortisol suppression and the basal midnight cortisol 
measurements (p=0.35). There was also no significant correlation shown between the morning 
serum cortisol suppression and the mid-night salivary cortisol measurements (p=0.38).  Cortisol 
measurements in both serum and saliva were found to have no association with the demographics 
of age and the numbers of previous miscarriages (p>0.05) (table VII-5).  
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Figure VIII 4. The correlation between the results of serum cortisol and salivary cortisol following 1mg 
Dexamethasone Suppression Test 
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R2 Linear = 0.309  
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Table VIII 5. The correlation between serum cortisol measurements and salivary cortisol measurements and 
the demographics 
 Serum cortisol 
suppression 
Morning salivary 
cortisol suppression 
Midnight basal salivary 
cortisol 
Age ρ= 0.45 ρ= 0.62 ρ= 0.06 
No. of previous miscarriages ρ= 0.54 ρ= 0.49 ρ= 0.33 
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3.4 The association between psychometric measures and cortisol measurements 
No significant correlation was found between cortisol measurements in serum and saliva and the 
each individual psychometric measures (ρ>0.05) (Table VII-6). 
 
Table VIII 6. The correlation between the scores of psychometric measurements and results of cortisol 
measurements in the 19 cases 
 
 
 
Serum cortisol 
Salivary cortisol 
Midnight salivary cortisol Morning salivary cortisol 
FPI ρ= 0.11 ρ= 0.63 ρ= 0.88 
PSS ρ= 0.81 ρ= 0.41 ρ= 0.66 
PANAS Positive Affect ρ= 0.82 ρ= 0.16 ρ= 0.99 
PANAS Negative Affect ρ= 0.23 ρ= 0.32 ρ= 0.62 
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V. Discussion 
The relationship between stress and cortisol alteration 
There is an increasing body of studies using cortisol as a biochemical marker in research on stress. 
In animal models, it has been demonstrated that assessment of the sensitivity of the HPA 
glucocorticoid feedback system is a better diagnostic tool for stress than the basal cortisol 
measurements (Kalin et al., 1981). In the human non-suppression following the Dexamethasone 
Suppression Test (DST) has been found to be associated with stress symptoms such as depression 
and stressful live events in which 35% patients were non-suppressors compared with only 6% of 
non-suppressors in healthy controls (Faravelli et al., 2010), suggesting that the DST is an useful 
screen test in stress assessment.  
 
In this study we hypothesized that chronic stress caused by RM impaired the feedback regulation 
of the HPA system. Therefore, we employed the usual low dose 1mg DST to measure the HPA 
response to the stress from RM. Apart from measuring the serum cortisol suppression, the novelty 
of the present study lies in employing concurrent salivary cortisol measurements during the DST 
to more precisely identify the HPA response to RM stress. To overcome interference of the cross-
reactivity of cortisone in the determination of cortisol concentration with immunoassays, the 
salivary cortisol assay was performed in collaboration with the clinical laboratory of the 
Manchester University using a novel robust liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) assay. In this study we found that the morning serum cortisol suppression is 
correlated with the suppression in the morning salivary cortisol, supporting the notion that 
salivary cortisol measurement is consistent with serum cortisol measurements and salivary cortisol 
is a sensitive surrogate to serum cortisol in the HPA function test for stress assessment.  
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In the present study we did not find any case of non-suppression in the morning serum cortisol 
following DST in women with stress from RM. With regard to the effect of stress on cortisol 
alteration, no correlation was shown between the intensity of stress in women with RM and the 
cortisol measurements both in serum and saliva. When using the cut-off value of late night 
salivary cortisol at 4 nmol/l (Newell-Price, 2009), only 3 out of 19 participants had high midnight 
salivary cortisol measurements. 
 
Despite of increasing interests in using cortisol as a biochemical marker to assess stress, empirical 
studies assessing the association between cortisol alteration and stress have yielded conflicting 
findings. In contrast to early studies where positive correlation between cortisol non-suppression 
in DST and stress were demonstrated (Quenby et al., 2005, Wingenfeld et al., 2007), other studies 
did not find the association between the feedback dysfunction of the HPA system and stress 
(Lazarus and Folkman, 1984, Lange et al., 2005). As an example, Lange et al found no increase in 
the incidence of cortisol non-suppression following DST in subjects with personality disorders 
compared with healthy controls (Lange et al., 2005). In another study examining the association 
between stress and the cortisol alteration in saliva in 78 nurses who experienced examination 
stress, they found no significant change in salivary cortisol concentration before and after stress 
(Takatsuji et al., 2008).  
 
It has been proposed that the type of stress may be an important factor in determining the DST 
response. For example, in a study assessing the effect of childhood trauma on the feedback 
dysregulation of the HPA system using DST as the method, they found that there was no 
significant difference in scores of psychometric measurements between suppressors and non-
suppressors. However, non-suppressors had a significantly higher occurence of some types of 
stress symptoms than suppressors, suggesting that certain types of stress cause activation of the 
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HPA dysfunction, rather than the severity of stress (Quenby et al., 2005). In addition, another 
study found an enhanced suppression of salivary cortisol following DST in women with stress 
from chronic pelvic pain, indicating that in contrast to the current assumption of non-suppression 
of cortisol in women with stress, enhanced suppression may 
exist in a stressful condition (Kwak-Kim and Gilman-Sachs, 2008) . In the current literature, the 
use of DST as a diagnostic method has been extended to a number of psychiatric disorders 
without consensus on the type of stress measured, the psychometric measures adapted and the 
dose of dexamethasone administered in DST. As a result of these methodological issues, it is not 
surprising that conflicting findings are presented between studies. 
 
Our study is the first study employing DST in the assessment of stress in women with RM. 
Assessment of stress using DST is an imprecise measure of the HPA axis function. Failure of 
cortisol suppression in response to dexamethasone represents an abnormal physiological state 
which can be the result of several separate dysfunctions involving activation and interaction of 
neuronal and endocrine pathways involved in the HPA systems. Failure of cortisol suppression in 
response to dexamethasone has been used as a screening test in several studies in psychiatry, but 
has not been used to assess stress responses in patients without psychiatric disorders but who are 
placed in abnormal stress situations, such as women experiencing recurrent miscarriages. 
Evaluation of the precise neuroendocrine changes in the HPA system in stress condition is beyond 
the scope of this study. Based on the findings presented in the current study, it is likely that 
subclinical stress experienced by women with RM does not impair the feedback regulation of the 
HPA system.  
 
The relationship between cortisol concentrations and pregnancy 
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Previous studies have found high serum cortisol concentrations are associated with a poor 
conception rate and an increased risk of miscarriage (Nepomnaschy et al., 2006, Demyttenaere et 
al., 1992). However, other studies failed to confirm an association between serum cortisol 
concentrations and the risk of miscarriage (Nelson et al., 2003a). The lack of consensus on the 
methods used to measure cortisol concentrations between studies may account for this variation. 
For example, some studies measured cortisol concentrations with serum samples 4 times a day in 
the first trimester (Seng et al., 2005) whereas others measured cortisol with first-morning urinary 
samples every other day three times a week (Nepomnaschy 2006). Therefore, the results from 
studies with different methodologies are not comparable and may lead to conflicting findings. 
 
In this prospective study we compared cortisol suppression following DST in both serum and 
saliva, and the basal midnight salivary cortisol concentration between unexplained RM women 
with different conception outcomes and pregnancy outcomes. No association was found between 
cortisol concentrations and the conception probability or pregnancy outcomes in women with 
unexplained RM. However, we should note that the finding from the present study was obtained 
from a group of women with cortisol suppression within normal physiological range. None of the 
cases in this study had non-suppression of cortisol. It will be of interest in the future to examine 
the impact of cortisol concentrations on pregnancy outcomes with a more diverse study population 
stratified by different degrees of cortisol suppression. In addition, the limitations of the number of 
patients with cortisol measurements and the insufficient numbers in each subgroup in the analysis 
comparing different pregnancy outcomes may be inadequate to pick up the true difference. In the 
future study these issues should be addressed by using a larger sample size. 
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VI. Conclusion  
In this study we found that women with unexplained RM had normal cortisol suppression in the 
low dose of 1mg Dexamethasone Suppression Test. Cortisol concentrations in women with RM 
have no predictive value on conception rates and pregnancy outcomes. Based on the results 
derived from this study, we speculate that chronic RM-related stress has no effect on HPA 
feedback dysregulation. The findings in the present study need to be verified in future studies. 
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Chapter IX: The correlation of various biochemical stress markers in 
women with unexplained RM 
Results  
A total of 19 women with unexplained RM had the measurements of all the stress markers, 
including NK cell measurements both in peripheral blood and endometrium, cortisol 
measurements both in serum and saliva, and the measurements of prolactin in plasma and its 
receptor in endometrium. Table IX-1 shows the correlation between NK cell measurements and 
cortisol measurements and prolactin measurements in the 19 women with unexplained RM. Table 
IX-2 shows the correlation between cortisol measurements and prolactin measurements in the 19 
women with unexplained RM.  
 
Cortisol measurements were found to be significantly associated with NK cell measurements. 
Serum cortisol suppression was found to be inversely correlated with pNK CDbright expression 
(ρ<0.05) (figure IX-1). A lesser degree of serum cortisol suppression is associated with an 
increased expression of pNK CDbright subset. Salivary cortisol measurements were found to have 
a significant association with uNK cell measurements (ρ<0.05) (table IX-2). Increased uNK cell 
measurements were associated with an increase in the basal mid-night salivary cortisol levels and 
a decrease in the morning salivary cortisol suppression (figure VIII-2,3) 
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Table IX 1. The correlation between NK cell measurements and the measurements of cortisol and prolactin (n=19) 
 
 NK cell measurements 
pNK CDdim% pNK CDbright% uNK% 
 
Cortisol 
measurements 
Serum cortisol suppression (nmol/l) ρ = 0.58 ρ = 0.02* ρ = 0.85 
Moring salivary cortisol suppression (nmol/l) ρ = 0.19 ρ = 0.59 ρ = 0.03* 
Midnight salivary cortisol(nmol/l) ρ = 0.14 ρ = 0.81 ρ = 0.02* 
 
Prolactin 
measurements 
Plasma prolactin (mIU/l) ρ = 0.12 ρ = 0.31 ρ = 0.87 
Prolactin receptor in luminal epithelium ρ = 0.39 ρ = 0.47 ρ = 0.48 
Prolactin receptor in glandular epithelium ρ = 0.73 ρ = 0.62 ρ = 0.32 
Prolactin receptor in stroma ρ = 0.79 ρ = 0.97 ρ = 0.82 
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Table IX 2. The correlation between the results of cortisol measurements and the plasma prolactin concentrations and the H scores of endometrial prolactin 
receptor (n=19) 
 
 Cortisol measurements (nmol/l) 
Serum cortisol suppression Salivary cortisol suppression Midnight salivary cortisol 
 
Prolactin 
measurements 
Plasma prolactin (mIU/l) ρ = 0.60 ρ = 0.51 ρ = 0.51 
prolactin receptor in luminal epithelium ρ = 0.76 ρ = 0.84 ρ = 0.83 
Prolactin receptor in glandular epithelium ρ = 0.76 ρ = 0.10 ρ = 0.75 
Prolactin receptor in stroma ρ = 0.51 ρ = 0.98 ρ = 0.75 
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Figure IX 1. The correlation between the results of peripheral NK CDbright cells and the 
concentrations of serum cortisol suppression following the Dexamethasone Suppression Test 
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Figure IX 2. The correlation between uNK cell measurements and midnight salivary cortisol 
measurements  
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Figure IX 3. The correlation between uNK cell measurements and the measurements of 
morning salivary cortisol suppression following the Dexamethasone Suppression Test 
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Discussion  
In the previous chapters of this thesis we have examined the relationship between 
psychometric measurements and the measurements of each biochemical stress 
markers. In this chapter we correlated the results of various biochemical stress 
markers with each other to further investigate whether there are interactions among 
these stress markers in women with RM. 
 
 Cortisol measurements have been found to be significantly associated with NK cell 
measurements. An inverse correlation between serum cortisol suppression following 
DST and pNK CDbright cells has been found. Morning salivary cortisol suppression 
following DST has a positive correlation with uNK cell measurements. Basal mid-
night salivary cortisol concentrations are positively associated with the increase in 
uNK cell measurements. Therefore, it seems that the cortisol concentrations can 
affect the numbers of pNK or uNK cells in women with RM or vice versa. The 
underlying reason for such an observation is unclear. Some previous studies have 
showed the effect of cortisol on inhibiting peripheral natural killer cells (van Ierssel 
et al., 1996) and uNK cell expression (Quenby et al., 2005). Future research needs to 
be conducted to clarify this issue. 
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Chapter X: Overall Conclusion 
In summary, in this thesis we found that women with RM had higher levels of stress 
than fertile women. Higher fertility stress levels are associated with a better 
pregnancy outcome in women with RM, suggesting that coping strategies may be of 
more prognostic value on subsequent pregnancy outcomes than measuring stress 
levels in women with RM. We also found that the increase in the pNK subset of 
CDdim cells was associated with a higher risk of a subsequent miscarriage in women 
with RM, suggesting the role of the increase of pNK CDdim subset in RM. No 
correlation was found between pNK cell measurements and uNK cell measurements, 
suggesting that pNK cell measurements do not reflect uNK cell measurements and 
therefore it is inappropriate to extrapolate the findings of NK cell measurements in 
peripheral blood to the endometrium. In this thesis low plasma prolactin 
concentrations within normal physiological range were associated with an increased 
risk of miscarriage in women with RM, suggesting that adequate plasma prolactin 
concentrations may benefit pregnancy. However, no significant difference in the 
expression of endometrial prolactin receptor was found between RM women and 
fertile women. In this thesis we did not find the effect of stress caused by RM on the 
feedback dysregualtion of the HPA axis. Cortisol measurements have been found to 
have no association with subsequent conception rates or pregnancy outcomes in 
women with RM.  
 
With regard to the interaction between various stress measurements, pNK CDbrigtht 
cells have been found to be inversely associated with the levels of fertility stress, 
suggesting a role of pNK CDbright cells as a sensitive biochemical marker in stress 
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assessment in women with RM. Cortisol measurements were found to be associated 
with NK cell measurements in women with RM or vice versa. The increase in serum 
cortisol concentrations after DST was associated with a decrease in pNK CDdim 
cells whereas the increase in salivary cortisol concentrations after DST was 
associated with an increase in uNK cells. In addition, the increase in the basal mid-
night salivary cortisol concentrations was associated with an increase in uNK cells. 
The exact mechanism of how cortisol affects NK cells in women with RM is not 
clear. 
 
Strength and weakness 
Strength 
The novelty of the work presenting in this thesis lies in the comprehensiveness of the 
measurements used in examining the role of stress in RM. This study employed a 
multifaceted approach including psychometric, endocrinological, immunological and 
histological measurements. This is the first study which thoroughly examined stress 
in women with RM from both psychological and physiological aspects. 
 
In the present study we only included a cohort of women with unexplained RM as 
the study population. It was clearly important to study a homogenous group of 
unexplained RM patients to enable us to exclude other causative factors of RM. This 
allowed stress to be studied as the only identifiable confounding factor affecting 
pregnancy in the present study analysis. 
 
At present there is no consensus on the definition of RM with regard to the numbers 
of previous miscarriages and previous live births. In this thesis we followed the 
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definition of RM consistent with European criteria proposed by ESHRE in 2006, i.e 
three or more consecutive miscarriages. Participants who had previous live births 
were also included in this study, as it has been shown that a preceding live birth has 
no impact on a subsequent pregnancy (van den Boogaard et al., 2010). 
 
Weakness  
One possible criticism of this study is the relatively small number of subjects 
presenting in the analyses. The limited number of the eligible referrals attending the 
RM clinic each week restricted us to recruit more participants. In the future a 
multicenter approach should be involved to overcome this issue. 
 
Other factors to be considered in the stress study are the ethnic, educational and 
occupational backgrounds. Among 36 women with unexplained RM presenting in 
the study, two of them were of Asian Indian origin and two of them were of African 
origin. The rest of the 32 participants were white Caucasian. The small number of 
minority ethnic group members did not allow us to perform a subgroup analysis to 
examine the difference in stress status stratified by ethnicity. Further information 
about educational and occupational background was not collected during the 
information collection from participants due to ethical concerns. The patients many 
have become anxious that their education or occupation was related to the cause of 
their miscarriages if these questions were asked by the investigators. This could 
potentially cause additional psychological burden and affect their stress status. In the 
future it will be of interest to include a more diverse population stratified by ethnic, 
educational and occupational backgrounds to compare the stress levels between these 
women.  
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Another concern in the present studies is that all the stress measurements were based 
on samples collected in the non-conception cycle. These results may not be 
extrapolated into changes in conception cycle where pregnancies are established. 
The psycho-neuroendocrine-immune network is altered during pregnancy, thus the 
results from nonconception cycles may be of limited predictive value for pregnancy. 
However, it is difficult to conduct a clinical research obtaining samples from 
ongoing pregnancy to precisely reflect the stress status of pregnant women with RM. 
 
In addition, another weakness of this thesis lies in the confounding effect of anxiety 
before venipuncture on random prolactin assays. Some patients may become very 
anxious or stressed before venipuncture.  Like plasma cortisol, the anxiety of 
venepuncture can cause a falsely elevated prolactin level. As a result, our hospital, 
on its intranet site, has a Cannulated Prolactin Protocol to re-assess basal prolactin 
levels for any hyperprolactinaemia after random levels. In our retrospective study on 
the relationship between plasma prolactin concentrations and pregnancy outcomes 
we obtained the data of the 174 consecutive women with RM, who had plasma 
prolactin measured between 1999 and 2009, from the existing clinical database. It is 
not clear whether this protocol was always followed in the clinic. 
 
Proposal for future studies 
Proposed prolactin receptor study 
Owing to the small numbers of biopsies in this study we could not determine if 
endometrial prolactin receptor measurements has a prognostic value on the outcome 
of a subsequent pregnancy in women with recurrent miscarriage. It is possible to 
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examine achieved endometrial specimens collected over the last 10 years from the 
RM clinic at the Jessop Wing Hospital, Sheffield to further investigate the 
relationship between the expression of prolactin receptor and pregnancy outcomes in 
women with RM. It is estimated that almost at least 100 biopsies could be retrieved 
for analysis. 
 
Proposed stress study 
The results of this thesis suggest that coping strategies may be of predictive value on 
subsequent pregnancy outcomes, more than pre-pregnant stress levels. Therefore, in 
the future it will be of interest to conduct a study assessing the relationship between 
stress coping strategies and pregnancy outcomes in women with RM. The pregnancy 
outcome of women with RM may be improved by using effective coping 
intervention tools such as the positive reappraisal intervention card (Lancastle and 
Boivin, 2008), instruments designed for improving quality of life for women 
experiencing fertility treatments (www. fertiqol.org) or information and support for 
women who suffer miscarriages available on the websites of miscarriage association 
(www.miscarraigeassociation.org.uk). 
 
The results of this research have implications for future clinical consultations 
where there is a need to help decrease the stress experienced by women with RM. 
Patients should be encouraged to adopt effective coping strategies and/or seek 
emotional support to optimize their pregnancy outcomes in conjunction with clinical 
treatments, although more research is needed in this area. It is anticipated that 
women with RM who adapt effective stress coping strategies may respond to stress 
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well with no activation of the HPA system, and no alteration in the measurements of 
natural killer cells, prolactin and cortisol. 
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Appendix III. Patient Information Sheet                    
               
                                                             Jessop Wing Hospital 
                                                             Tree Root Walk Road 
                                                             S10 2SF 
                                                             Sheffield 
Stress and Recurrent Miscarriage Study (STH 15026) 
Patients Information Sheet 
An invitation to take part in medical research 
We would like to invite you to take part in a research study. Before you 
decide it is important for you to understand why the research is being done 
and what it will involve. If you would like further information please contact: 
Dr Wei Li on 07502255073 or Prof T.C. Li on 0114 226 1064. The research 
study will form the basis of an MD thesis. 
 
What is the purpose of the study? 
In 50% of women with recurrent miscarriage (RM) the exact cause is 
unknown, one hypothesis is that stress plays a significant role on recurrent 
miscarriage via its effect on the brain which in turn affects the hormone and 
immune system. In this study we aim to assess the level of stress in women 
attending the RM Clinic and relate the measurements to reproductive 
hormone and the immune cells. 
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Validated Questionnaires, blood samples, a saliva sample and biopsy of the 
lining of the uterus will be collected to measure stress markers, hormone and 
immune cells. The result of this study will provide new data on stress in 
women with RM and the predictive value of stress on a subsequent 
pregnancy. 
 
Why have I been chosen? 
You have been chosen because you have experienced recurrent 
miscarriages (3 or more). We hope to find out if stress may be a contributory 
factor for your repeated losses. With your participation, we can understand 
more about stress and RM. 
 
With your permission, we will inform your GP that you are taking part in this 
study. 
 
Do I have to take part? 
No. Taking part is entirely voluntary. If you prefer not to take part, you don’t 
have to give a reason. Your clinical care will not be affected in any way. If 
you agree to take part, but later change your mind, you may withdraw at any 
time without affecting your care in any way. 
 
If you withdraw from the study later, the indentifiable data and tissue already 
collected with consent would be retained and used in the study unless you 
request them to be destroyed.  
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What will I have to do if I take part? 
If you agree to take part in this study 
 
(1) You will be asked to complete the questionnaires, have a blood sample 
(about one teaspoon) and a salivary sample taken. These will be taken to 
measure your stress levels at your first visit in the clinic.  
 
(2) On your second visit which is usually on day 21 of your menstrual cycle 
(or 7 days after ovulation), a blood sample (about two teaspoon volume) will 
be obtained to measure progesterone as part of the routine investigation for 
your condition; a portion of the blood sample obtained will be used to 
measure an immune cell (eg. NK cell). In addition a biopsy of the lining of 
the uterus will be obtained to measure immune cells and stress receptors. 
The endometrial biopsy will be performed as an outpatient procedure. The 
biopsy procedure itself will take about 10 seconds.  
 
 
(3) At your third visit which is usually on day 2-5 of the cycle, a blood sample 
(about 3 teaspoon volume) will be obtained for hormone tests as part of the 
routine investigation for your condition. Prior to this visit you will be asked to 
take a tablet the night before your visit (Dexamethasone Suppression Test). 
Dexamethasone is a tablet which usually suppresses stress hormone, and 
during your visit you will have a blood sample (about one teaspoon volume) 
and salivary sample collected to measure stress markers. For the instruction 
of Dexamethasone Suppression Test please see the attached leaflet. 
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(4) As part of your routine investigation, you will be asked to reattend the 
clinic at about 2 months later to discuss the results of your investigations. At 
this visit you will be asked to complete the questionnaires for the second time 
and have your blood sample (one teaspoon volume) and salivary sample 
taken to measure stress markers. 
 
(5) If you conceive again, we will see you when you are 6-8 weeks pregnant 
as part of your routine care. This will be for an ultrasound examination to 
confirm that the pregnancy is progressing normally. At this visit you will be 
asked to complete the questionnaires again and have your blood and 
salivary sample collected as before. 
 
(6) If your pregnancy reaches 14 weeks successfully or if you miscarry again, 
and or if you have not conceived 4 months after the initial visit, you will be 
seen again in the clinic when you will be asked to complete the 
questionnaires for the final time as well as have your blood and salivary 
sample taken. 
 
Confidentiality 
All reasonable steps will be taken to ensure confidentiality. Any information 
collected in the 4 validated questionnaires is anonymous and can only be 
used with your permission by the clinicians involved in your care. All the 
information that is collected about you during the course of the research will 
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be kept strictly confidential. When the results are published, no names will be 
used, and it will not possible to identify anyone who has taken part. 
 
 
Will my taking part involve any extra visit? 
No, it will not involve extra visits and the additional investigations have all 
been planned during your routine visits. 
 
What are the possible risks of taking part? 
We don’t anticipate any health risks as a result of your taking part in this 
study. 
 
The endometrial biopsy is a very commonly performed outpatient 
investigative procedure in gynaecology. It may be uncomfortable and 
sometimes painful, but the procedure usually lasts only a few seconds. 
Infection is a very rare complication of the procedure. It is not necessary to 
do a pregnancy test prior the biopsy, but if you are concerned that you may 
be pregnant, we would advise you not to proceed with the biopsy.  
 
Questionnaires: There are 4 questionnaires for you to complete on 3-4 
occasion. It may take 30-40 minutes on each occasion. You will be asked 
about how you feel about the recurrent miscarriages and its impact on your 
relationship. You may find some of the questionnaires of a sensitive nature. 
However, you don’t have to complete every questionnaire if you don’t feel 
comfortable about doing so. 
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What will happen to the results of the research study? 
The results of this research will help guide future management of patients. 
The results will be written up and published in medical journals.  
 
Storage of samples: The endometrial sample will be used to measure the 
presence of various stress markers. Part of the specimens will be frozen and 
stored up to for 3 years. We will only keep the specimen for more than 3 
years if you consent to it. The specimen will be stored in line with the Human 
Tissue Act. 
 
Who is organizing the research? 
The research is being conducted by a team of clinicians and scientists who 
work in the Royal Hallamshire Hospital and University of Sheffield. The team 
is led by Professor TC Li who has been running the recurrent miscarriage 
clinic in Sheffield for 15 years. 
 
What if I wish to complain about the way in which this study has been 
conducted?  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and are 
not compromised in any way because you have taken part in a research 
study. You can use the normal Sheffield Teaching Hospital complaints 
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procedure and contact: Miss Alison Neild, Head of Patient Services, B Floor, 
Royal Hallamshire Hospital 0114-226-1766. 
 
What do I do now? 
Now you have read the information sheet, if you are happy to participate, 
please complete the consent form and return it to the informing clinician, then 
the detail of your appointment and further care will be arranged. 
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Appendix IV. Data Collection Sheet 
Case No.  Date of birth  Family history of 
RM 
Yes  Height  Weight  
No 
Smoke  coffee  Alcohol  :           menstruation regularity Yes 
Amount   Amount   Units  No 
Occupation  Ethnicity   
 
 
Past Pregnancy history 
Date of pregnancy Pregnancy outcome 
  
  
  
  
  
  
  
  
  
 
 
 
 
Hormonal profile 
Items. Date Result 
LH   
FSH   
Estrodiol   
Progesterone   
Testosterone   
FAI   
Prolactin   
Pregnancy outcome 
Subsequent pregnancy Yes   LMP: 
No Reason:  
Pregnancy Outcome Live birth Miscarriage Still Birth Ectopic preg. TOP 
Gestation Week  Gestation Week    
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Appendix V. Flow Chart of Sample Collection 
How Do You Collect Your Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On day1 of next cycle On the first day you start to bleed, telephone the Pregnancy Support Service (PSS) 
on 0114 2268589 to arrange your Dexamethasone test 
On day2-5 of cycle Attend PSS on Ward G1 at 8:15 to 8:30 in the morning for your blood test. Please 
don’t forget to take Dexamethasone tablet the night before you attend 
On day7 of your cycle Start to time the day of your ovulation with Ovulation Test kits, on the day of your 
ovulation contact PSS for your biopsy arrangement 
2 months after your first visit Return the clinic discussing the results of your tests with doctors 
On 7-10 days after ovulation Attend G1 for the biopsy of the line of your womb and blood test. Please make 
sure you use condoms or we will be unable to take the biopsy 
At your first appointment Bring your written consent with you to your appointment 
We will continue caring you after this point, if you get pregnant 
subsequently or repeat miscarriage, please contact us. We are here for you. 
 YOU WILL HAVE BEEN ASKED TO USE A BARRIER METHOD OF 
CONTRACEPTION UNTIL YOUR RESULTS HAVE BEEN 
DISCUSSED WITH YOU, IT IS ESSENTIAL YOU DO THIS ON 
EVERY OCCASION IF YOU ARE HAVING THE BIOPSY TEST 
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Appendix VI. Study Questionnaires                                                
                  
 
 
          
Stress and Recurrent Miscarriage Study 
Infertility-related Stress Questionnaires 
 
Name: _____________ 
Date: ______________ 
 
Please answer every question.  Some questions may look like others, but 
each one is different.  Please take the time to read and answer each 
question carefully by ticking the box that best represents your response. 
There are no right or wrong answers, don’t spend too much time on any 
one statement but give the answer which seems to describe your present 
situation best. 
 
 Thank you for taking the time to complete these questionnaires 
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Fertility Problem Inventory 
 
Instruction for completing the questionnaire 
 
The following statements express different opinions about a fertility problem.  Please place a 
number on the line to the left of each statement to show how much you agree or disagree 
with it.  
 
 
Please answer every item.  Use the following response categories: 
 
  6 = strongly agree 
  5 = moderately agree 
  4 = slightly agree 
  3 = slightly disagree 
  2 = moderately disagree 
  1 = strongly disagree 
 
 
 1. ___ Couples without a child are just as happy as those with children. 
 
 2. ___ Pregnancy and childbirth are the two most important events in a couple's 
relationship. 
 
 3. ___ I find I've lost my enjoyment of sex because of the fertility problem. 
 
 4. ___ I feel just as attractive to my partner as before. 
 
 5. ___ For me, being a parent is a more important goal than having a satisfying 
career. 
 
 6. ___ My marriage needs a child (or another child). 
 
 7. ___ I don't feel any different from other members of my sex. 
 
 8. ___ It's hard to feel like a true adult until you have a child. 
 
 9. ___ It doesn't bother me when I'm asked questions about children. 
 
10. ___ A future without a child (or another child) would frighten me. 
 
11. ___ I can't show my partner how I feel because it will make him/her feel upset. 
 
12. ___ Family don't seem to treat us any differently. 
 
13. ___ I feel like I've failed at sex. 
 
14. ___ The holidays are especially difficult for me. 
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                                       6     =    strongly agree 
   5 = moderately agree 
   4 = slightly agree 
   3 = slightly disagree 
   2 = moderately disagree 
   1 = strongly disagree 
 
 
15. ___ I could see a number of advantages if we didn't have a child (or another 
child). 
 
16. ___ My partner doesn't understand the way the fertility problem affects me. 
 
17. ___ During sex, all I can think about is wanting a child (or another child). 
 
18. ___ My partner and I work well together handling questions about our infertility. 
 
19. ___ I feel empty because of our fertility problem. 
 
20. ___ I could visualize a happy life together, without a child (or another child). 
 
21. ___ It bothers me that my partner reacts differently to the problem. 
 
22. ___ Having sex is difficult because I don't want another disappointment. 
 
23. ___ Having a child (or another child) is not the major focus of my life. 
 
24. ___ My partner is quite disappointed with me. 
 
25. ___ At times, I seriously wonder if I want a child (or another child). 
 
26. ___ My partner and I could talk more openly with each other about our fertility 
problem.   
 
27. ___ Family get-togethers are especially difficult for me. 
 
28. ___ Not having a child (or another child) would allow me time to do other 
satisfying things. 
 
29. ___ I have often felt that I was born to be a parent. 
 
30. ___ I can't help comparing myself with friends who have children. 
 
31. ___ Having a child (or another child) is not necessary for my happiness. 
 
32. ___ If we miss a critical day to have sex, I can feel quite angry. 
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                                      6 = strongly agree 
   5 = moderately agree 
   4 = slightly agree 
   3 = slightly disagree 
   2 = moderately disagree 
   1 = strongly disagree 
 
 
33. ___ I couldn't imagine us ever separating because of this. 
 
34. ___ As long as I can remember, I've wanted to be a parent. 
 
35. ___ I still have lots in common with friends who have children. 
 
36. ___ When we try to talk about our fertility problem, it seems to lead to an 
argument. 
 
37. ___ Sometimes I feel so much pressure, that having sex becomes difficult. 
 
38. ___ We could have a long, happy relationship without a child (or another child). 
 
39. ___ I find it hard to spend time with friends who have young children. 
 
40. ___ When I see families with children I feel left out. 
 
41. ___ There is a certain freedom without children that appeals to me. 
 
42. ___ I will do just about anything to have a child (or another child). 
 
43. ___ I feel like friends or family are leaving us behind. 
 
44. ___ It doesn't bother me when others talk about their children. 
 
45. ___ Because of infertility, I worry that my partner and I are drifting apart. 
 
46. ___ When we talk about our fertility problem, my partner seems comforted by 
my comments. 
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Perceived Stress Scale 
 Instructions: The questions in this scale ask you about your feelings and thoughts 
during the last month.  In each case, please circle how often you felt or thought a certain 
way.  
  
1. In the last month, how often have you been upset because of something that happened 
unexpectedly? 
     0=never         1=almost never         2=sometimes          3=fairly often          4=very often  
 
2. In the last month, how often have you felt that you were unable to control the important 
things in your life? 
     0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
3. In the last month, how often have you felt nervous and "stressed"? 
      0=never         1=almost never         2=sometimes          3=fairly often          4=very often  
4. In the last month, how often have you felt confident about your ability to handle your 
personal problems? 
      0=never         1=almost never         2=sometimes          3=fairly often          4=very often  
5. In the last month, how often have you felt that things were going your way? 
      0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
6. In the last month, how often have you found that you could not cope with all the things 
that you had to do? 
       0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
7. In the last month, how often have you been able to control irritations in your life? 
      0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
8. In the last month, how often have you felt that you were on top of things? 
     0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
9. In the last month, how often have you been angered because of things that were outside 
of your control? 
       0=never         1=almost never         2=sometimes          3=fairly often          4=very often 
10. In the last month, how often have you felt difficulties were piling up so high that you 
could not overcome them? 
        0=never         1=almost never         2=sometimes          3=fairly often          4=very 
often 
 
 248 
 
PANAS 
Directions 
This scale consists of a number of words that describe different feelings and 
emotions.  Read each item and then circle the appropriate answer next to 
that word.  Indicate to what extent you have felt this way during the past 
week. 
 
Use the following scale to record your answers. 
 
(1) = Very slightly or 
not at all 
(2) = A little (3) = Moderately (4) = Quite a bit (5) = Extremely 
 
 Very slightly 
or not at all 
 
A little 
 
Moderately 
 
Quite a bit 
 
Extremely 
1. Interested 1 2 3 4 5 
2. Distressed 1 2 3 4 5 
3. Excited 1 2 3 4 5 
4. Upset 1 2 3 4 5 
5. Strong 1 2 3 4 5 
6. Guilty 1 2 3 4 5 
7. Scared 1 2 3 4 5 
8. Hostile 1 2 3 4 5 
9. Enthusiastic 1 2 3 4 5 
10. Proud 1 2 3 4 5 
11. Irritable 1 2 3 4 5 
12. Alert 1 2 3 4 5 
13. Ashamed 1 2 3 4 5 
14. Inspired 1 2 3 4 5 
15. Nervous 1 2 3 4 5 
16. Determined 1 2 3 4 5 
17. Attentive 1 2 3 4 5 
18. Jittery 1 2 3 4 5 
19. Active 1 2 3 4 5 
20. Afraid 1 2 3 4 5 
 
Copyright statement: "From "Development and validation of brief measures of 
positive and negative affect:  The PANAS scales," by D. Watson, L. A. Clark, and A. 
Tellegen, 1988, Journal of Personality and Social Psychology, 54, 1063-
1070.  Copyright © 1988 by the American Psychological Association.  Reproduced 
with permission." 
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Appendix VII. Copy Right Permission Letter 
 
Dear Li Wei, 
 
I appreciate your interest in the PANAS.  Please note that to use the =ANAS, you need both our 
permission and the permission of the American Psyc=ological Association (APA), which is the official 
copyright holder of the =nstrument.  I am pleased to grant you permission to use the PANAS in =our 
research.  Moreover, because I am copying this email to APA, you =o not have to request permission 
separately from APA; this single e-mail c=nstitutes official approval from both parties. 
 
We make the PANAS available without charge for non-commercial research purp=ses.  We do 
require that all printed versions of the PANAS include a =ull citation and copyright 
information.  Thus, any printed copies sho=ld state: 
 
"From "Development and validation of brief measures of positive a=d negative affect:  The PANAS 
scales," by D. Watson, L. A. Clark= and A. Tellegen, 1988, Journal of Personality and Social 
Psychology, 54, =063-1070.  Copyright © 1988 by the American Psychological 
Associ=tion.  Reproduced with permission." 
 
Finally, as requested, I have attached a sample copy of the PANAS that show= how the scales should 
be scored. 
 
Good luck with your research. 
 
Sincerely, 
 
David Watson 
 
------------------------------------------- 
 
David Watson, Ph.D. 
F. Wendell Miller Professor of Psychology 
Editor, Journal of Abnormal Psychology  
 
Department of Psychology 
E11 Seashore Hall 
University of Iowa 
Iowa City, IA 52242-1407 
319-335-3384 (voice) 
319-335-0191 (fax) 
 
E-mail: david-watson@uiowa.edu 
Webpage: http://www.psychology.uiowa.edu/Faculty/Watson/Watson.html 
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Appendix VIII. Works Arising From This Thesis 
 
Publications: 
The relationship between plasma prolactin concentration and pregnancy outcome in 
women with recurrent miscarriage. W. Li, N. Ma, S.M. Laird, T.C. Li, submitted. 
 
Measurements of CD56+ cells in peripheral blood and endometrium by flow 
cytometry and immunohistochemical staining in situ. S.M. Laird, N. Mariee, W. Li, 
TC. LI, submitted. 
 
Presentations: 
The relationship between plasma prolactin concentrations and pregnancy outcomes 
in women with recurrent miscarriage. Poster presentation, ESHRE 2010, Rome. 
 
 
The relationship between plasma prolactin concentrations and pregnancy outcomes 
in women with recurrent miscarriage. Poster presentation, Annual school research 
meeting, University of Sheffield, 2010. 
 
The value of cortisol suppression test in the evaluation of the HPA activation in 
women with recurrent miscarriage. Oral presentation, Second year student 
presentation, University of Sheffield Medical School, 2009. 
 
The role of stress in recurrent miscarriage. Oral presentation. First year student 
presentation. University of Sheffield, 2008. 
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Appendix IV. Copies of Abstract 
The Relationship between Plasma Prolactin Concentration and 
Pregnancy Outcome in Women with Recurrent Miscarriage 
W Li
1,5
, N Ma
2
, S M Laird
3
, W L Ledger
1
, TC Li
4 
 
1
Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, S102SF, UK 
2
Hysteroscpic Centre, Fuxing Hospital, University of Medical Sciences, Beijing, 100038, China 
3
Biomedical Research Centre, Sheffield Hallam University, Sheffield, S11WB, UK 
4
Biomedical Research Unit, Jessop Wing, Tree Root Walk, Sheffield S10 2SF, UK 
5
To whom correspondence should be addressed: leeweiwater@yahoo.com.cn 
 
Background: The role of prolactin in pregnancy is controversial. Some early studies have 
reported on the high prevalence of hyperprolactinaemia in women with recurrent miscarriage 
(RM) and the possible deleterious effect of high prolactin on pregnancy. However, a few 
recent studies have shown that prolactin may have a beneficial role in pregnancy through 
signalling decidualization and embryo implantation. The aim of this study was to evaluate the 
relationship between the plasma prolactin concentration and pregnancy outcomes in women 
with RM. Methods: Plasma prolactin was measured in 174 women with unexplained RM in 
the early follicular phase in pre-pregnancy state. Among these women, pregnancy outcomes 
were correlated with plasma prolactin levels in 109 women with unexplained RM. Results: 
Of the 109 women with unexplained RM and subsequent pregnancies, those who miscarried 
had significantly (ρ=0.01) lower (Mean ± SD) plasma prolactin levels (240+108.3 mIU/l) 
compared with those who had a live birth (308+164.8 mIU/l). In addition women with 
prolactin concentrations lower than the mean level had a significantly higher miscarriage rate 
(34/64, 53.1%) than those with prolactin concentrations higher than the mean level (15/45, 
33.3%) (ρ<0.05). Conclusions: Low plasma prolactin level is associated with an increased 
risk of miscarriages in a subsequent pregnancy. 
 
Key words: prolactin / hyperprolactinaemia / pregnancy outcome / recurrent miscarriage 
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Introduction 
Recurrent miscarriage (RM) is defined as three or more consecutive spontaneous 
miscarriages in the first trimester (ESHRE, 2006). It is a heterogeneous condition with a 
number of possible underlying causes. To date several aetiological factors of RM have been 
identified, including parental chromosomal anomalies, uterine pathology, haematological 
abnormalities, endocrinological disorders and immunological factors. However, in 50% of the 
cases, the cause of RM still remains unexplained. Most previous studies in relation to the 
endocrine abnormalities of RM have focused on the luteal phase deficiency (LPD) and 
PCOS (polycystic ovarian syndrome) (Cocksedge et al., 2009, Palomba et al., 2006, Nardo 
et al., 2002). Little effort has been made on the investigation of the role of prolactin in RM.  
 
Prolactin is a polypeptide hormone synthesized by the lactotroph cell in the anterior pituitary 
gland and the extrapituitary sites such as mammary gland, placenta and uterus (Goffin et al., 
2002, Eyal et al., 2007, Reis et al., 2002). Apart from the lactation and endocrine effects, 
prolactin may have the luteotrophic function by potentiating the steroidgenic effect of 
luteinizing hormone (LH) in granulosa-luteal cells and inhibiting the 20α-hydroxysteroid 
dehydrogenase enzyme which inactivates progesterone. Prolactin may also be luteolytic by 
inducing programmed cell death in the corpora lutea mediated by CD3 lymphocytes 
(Freeman et al., 2000, Kanuka et al., 1997, Richards and Williams, 1976). Therefore, 
prolactin plays an important role in maintaining corpus luteum function and the subsequent 
steroidgenesis of progesterone secretion, thus affecting pregnancy in this way. The exact 
mechanism of both the luteotrophic and luteolytic effects of prolactin is still unclear.  
 
Recently the role of prolactin in RM has attracted some attention. Several studies have 
previously reported on the high prevalence of hyperprolactinaemia in the follicular phase in 
women with RM and the suppression of prolactin secretion with bromocriptin to improve 
pregnancy outcome (Hirahara et al., 1998, Csemiczky et al., 2000, Bussen et al., 1999), 
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suggesting that high prolactin levels may be a possible aetiological factor of RM. However, 
our earlier study showed that hyperprolactinaemia rarely occurs in women with RM  (2.5%, 
3/122)  (Li et al., 2000). In some studies it has been suggested that an adequate level of 
serum prolactin is essential to maintain corpus luteum function (Gåfvels et al., 1992) and 
establish a successful pregnancy(Oda et al., 1991). In IVF treatment it has been observed 
that transient hyperprolactinaemia is associated with a better chance of successful 
pregnancy outcomes (Ozaki et al., 2001). The inadequate expression of prolactin and its 
receptor in endometrium during the implantation window has been found to cause premature 
luteolysis and subsequent infertility or recurrent miscarriages (Garzia et al., 2004). 
Therefore, this raises the question of whether or not high prolactin level is associated with an 
increased risk of recurrent miscarriage. Due to the paucity of the studies in this area, the 
relationship between the prolactin level and RM is still unclear. The aim of this retrospective 
study was to investigate the relationship between serum prolactin concentrations and the 
pregnancy outcomes in a large group of women with unexplained RM.  
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Materials and Methods 
Human subjects 
A series of 174 consecutive women with unexplained RM, who had plasma prolactin 
concentrations measured in the early follicular phase from January 1999 to September 
2009, were included in this study. All the patients who conceived again after the referral 
were offered the telephone pregnancy counselling service as part of tender loving care 
throughout their subsequent pregnancies. Therefore, their pregnancy outcomes were 
followed and documented by the pregnancy support team. No treatment was given to this 
group of women apart from the tender loving care.   
 
Inclusion criteria 
All the subjects underwent thorough investigations according to an established protocol (Li, 
1998), including maternal and paternal karyotypes, prothrombotic studies, antiphospholipid 
antibody screen, thyroid function test and thyroid antibodies, FSH, LH, oestradiol, 
progesterone, androgen profile, prolactin, transvaginal ultrasonography and 
hysterosalpingography. Hysteroscopy was only performed if an abnormality was suspected 
on pelvic ultrasound or hysterosalpingography. 
 
Unexplained RM fulfilled the criteria of normal parental chromosomal analysis, absence of 
endocrinological abnormalities including normal analysis of thyroid function test and normal 
levels of FSH, LH, oestradiol, progesterone, prolactin and androgen profile, test negative for 
antiphospholipid antibodies and lupus antibodies, normal coagulation studies and absence 
of structural uterine abnormalities.  
 
Study Setting 
The Recurrent Miscarriage Clinic at Jessop Wing for Women, Royal Hallamshire Hospital, 
Sheffield, UK 
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Outcome measures 
Pregnancy outcome was measured as the first pregnancy outcome after referral. In patients 
who conceived more than once during the study period, only the first pregnancy was 
considered. 
 
Prolactin measurement 
Blood samples for plasma prolactin investigations were taken in the early follicular phase. 
Prolactin assay was performed by automated microparticle enzyme-immunoassay (Abbott 
Axsym Analyser, Abbott Diagnostics) at the Clinical Chemistry Department, Royal 
Hallamshire Hospital. The intra-and inter-assay coefficient of variation for prolactin 
measurement was 3.7% and 11.5%. The presence of hyperprolactinaemia was defined as 
plasma prolactin concentration > 660 mIU/l. 
 
Data Analysis 
Results were expressed as numbers, mean ±SD, range and percentages as appropriate. 
Normal distribution of prolactin value was tested with Kolmogorov-Smirnov test. Differences 
in plasma prolactin concentrations between women who subsequently miscarried and those 
who had a live birth were analysed with T test. The difference in the miscarriage rate 
between the two subgroups was analysed with Pearson x2 test. Statistical significance was 
set at p value <0.05 and analysis were performed using SPSS (Statistical Package for the 
Social Sciences) version 15. 
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Results 
A total of 174 women with unexplained RM had their plasma prolactin measured during the 
study period. The mean age (±SD) was 32.2 (± 5.6) years; the median number of previous 
miscarriages was 4 (ranged from 3 to14). The mean (±SD) prolactin concentration was 226 
(±121) mIU/l. Among those 174 women with unexplained RM, 40 of them did not conceive 
during the study period and 9 of them lost follow-up. The remaining 125 women with 
unexplained RM conceived again after the referral. The differences of the clinical profile 
between women who conceived (n=125) and those who did not conceived (n=40) are shown 
in table 1. As expected, women who did not conceived were significantly older than those 
who conceived (P< 0.05). Women who conceived again had higher mean prolactin 
concentrations than those who did not conceive. However, the difference was not significant.  
 
Table I. The differences between 125 women who conceived again and 40 women who did 
not conceived during the study period 
 Women who conceived Women who did not 
conceive 
p value 
(<0.05) 
 
N 125 40  
Age  31.0  ± 6.0 32.6  ± 5.5 0.02* 
No. of previous miscarriages 4 (3-10) 4 (3-14) 0.47 
Prolactin concentrations 234.5  ± 125.8 196.3  ± 98.8 0.26 
* Significant 
 
Among those 125 women with unexplained RM who conceived again, 6 women had ectopic 
pregnancies and 10 women had mid-term terminations of pregnancies due to fetal 
deformation, such as joint twins and Down’s syndrome. Therefore, they were excluded from 
the study analysis. A total of 109 women with subsequent pregnancies during the study 
period were included in the study analysis. The mean age was 31.9 (±5.2) years. The 
median of the numbers of previous miscarriages was 3 (ranged from 3 to 7). The mean 
concentration of prolactin was 278 (±146) mIU/L. 
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In the 109 subsequent pregnancies, 49 (45%) pregnancies resulted in the first trimester loss 
whereas 60 (55%) pregnancies resulted in live birth. Women with a subsequent live birth 
had significantly (ρ=0.01) higher prolactin concentrations (308±164.8mIU/l) than those with a 
subsequent miscarriage (240±108.3mIU/l) (figure I).  
 
 
 
Figure I: Prolactin concentrations in women who subsequently had a live births and those who had a miscarriage 
 
These 109 women were further divided into two subgroups according to the mean value of 
the prolactin measurements. 45 women with prolactin concentrations above the mean level 
were allocated into high normal prolactin group and 64 women with those below the mean 
level were allocated into low normal prolactin group (Table II). The miscarriage rate in 
women with high normal prolactin (15/45, 33.3%) was significantly lower (p<0.05) than that 
in women with low normal results (34/64, 53.1%). 
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Table II. The difference in miscarriage rates between the two subgroups 
  
High normal prolactin subgroup 
(prolactin≥278mIU/l) 
n=45  
 
Low normal prolactin subgroup 
(prolactin<278mIU/l) 
n=64  
 
 
 
 p value 
(<0.05) 
 
Age 
(mean± SD ) 
31.5 ± 4.5yrs 
 
32.1 ± 5.5yrs 0.66 
No. of previous miscarriages 
(median, range) 
3 (3-6) 3 (3-7) 
 
0.47 
Prolactin concentration 
(mean± SD ) 
397 ± 85 mIU/l 
 
181 ± 56 mIU/l 0.00* 
No. of miscarriages 
(n, %) 
15 (33.3%) 
 
34(53.1%) 0.04* 
*significant 
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Discussion 
The relationship between the plasma prolactin concentration and pregnancy outcome 
In this study we found that low concentrations of plasma prolactin in women with RM are 
associated with a high risk of miscarriage in a subsequent pregnancy. To examine the 
relationship between the prolactin level and pregnancy outcome, we only included a cohort 
of patients with unexplained RM in which other possible causes of RM have been excluded 
to ensure that prolactin is the only factor affecting pregnancy outcome. The relationship 
between the plasma prolactin concentration and the outcome of assisted conception 
treatment has been examined in several studies. Ozaki et al (2001) compared the plasma 
prolactin concentrations between women who had subsequent live births following IVF 
treatment and those who had early pregnancy losses. They found that women with 
successful pregnancies had significantly higher prolactin levels than those with early losses 
(Ozaki et al., 2001). In a study by Gonen and Casper (1989) transient hyperprolactinaemia 
following ovarian stimulation was found to be associated with a better chance of pregnancy 
following IVF treatment. Before HCG administration, there was no significant difference in 
the basal prolactin level between women who subsequently conceived and those who did 
not conceive (11.1±0.6ug/l vs 10.1±0.4ug/l). After HCG administration, the prolactin level in 
the pregnant group was significantly higher than that in nonpregnant group (20.8±1.6ug/l vs 
16.0±0.9ug/l) (Gonen and Casper, 1989). It is not yet understood why in assisted conception 
women with high prolactin levels had better pregnancy outcomes. It has been observed that 
women with higher prolactin concentrations had significantly higher fertilization rates and 
cleavage rates of oocytes in IVF treatment than those with low prolactin concentrations (Oda 
et al., 1991).  
 
The relationship between the prolactin concentration and the outcome of spontaneous 
pregnancy, especially in women with a history of recurrent pregnancy loss has not been 
previously studied. In our study, we found women who subsequently miscarried had lower 
plasma prolactin concentrations than those who had a live birth. We also found that plasma 
prolactin level appears to have a prognostic value on the outcome of pregnancy in women 
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with RM, with low levels having a worse outcome than high normal levels. Thus our data 
supports the notion that low prolactin level is associated with an adverse pregnancy 
outcome. 
 
The mechanism of prolactin action: 
Whilst some studies showed that high prolactin levels had an inhibitory effect on GnRH 
releases and HCG-induced ovulation, and a negative regulatory function on endometrial 
decidualization (Milenković et al., 1994, Liu et al., 1997, Eyal et al., 2007), other studies 
have reported a beneficial role of prolactin in pregnancy. Serum prolactin was found to have 
a beneficial effect on maintaining corpus luteum in early pregnancy via modulating 
luteinizing hormone/chorionic gonadotrophin  (LH/CG) receptors (Gåfvels et al., 1992). 
LH/CG receptors are expressed in corpus luteum tissue and chorionic villous macrophages 
after implantation (Sonoda et al., 2005, Saint-Dizier et al., 2004). In a rat model it has been 
demonstrated that inhibition of serum prolactin secretion with bromocriptine during early 
pregnancy deceased LH/CG receptors and led to premature luteolysis, subsequently 
resulting in miscarriage. This effect can be reversed by prolactin supplementation after 
implantation (Gåfvels et al., 1992, Chan et al., 1980).  
 
Prolactin and its receptor have also been identified in the endometrium (Eyal et al., 2007, 
Mak et al., 2002, Reis et al., 2002). Lack of expression of the endometrial prolactin during 
the implantation window have been shown to be associated with repeated pregnancy loss 
(Garzia et al., 2004). Prolactin and its receptor are expressed in the glandular epithelium and 
a subset of endometrial stromal cells with maximal expression seen during the mid-late 
secretory phase of the cycle. Prolactin production by stromal cells increases dramatically 
during the decidualization process associated with embryo. The time and sites of its 
expression in endometrium tissue suggests a crucial role for prolactin and its receptor in 
establishment and maintenance of early pregnancy. Prolactin may affect decidualization 
through modifying the expression of adhesion and proteolytic molecules, facilitating 
trophoblast cell invasion following extracellular matrix degradation of the endometrium 
(Starzyk et al., 1999, Ormandy et al., 1997, Horseman et al., 1997). Prolactin receptors have 
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also been identified in uterine natural killer (uNK) cells (Gubbay et al., 2002). The distinctive 
presence of uterine CD56bright NK cells around trophoblast cells during implantation and 
the positive association between the density of uNK expression and the blood vessel 
formation suggest that they play an important role in angiogenesis and immunoregulation in 
the fetal-maternal interface in early pregnancy (Quenby et al., 2008).  Therefore, prolactin 
may also affect uterine NK cells function or differentiation and thus affect implantation in this 
way. 
 
In conclusion, we found that in women with unexplained RM a low prolactin level is 
associated with an increased risk of miscarriage. The exact reason for the observation is 
unclear but it seems likely that an adequate level of prolactin concentration is needed for the 
maintenance of successful pregnancies. Future studies should be directed to the evaluation 
of prolactin and its receptor in the endometrium to ascertain the mechanism of reproductive 
failure in conditions associated with low prolactin concentration. 
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Abstract 
BACKGROUND: Several studies have suggested that peripheral blood and 
/or endometrial CD56+ cells may be increased in women with recurrent 
implantation failure or recurrent miscarriage. However the relationship 
between numbers of peripheral blood NK cells and uterine NK cells is 
uncertain and there is also some uncertainty about comparing results of 
studies of endometrial CD56+ where they have been measured by 
immunohistochemistry and flow cytometry. 
METHOD: Endometrial biopsy samples, together with a blood sample, were 
obtained from women with recurrent miscarriage (n=25) in the mid-luteal 
phase of the cycle. Numbers of total CD56+ cells, CD56+ CD16- and 
CD56+CD16+ cells in peripheral blood were measured by flow cytometry, 
while the number of CD56+ cells in the equivalent endometrial biopsy sample 
were determined by immunohistchemistry. In addition endometrial biopsy 
samples were obtained from normal fertile women (n=20) at different times in 
the cycle. The biopsy was divided into two parts; one part was used to 
measure CD56+ and CD45+ cells by flow cytometry, while the other part was 
used to determine numbers of CD56+ and CD45+ cells by immunostaining.  
RESULTS: There was no correlation between the numbers of total CD56+, 
CD56+CD16- or CD56+CD16+ in peripheral blood and the number of 
endometrial CD56+ cells in the same women in the recurrent miscarriage 
group. However in the endometrial biopsy samples from fertile women a 
significant correlation was found between the measurement of CD56+ cells 
by flow cytometry and immunohistochemistry both when the cell numbers 
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were expressed as a percentage of total cells (correlation=0.497, P=0.026) 
or as a percentage of CD45+ cells (correlation=0.570, P=0.009).    
CONCLUSION: The results suggest that measurements of CD56+ cells in 
peripheral blood do not correlate with endometrial CD56+ cell numbers and 
therefore it is inappropriate to extrapolate results obtained from peripheral 
blood to what is happening in the endometrium and decidua. However 
measurements of endometrial CD56+ cells by flow cytometry and 
immunostaining seem to correlate well and therefore differences in results 
from different studies cannot be attributed to differences in methodology.  
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Introduction 
Natural killer (NK) cells, which form part of the innate immune system, are 
found in peripheral blood and in the endometrium of humans.  However the 
characteristics and possible functions of peripheral blood and endometrial 
NK cells are very different. The majority (90%) of the peripheral blood NK 
cells express the characteristic NK cell markers, CD56, CD16 and CD3. In 
contrast the majority (90%) of NK cells  found in the endometrium (uNK cells) 
express high levels of CD56, but are CD16 and CD3 negative. The 
remaining 10% of uNK cells resemble peripheral blood NK cells and are 
CD16+. Expression of NK cell receptors also differs between peripheral 
blood and uNK cells within any one individual. The numbers of uNK cells in 
the endometrium increase dramatically during the secretory phase of the 
menstrual cycle and remain high during the first trimester of pregnancy 
(Bulmer et al. 1991; Laird et al. 2003).  
Although uNK cells and peripheral blood NK cells are clearly separate 
populations, there is considerable debate about whether the increase in uNK 
cell numbers during the secretory phase of the cycle is due to the recruitment 
of immature cells from peripheral blood followed by proliferation and 
differentiation in the endometrium, or due to proliferation of uNK cells in situ 
(Bulmer and Lash 2005; Santoni et al. 2008). A number of factors are 
postulated to control this proliferation and differentiation process, including 
IL15 (Kitaya et al 2005) and various chemokines (Manaster and Mandelboin. 
2008).    
There are numerous reports of increased numbers of uNK cells or peripheral 
blood NK cells in women who suffer recurrent miscarriage or recurrent 
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implantation failure after IVF (Quenby et al. 1999; Tuckerman et al. 2010; 
Thum et al. 2004; Coulam et al. 1995: Kwak et al. 1995; Ledee-Bataille et al. 
2004; King et al. 2010). However other studies have shown no differences in 
levels of peripheral blood NK cells or uNK cells in these groups of women 
(Shimada et al. 2004). In addition, further studies have shown that 
measurement of uNK in non-pregnant endometrium of women with recurrent 
miscarriage or measurement of peripheral blood NK cells in women 
undergoing IVF are not predictive of pregnancy outcome (Tuckerman et al. 
2007; Thum et al. 2005).   
Measurements of NK cells in blood are traditionally measured by flow 
cytometry, while those in endometrial tissue may be measured by flow 
cytometry (Lachapelle et al. 1996) or immunocytochemical staining in situ 
(Quenby et al. 1999: Tuckerman et al. 2007). It is thought that the differences 
in results of different studies may be due to the use of these different 
methods of CD56+ measurement.  
Measurements of either peripheral blood NK cells or uNK cells are beginning 
to be used in clinical practice (Quenby et al. 2005). However the lack of 
clarity between the different methods used and the relationship between 
peripheral blood NK cells and uNK cells makes interpretation of the results 
difficult. There are no studies to-date which have correlated peripheral blood 
NK cells with uNK cells or that have correlated measurement of endometrial 
uNK cells by flow cytometry and immunostaining. We have therefore a) 
measured peripheral blood NK cells by flow cytometry and compared their 
numbers to those in the endometrium collected from the same women at the 
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same time and b) measured endometrial uNK cells in the same endometrial 
biopsy sample by flow cytometry and immunostaining. 
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Materials and Methods 
Human Subjects 
Endometrial biopsies were obtained from women attending the Jessop Wing, 
Sheffield Teaching Hospitals. All samples were collected with informed 
patients consent and ethical committee approval was obtained for the study. 
Two groups of women were recruited. The first group (n=25) were women 
attending the recurrent miscarriage clinic, with unexplained recurrent 
miscarriage defined according to our established protocol (Li 1998). As part 
of their on-going investigation a timed endometrial biopsy was taken. Daily 
measurements of LH in either serum or urine was used to identify the LH 
surge and the endometrial biopsy was collected with a Pipelle sampler 
between days LH+7 and LH+9. Biopsies were immediately fixed overnight in 
formalin and then embedded in wax using an automated process. A 10 ml 
and a 5 ml blood sample were taken at the same time as the biopsy; the 10 
ml sample was used for hormone measurements while the other 5 ml was 
processed immediately for flow cytometry. The second group of women 
(n=20) were normal fertile women undergoing surgery for non-endometrial 
pathology. All these women were aged between 20 and 45 and had 
menstrual cycles of between 25 and 35 days, had normal uterine anatomy, 
had no steroid treatment for at least 2 months prior to the study. Samples 
obtained from the operating theatre were divided into 2 parts; one part was 
fixed and embedded in wax to detect CD56+ cells by immunohistochemistry, 
while the other part was used for flow cytometry. Menstrual cycle dating of 
these biopsies was carried out from the date of the last menstrual period and 
by the morphological appearance of the immunostained sections.    
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Hormone assays 
Serum was immediately separated from cells by centrifugation and stored at 
-20ºC until assay. Levels of oestradiol and progesterone were determined by 
chemiluminesescent assay (Abbott Axstm analyser: Abbott diagnostics). 
Levels of LH and FSH were measured using the Advia Centaur assay 
system (Bayer-Siemens plc). The intra and inter assay coefficients of 
variation were: oestradiol 7.9% and 11.9%; progesterone 6.8% and 12.4%; 
LH 4.5% and 10.4%; FSH 5.9% and 8.0%.  
Immunohistochemistry for CD56 and CD45 
5 µm sections were dewaxed in xylene, rehydrated through descending 
alcohols to Tris buffered saline pH 7.6 (TBS), and quenched in 0.3% 
hydrogen peroxide in methanol for 20 minutes. A negative control in which 
the specific antibody was replaced by an equivalent concentration of mouse 
IgG was included for each marker. 
After washing, unmasking was performed in an 800W microwave oven in 10 
mmol/l citrate buffer pH 6.0. Buffer was heated in the microwave oven until 
boiling. Slides were added to the buffer, and left covered at high heat for 3 
mins. Slides were further incubated for 12 mins on medium heat and allowed 
to cool for 20 mins. An ABC kit (Vector Laboratories, UK) was used 
according to the manufacturer’s instructions and the following adaptations. 
Slides were washed in TBS and blocked in blocking buffer containing 250 µl 
avidin/ml (Vector Laboratories, UK) for 1 hour at room temperature, and 
incubated overnight at +4ºC with either a mouse monoclonal primary anti-
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CD56 antibody (NCL-CD56-504 Novacastra Laboratories Ltd, UK ) diluted 
1:50, or a mouse monoclonal anti-CD45 antibody (Dako M0701) diluted 1:50  
in antibody buffer containing 250 µl/ml biotin. The addition of avidin in the 
blocking buffer and biotin with the antibody blocks endogenous activity. 
Slides were washed in TBS throughout, and after application of secondary 
antibody and Vectorstain, positive cells were visualised by incubation with 
peroxidase substrate (3.3'diaminobenzidene terahydrochloride; Vector 
Laboratories, UK). Slides were washed in distilled water and counterstained 
with 20% haematoxylin for 30 minutes, differentiated, dehydrated through 
ascending alcohols, cleared in xylene and mounted in Vectormount (Vector 
Laboratories, UK). 
Flow Cytometry 
For comparisons between methods of analysis of CD56+ cells in the same 
endometrial biopsy the part of the sample used for flow cytometry was 
collected into 1 ml of RPMI 1640 medium containing 100 IU/ml penicillin, 100 
mg/ml streptomycin and 10% heat inactivated pooled human serum. The 
tissue was chopped into small pieces and strained through a cell strainer (70 
µm). The tissue that passed through the strainer was incubated with red 
blood cell lysing buffer for 5 mins and then the cell suspension was 
centrifuged at 300 g for 5 mins. The cell pellet was washed in PBS and after 
a further centrifugation at 300 g was re-suspended in 1 ml cold FACS buffer. 
The total number of cells was counted using a haemocytometer. Cell 
suspensions (200 µl) were then incubated with either no antibodies (negative 
control), or 5 µl anti CD45 fluorescein isothiocyanate, 5 µl anti CD56 
allophycocyanin, 5 µl anti CD45 fluorescein isothiocyanate plus anti CD56 
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allophycocyanin, or isotype controls in the dark, on ice for 30 mins. All 
antibodies were obtained from BD Biosciences, Oxford, UK. After incubation 
cold FACs buffer (500 µl) was added to each cell suspension, which were 
pelleted at 400 g for 4 minutes. The cell pellet was washed again in FACs 
buffer and resuspended in 300 µl of 1% paraformaldehyde and kept in the 
dark until analysed using a BD FACS Caliber flow cytometer. 
For measurements of CD56+ cells in peripheral blood, leucocytes were 
prepared from the 5 ml blood sample using Lymphoprep 1.077. The cells at 
the interface were washed in PBS and re-suspended in PBS prior to 
counting. 1x106 cells were incubated with either 20 ul of anti CD56 
allophycocyanin, 20 ul anti CD45 fluorescein isothiocyanate, 20 ul anti CD16 
phycoerythrin, 20 ul of all antibodies, 20 ul of isotype control antibodies or no 
antibody (negative control). After incubation the cells were fixed and 
analysed as described above. 
Analysis 
For immunohistochemistry the numbers of CD56 positive, CD45 positive and 
total number of negative stromal cells were counted in 10 X 400 
magnification microscopic fields for each biopsy. The number of CD56+ cells 
was expressed as a percentage of either all stromal cells or as a percentage 
of CD45+ cells.  
For flow cytometry the numbers of CD56+ cells were calculated as either a % 
of total cells in the sample or as a % of CD45+ cells found in the sample.  
The relationships between the numbers of endometrial cells measured by 
flow cytometry and immunohistochemistry in normal control women and the 
numbers of peripheral blood CD56+ cells measured by flow cytometry and 
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endometrial CD56+ cells measured by immunohistochemistry in women with 
recurrent miscarriage was determined using the Pearson correlation test. 
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Results 
The age and peripheral blood levels for LH, FSH, progesterone and 
oestradiol for the 25 recurrent miscarriage women are shown in Table 1. The 
concentrations of each hormone are within the normal range. 
Figure 1 shows the immunohistochemical staining for CD45+ and CD56+ 
cells in the proliferative and secretory endometrium from the group of normal 
fertile women. In proliferative phase endometrium CD45+ and CD56+ cells 
were present as individual cells scattered throughout the stroma, while 
secretory phase endometrium contained more CD45+ and CD56+, which 
were also present as clumps of cells (Figure 1a - d). Figure 1 e and f shows 
immunohistochemical staining in secretory phase endometrium from women 
with recurrent miscarriage. It shows CD56+ cells present as individual or 
groups of cells. 
Figure 2 shows the relationship between endometrial CD56+ cells and 
peripheral blood CD56+ cells in the group of recurrent miscarriage women. 
There was no significant correlation between numbers of endometrial CD56+ 
cells and total peripheral blood CD56+, or the CD56+CD16+, CD56+CD16- 
subsets of CD56+ cells. 
There was also no correlation between the numbers of endometrial CD56+ 
cells or peripheral blood CD56+ cells (or subsets) and the concentration of 
plasma LH, FSH, oestradiol or progesterone (data not shown). 
Figure 3 shows the numbers of CD56+ cells in the endometrium obtained at 
different times in the menstrual cycle from individual normal fertile women 
measured by immunohistochemistry. Although there is some variation, the 
numbers are low during the proliferative and early secretory phase of the 
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cycle and only start to increase from the mid-late secretory phase. A similar 
pattern of distribution during the cycle was obtained when the numbers of 
CD56+ cells were measured by flow cytometry (data not shown).  
Figure 4 shows the relationship between numbers of endometrial CD56+ 
cells measured by flow cytometry and by immunohistochemistry in the same 
endometrial biopsy samples obtained from normal fertile women throughout 
the menstrual cycle. When expressed as a percentage of all cells the 
measurements of CD56+ cells by flow cytometry were lower (0.1-18%) than 
measurements obtained by immunohistochemistry (3.8-52.8%), whereas 
when expressed as a percentage of CD45+ cells both methods gave more 
comparable results (range 3.8-61% for flow cytometry and 10.8-70% for 
immunohistochemistry).There was a significant correlation between the 
measurement of cells by flow cytometry and immunohistochemistry both 
when the cell numbers were expressed as a percentage of total cells 
(correlation=0.497 P=0.026) or as a percentage of CD45+ cells 
(correlation=0.570 P=0.009).   
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Discussion 
Previous studies on the possible role of uNK cells in pregnancy outcome 
have produced contradictory results; some studies have shown that women 
with reproductive failure such as repeated implantation failure or recurrent 
miscarriage have increased numbers of uNK cells while others have 
suggested that there is no difference or reduced numbers (Thum et al. 2004; 
Moffat et al. 2004; King et al. 2010; Bulmer et al. 2010). It has been 
suggested that this may be due to measurement of NK cells in different 
compartments (eg blood, endometrium or decidua) or by different 
methodologies (eg immunohistochemistry or flow cytometry) (Laird et al. 
2003).  
In this study we have investigated numbers of NK cells in the endometrium 
and peripheral blood in samples obtained at the same time from the same 
individual woman in a group of women undergoing investigation for recurrent 
miscarriage. We found no correlation between numbers of total CD56+, 
CD56+CD16- or CD56+CD16+ and endometrial CD56+ cells in these 
women. A limitation of the study is that it was carried out in women with 
recurrent miscarriage; a comparable study in control fertile women would 
also be of interest. However recruitment of large numbers of fertile women to 
studies which require taking simultaneous blood and biopsy samples is 
difficult. There are very few studies comparing numbers of CD56+ 
endometrial and peripheral blood cell numbers even in patients with 
reproductive disorders attending clinics for diagnosis and treatment, 
suggesting the difficulties in the logistics of such studies.  
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The fact that there is no correlation between peripheral blood NK cell number 
and uNK cell number raises questions about the role of studies and 
measurements of peripheral blood NK cells in reproductive medicine.  
Measurements of peripheral blood NK cells by flow cytometry are 
considerably easier, as they do not require obtaining an endometrial biopsy 
sample, which is invasive.  Flow cytometry can also easily detect sub-
populations of CD56+ cells such as CD56+CD16+ and CD56+CD16-, which 
are postulated to play different roles in pregnancy failure (Laird et al. 2003). 
However the numbers of peripheral blood NK cells may not relate to those 
seen in the endometrium and therefore it may be inappropriate to extrapolate 
results from peripheral blood to what is happening in the endometrium. In 
addition a recent study has shown that peripheral blood NK cells are 
increased at times of stress and that the stress of obtaining a blood sample 
may artificially increase peripheral blood NK cells (Shakhar et al. 2006) again 
questioning the use of peripheral blood NK cell measurements in the 
diagnosis and treatment of recurrent miscarriage and other reproductive 
disorders. 
Peripheral blood and endometrial and uNK cells are in contact with different 
areas of the developing placenta; the peripheral blood baths the 
syncytiotrophoblasts, while endometrial and decidual cells are in contact with 
the invading trophoblast. It is thought that the endometrial and decidual NK 
cells are more likely to be involved in reproductive pathologies because of 
their proximity to the implantation process. Peripheral blood NK and uNK 
cells are likely to have different functions. Peripheral blood NK cells are part 
of the innate immune system and are involved in the protection against 
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infection. The precise role of uNK cells in the implantation process is 
unknown, but could include direct interaction with MHC molecules on the 
invading trophoblast, production of chemokines and cytokines, angiogenesis 
and spiral artery remodelling or innate immunity (Bulmer et al. 2010; Bulmer 
and Lash 2005; Quenby et al. 2009).  
We also compared the numbers of endometrial uNK cells measured by 
immunohistochemistry and flow cytometry in endometrial biopsy samples 
obtained at the same time from individual fertile control women.  For 
endometrial biopsy samples immunohistochemistry is usually used to 
determine the number of CD56+ cells. The advantage of this technique is 
that it can be carried out on relatively small samples of tissue and, once 
fixed, the tissue can be processed at the convenience of the laboratory. 
Larger endometrial biopsy samples are required to obtain sufficient cells for 
flow cytometry and the tissue needs to be processed immediately. However 
the advantage of the flow cytometry method is that it is able to determine 
sub-populations of CD56+ cells, which can only be carried out by double 
staining or staining on serial sections by immunohistochemistry.  
Our study showed a correlation between the numbers of CD56+cells 
measured by the 2 different methods. We expressed these measurements 
as CD56+ cell numbers as a percentage of all cells and CD56+ cells as a 
percentage of CD45+ cells for both methodologies. When expressed as a 
percentage of all cells the measurements of CD56+ cells by flow cytometry 
were lower (0.1-18%) than measurements obtained by 
immunohistochemistry (3.8-52.8%), whereas when expressed as a 
percentage of CD45+ cells the methods gave more comparable results 
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(range 3.8-61% for flow cytometry and 10.8-70% for immunohistochemistry). 
This means that care should be taken in comparing absolute numbers of 
uNK cells using the two different methodologies either within the same study 
or between studies. It also means that before measurement of uNK cells is 
translated into clinical practice a decision needs to be made about the 
chosen methodology of measurement.  
Although absolute values of CD56+ cells measured in each biopsy differed 
using the different methods there was a correlation in the cell numbers 
obtained, meaning that biopsies where there were high numbers of CD56+ 
cells were at the high end of the range in each method used. This means 
that in studies comparing numbers of CD56+ cells in two different groups of 
women or before and after treatments differences in results may not be due 
to differences in the methods used to detect the cells as long as the same 
method is used for all groups in the same study. 
In a previous study we reported that the numbers of CD56+ cells in 
endometrium obtained from a small group of control women (n=10) on days 
LH+7-LH+9 of the menstrual cycle was 2.2-13.9% (Tuckerman et al. 2007). 
In the current study the numbers ranged from 3.9-52.8%. However in this 
study samples were taken from throughout the menstrual cycle. A massive 
increase in CD56+ cells into the endometrium at the end of the cycle just 
prior to menstruation has been reported (Salamonsen & Lathbury 2000) and 
very high numbers of CD56+ cells were also only found in the endometrium 
in samples obtained during the late secretory phase of the cycle in this study. 
Of the 7 samples obtained in this study in the mid-secretory phase of the 
 296 
 
cycle (days 19-23), only 1 was slightly (14.6%) above the 13.9% upper value 
reported in the previous study.    
In conclusion we have shown no correlation between numbers of CD56+ 
cells in endometrium and peripheral blood in a group of women with 
recurrent miscarriage, suggesting that it is inappropriate to extrapolate 
findings in peripheral blood to the endometrium and decidua. In addition we 
have shown a correlation between measurements of endometrial NK cells by 
flow cytometry and immunohistochemistry, which suggests that differences in 
results seen in some studies cannot be attributed to the different 
methodologies used. 
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Legends to Figures 
Figure 1. Photomicrograph of immunostaining for a) CD45 in proliferative 
endometrium from a fertile woman b) CD56 in proliferative endometrium from 
a fertile woman c) CD45 in secretory endometrium from a fertile woman d) 
CD56 in secretory endometriun from a fertile woman e) and f) CD56 in 
secretory endometrium from 2 different women with recurrent miscarriage. 
(Magnification X400). 
Figure 2. Relationship between numbers of endometrial CD56+ cells 
assessed by immunohistochemistry and a) total peripheral blood CD56+ 
cells b) CD56+CD16+ peripheral blood cells and c) CC56+CD16- peripheral 
blood cells in recurrent miscarriage women (n=25). 
Figure 3. Variation in numbers of endometrial CD56+ cells assessed by 
immunohistochemistry in biopsy samples obtained from fertile women 
throughout the menstrual cycle (n=20). 
Figure 4. Correlation between measurement of endometrial CD56+ cells 
measured by immunohistochemistry and flow cytometry expressed as a) % 
of all cells and b) % CD45+ cells in fertile women (n=20). 
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Table 1. Age and hormone data for recurrent miscarriage patients 
 Median (Range) 
 Age 36 (25-42) years 
LH 5 (2.4-9.2) IU/L 
FSH 6.4 (2.9-12.6) IU/L 
Progesterone 42.9 (16.8-168) nmol/l 
Oestradiol 171 (71-378) pmol/l 
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